

**PROGRAMME
AND
ABSTRACTS**

Thorax

British Thoracic Society Winter Meeting 2011


The Queen Elizabeth II Conference Centre
Broad Sanctuary
Westminster
London SW1P 3EE


**7 to 9 December 2011
Programme and Abstracts**

Royal College of Physicians CPD approved
(code: 66375–18 credits)

Map to QEII Conference Centre


PowerPoint preview facilities will be available throughout the three days of the Meeting in the Thames Room on the first floor of the Centre. All presenters and chairs should report to the Speakers' section of the Registration Desks on arrival.





 The nearest tube stations are St James's Park and Westminster on the District and Circle Lines.

Bus routes 24, 11 and 511 all stop nearby.

 Parking facilities are available nearby, but are very limited.


 Victoria Station is approximately 15 minutes' walk down Victoria Street from the Conference Centre.

QEII Conference Centre – Ground and First Floors




Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEII Conference Centre – Second and Third Floors



Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

QEI Conference Centre – Fourth, Fifth and Sixth Floors



Full cafe facilities will be open from 8.00am to 4.00pm each day in the Pickwick Suite on the 1st floor. A snack bar, serving hot and cold drinks, sandwiches and confectionery only, will be open in the Whittle & Fleming Rooms on the 3rd floor, also from 8.00am to 4.00pm daily.

PROGRAMME AT A GLANCE

WEDNESDAY 7 DECEMBER 2011

Time	Details	Location/Floor
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd
8.45am – 4.00pm	Poster viewing	P1-P11 Pulmonary vascular disease
Authors present		P12-P19 Interferon-gamma assays in TB diagnosis
10.00am – 11.00am		P29-P36 Thinking outside the lung: improving the safety of pleural procedures
		P37-P49 COPD: a systemic disease or a co-morbid condition?
		P50-P65 Tuberculosis: from diagnosis to management
		P66-P75 Respiratory critical care
		P76-P83 Paediatric asthma
8.45am – 4.00pm	Moderated poster viewing	P20-P28 Sleep: clinical studies
8.15am – 8.45am	BTS Journal Club	Lung transplantation
8.30am – 10.15am	Symposium	Tuberculosis: improving clinical outcomes through cutting edge care
8.30am – 10.15am	Spoken session	S1-S6 Occupational lung disease
8.30am – 10.15am	Spoken session	S7-S12 Clinical studies in asthma
8.30am – 10.30am	Joint BTS/BALR symposium (part I)	Personalised medicine: science fact or science fiction? The future
8.30am – 10.30am	Spoken session	S13-S19 Unravelling airway infection in COPD
8.45am – 10.30am	Spoken session	S20-S25 Pulmonary thromboembolism: acute and chronic studies
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd
10.30am – 12.15pm	Symposium	Advances in cystic fibrosis – lessons for research in chronic lung diseases
10.30am – 12.15pm	Symposium	Optimal management of pulmonary thromboembolism in 2011
10.30am – 12.15pm	Spoken session	S26-S31 Pulmonary rehabilitation: delivery and evaluation of care
10.45am – 12.30pm	Spoken session	S32-S37 Novel mechanisms driving airway inflammation in asthma
10.45am – 12.30pm	Spoken session	S38-S43 Advances in screening and diagnosis of TB
11.00am – 1.00pm	Joint BTS/BALR symposium (part II)	Personalised medicine: science fact or science fiction? The present
12.15pm – 2.00pm	LUNCH	Cash catering only
12.30pm – 1.15pm	The Snell Memorial Lecture	The changing face of occupational lung disease
12.45pm – 2.10pm	Poster discussion	P1-P11 Pulmonary vascular disease
1.00pm – 2.00pm	Poster discussion	P12-P19 Interferon-gamma assays in TB diagnosis
1.15pm – 2.15pm	Symposium	PRO-active – introduction to a new outcome tool for COPD
1.30pm – 3.15pm	Joint BTS/BPRS symposium	Air pollution and children's health
1.45pm – 3.00pm	Moderated poster discussion	P20-P28 Sleep: clinical studies
2.00pm – 3.00pm	Poster discussion	P29-P36 Thinking outside the lung: improving the safety of pleural procedures
2.00pm – 3.30pm	Spoken session	S44-S48 Cystic fibrosis: bench to bedside
2.00pm – 3.45pm	Symposium	Developing new therapies in COPD
2.15pm – 3.45pm	Poster discussion	P37-P49 COPD: a systemic disease or a co-morbid condition?
2.15pm – 4.15pm	Poster discussion	P50-P65 Tuberculosis: from diagnosis to management
2.30pm – 3.45pm	Poster discussion	P66-P75 Respiratory critical care
3.00pm – 4.30pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd and Mountbatten Lounge/5 th (3.15pm-3.30pm)
3.30pm – 4.30pm	Poster discussion	P76-P83 Paediatric asthma
4.15pm – 4.45pm	The BTS President's Address	"The Society and the Young Ones: the Speciality and the Special One"
4.45pm – 5.00pm	Presentation	Presentation of the BTS Medal
5.00pm – 5.30pm	BTS AGM	BTS Annual General Meeting (BTS members only)

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

Thursday 8 December 2011

PROGRAMME AT A GLANCE

Time	Details	Location/Floor		
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd		
8.45am – 4.00pm	Poster viewing	P84-P92	Interstitial lung disease: from bench to bedside and back again	Whittle & Fleming Rooms/3 rd
Authors present 10.00am – 11.00am		P93-P106	Integrated respiratory care	
		PI07-PI14	Managing asthma: inhaled therapy and beyond	
		PI15-PI22	Cellular responses in the aetiology of COPD	
		PI23-PI29	Challenges in smoking cessation	
		PI30-PI39	Respiratory physiology: new tools, old concepts	
		PI40-PI51	Pulmonary rehabilitation: a challenging exercise?	
		PI52-PI64	Lung cancer: advances in diagnosis and delivery of care	
		PI65-PI77	Infections: from vaccination to treatments	
8.15am – 8.45am	BTS Journal Club		Pleural disease	Fleet Room/2 nd
8.30am – 10.15am	Joint BTS/BTOG symposium		Is the earlier diagnosis of lung cancer feasible and will it make any difference?	Churchill Auditorium/Ground
8.30am – 10.15am	Joint BTS/BPRS symposium		The long term sequelae of early life lung insults	St James's Suite/4 th
8.30am – 10.15am	Spoken session	S49-S54	Cellular studies in obstructive lung disease	Westminster Suite/4 th
8.30am – 10.15am	Spoken session	S55-S60	Clinical and mechanistic studies in thoracic malignancy	Henry Moore Room/4 th
8.30am – 10.15am	Spoken session	S61-S66	Pleural infection and pneumonia	Elizabeth Windsor Room/5 th
8.45am – 10.30am	Symposium		Sarcoidosis	Mountbatten Room/6 th
8.45am – 10.30am	Spoken session	S67-S72	Linking mechanisms to prognosis in pulmonary arterial hypertension	Rutherford Room/4 th
8.45am – 10.30am	Spoken session	S73-S78	Cell pathways in lung inflammation and injury	Abbey Room/4 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd		
10.30am – 12.15pm	Symposium		Plenary scientific symposium	Churchill Auditorium/Ground
10.30am – 12.15pm	Spoken session	S79-S84	Severe asthma in children and adults	Elizabeth Windsor Room/5 th
11.00am – 12.15pm	Symposium		Asbestos related disease research – BLF session	Abbey Room/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only		
				Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	The BTS Lecture		Mechanisms in the development of emphysema	Churchill Auditorium/Ground
12.30pm – 1.45pm	Open meeting		BTS/SIGN Asthma Guideline	Westminster Suite/4 th
1.30pm – 2.45pm	Poster discussion	P84-P92	Interstitial lung disease: from bench to bedside and back again	Henry Moore Room/4 th
1.45pm – 3.30pm	Poster discussion	P93-P106	Integrated respiratory care	Abbey Room/4 th
1.45pm – 3.30pm	Symposium		The airways microbiome	Mountbatten Room/6 th
1.45pm – 3.30pm	Spoken session	S85-S90	Lung cancer: advances in treatment	Elizabeth Windsor Room/5 th
2.00pm – 3.00pm	Poster discussion	PI07-PI14	Managing asthma: inhaled therapy and beyond	St James's Suite/4 th
2.00pm – 3.30pm	Symposium	T1-T6	BTS/BLF/BALR Early Career Investigator Award symposium	Westminster Suite/4 th
2.00pm – 3.45pm	Symposium		Sleep disorders and the brain	Churchill Auditorium/Ground
2.00pm – 3.45pm	Spoken session	S91-S96	COPD: systemic manifestations and cardiovascular disease	Rutherford Room/4 th
3.15pm – 4.15pm	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd		
3.30pm – 4.30pm	Poster discussion	PI15-PI22	Cellular responses in the aetiology of COPD	St James's Suite/4 th
3.30pm – 5.15pm	Spoken session	S97-S102	BMP signalling in pulmonary hypertension	Henry Moore Room/4 th
3.45pm – 4.45pm	Poster discussion	PI23-PI29	Challenges in smoking cessation	Mountbatten Room/6 th
4.00pm – 5.15pm	Poster discussion	PI30-PI39	Respiratory physiology: new tools, old concepts	Abbey Room/4 th
4.00pm – 5.30pm	Poster discussion	PI40-PI51	Pulmonary rehabilitation: a challenging exercise?	Elizabeth Windsor Room/5 th
4.00pm – 5.45pm	Symposium		The role of infection in asthma pathogenesis	Churchill Auditorium/Ground
4.00pm – 5.45pm	Poster discussion	PI52-PI64	Lung cancer: advances in diagnosis and delivery of care	Westminster Suite/4 th
4.00pm – 5.45pm	Poster discussion	PI65-PI77	Infections: from vaccination to treatment	Rutherford Room/4 th
5.45pm – 7.15pm	The President's Reception and Award Presentations – All welcome!			Benjamin Britten Lounge/3 rd

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

PROGRAMME AT A GLANCE

Friday 9 December 2011

Time	Details	Location/Floor		
8.00am – 9.00am	COFFEE/TEA	Whittle & Fleming Rooms/3 rd		
8.45am – 2.00pm	Poster viewing	P178-P190	Improving the investigation of suspected respiratory disease	Whittle & Fleming Rooms/3 rd
Authors present 10.00am – 11.00am		P200-P208	To wheeze or not to wheeze: is it all asthma?	
		P209-P223a	COPD: exacerbations, survival and end of life care	
		P224-P233	Models of care delivery	
		P234-P243	Improving delivery of care in cystic fibrosis	
		P244-P251	Acute and chronic respiratory infections	
		P252-P265	COPD and drugs: new and old concepts	
		P266-P276	NIV: COPD, neuromuscular disease and obesity	
8.45am – 2.30pm	Moderated poster viewing	P191-P199	Lung cancer: clinical studies	Mountbatten Lounge/5 th
8.15am – 8.45am	BTS Journal Club		Pulmonary hypertension	Fleet Room/2 nd
8.30am – 10.00am	Symposium		The outcomes strategy for COPD and asthma	Churchill Auditorium/Ground
8.30am – 10.15am	Symposium		Resection rates	Mountbatten Room/6 th
8.30am – 10.15am	Spoken session	SI03-SI08	Clinical studies in bronchiectasis	Westminster Suite/4 th
8.30am – 10.15am	Spoken session	SI09-SI14	ILD mechanisms	Henry Moore Room/4 th
8.30am – 10.15am	Spoken session	SI15-SI20	Respiratory muscles, exercise and ventilation	Abbey Room/4 th
8.45am – 10.15am	Joint BTS/UKRRC symposium		MRC/ABPI COPD Consortium	Elizabeth Windsor Room/5 th
8.45am – 10.30am	Spoken session	SI21-SI26	Mast cells, smooth muscle and inflammation in asthma	St James's Suite/4 th
10.00am – 11.00am	COFFEE/TEA	Whittle & Fleming Rooms, Benjamin Britten Lounge/3 rd		
10.15am – 12.00pm	Spoken session	SI27-SI32	Lung infections: mechanisms of disease	Henry Moore Room/4 th
10.30am – 11.15am	Update session		NIHR respiratory funding	Elizabeth Windsor Room/5 th
10.30am – 12.00pm	Symposium		Physiology of the elite athlete: the lead up to London 2012	Churchill Auditorium/Ground
10.30am – 12.15pm	Symposium		Secondary pulmonary hypertension	Mountbatten Room/6 th
10.30am – 12.15pm	Spoken session	SI33-SI38	ILD: clinical studies	Westminster Suite/4 th
10.30am – 12.30pm	Spoken session	SI39-SI44a	Pathophysiology and management of cough	Abbey Room/4 th
10.45am – 12.30pm	Symposium		'Late breaking news' – the best of British respiratory audit	St James's Suite/4 th
12.15pm – 2.00pm	LUNCH	Cash catering only		Pickwick Suite/1 st Whittle & Fleming Rooms/3 rd
12.30pm – 1.15pm	The Moran Campbell Lecture		Lung physiology and advances in COPD research	Churchill Auditorium/Ground
12.30pm – 1.15pm	Open meeting		Comprehensive Clinical Research Networks	Rutherford Room/4 th
1.00pm – 2.45pm	Poster discussion	P178-P190	Improving the investigation of suspected respiratory disease	Abbey Room/4 th
1.30pm – 2.30pm	Moderated poster discussion	P191-P199	Lung cancer: clinical studies	Mountbatten Lounge/5 th
1.30pm – 2.45pm	Poster discussion	P200-P208	To wheeze or not to wheeze: is it all asthma?	Henry Moore Room/4 th
1.30pm – 3.15pm	Symposium		Walking the translational pathway to new IPF therapies	Mountbatten Room/6 th
1.30pm – 3.30pm	Poster discussion	P209-P223a	COPD: exacerbations, survival and end of life care	Westminster Suite/4 th
1.45pm – 3.00pm	Poster discussion	P224-P233	Models of care delivery	St James's Suite/4 th
1.45pm – 3.30pm	Symposium		Pathophysiology of critical care-acquired weakness	Churchill Auditorium/Ground
2.00pm – 3.15pm	Poster discussion	P234-P243	Improving delivery of care in cystic fibrosis	Rutherford Room/4 th
2.00pm – 3.15pm	Poster discussion	P244-P251	Acute and chronic respiratory infections	Elizabeth Windsor Room/5 th
3.00pm – 4.45pm	Poster discussion	P252-P265	COPD and drugs: new and old concepts	Abbey Room/4 th
3.30pm – 5.00pm	Poster discussion	P266-P276	NIV: COPD, neuromuscular disease and obesity	Mountbatten Room/6 th
3.00pm – 4.45pm	COFFEE/TEA	Benjamin Britten Lounge/3 rd		

Coffee and tea is complimentary **ONLY** during the coffee/tea break times shown above. Outside these times, drinks may be purchased from the cafe in the Pickwick Suite (1st floor), or the snack bar in the Whittle & Fleming Rooms (3rd floor).

ADDITIONAL SESSIONS

Other events during the Winter Meeting will include the following sessions. Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 7 DECEMBER 2011

12.30pm – 1.30pm

Henry Moore Room, 4th floor

OPEN MEETING

LAUNCH OF CF PEER REVIEW

During the Open Meeting of the BTS Cystic Fibrosis SAG, CF Peer Review will be launched.

1.15pm – 2.15pm

Rutherford Room, 4th floor

SYMPOSIUM

PRO-ACTIVE – INTRODUCTION TO A NEW OUTCOME TOOL FOR COPD

Please see page xvii for full programme details.

1.15pm – 2.15pm

Wesley Room, 4th floor

OPEN MEETING

BRITISH ASSOCIATION FOR LUNG RESEARCH (BALR)

THURSDAY 8 DECEMBER 2011

10.00am – 11.00am

Chaucer Room, 4th floor

'DROP IN' SESSION

THE ROLE OF NURSES AND AHPs IN DELIVERING THE STRATEGY

This session will be led by Anne Moger (Nurse Advisor to the Department of Health Respiratory Programme) with SHA Leads, nurse and AHP colleagues. It will offer an opportunity to discuss the next steps for nurses and AHPs in implementing the Strategy. This session will be a market place where delegates will have the opportunity to discuss 'how to' design and deliver a range of services, eg PR, HOS-AR, etc.

12.30pm – 1.45pm

Westminster Suite, 4th floor

OPEN MEETING

BTS/SIGN ASTHMA GUIDELINE

This session will provide an update on progress of the Asthma Guideline and work in relation to patient information.

FRIDAY 9 DECEMBER 2011

8.30am – 10.00am

Churchill Auditorium, Ground floor

SYMPOSIUM

THE OUTCOMES STRATEGY FOR COPD AND ASTHMA – 'TURNING THE STRATEGY INTO REALITY'

Please see page xxxiii for full programme details

10.30am – 11.30am

Chaucer Room, 4th floor

'DROP IN' SESSION

THE OUTCOMES STRATEGY FOR COPD AND ASTHMA

An opportunity for delegates to discuss the Strategy with Professor Sue Hill (Chief Scientific Officer, Department of Health) and Dr Robert Winter (National Clinical Director for Respiratory Disease, Department of Health)

11.45am – 12.45pm

Chaucer Room, 4th floor

'DROP IN' SESSION

DESIGNING SERVICES TO DELIVER THE STRATEGY

An opportunity for SHA Cluster Medical Directors, Trust Medical Directors and all those responsible for service design to discuss delivering the Strategy with Professor Sue Hill (Chief Scientific Officer, Department of Health), Dr Robert Winter (National Clinical Director for Respiratory Disease, Department of Health) and Phil Duncan (Director, Lung Improvement Programme)

12.30pm – 1.15pm

Rutherford Room, 4th floor

OPEN MEETING

COMPREHENSIVE CLINICAL RESEARCH NETWORKS

Please see page xxxvii for full programme details

1.00pm – 1.30pm

Elizabeth Windsor Room, 5th floor

OPEN MEETING

ROYAL COLLEGE OF PHYSICIANS

IMPROVING LUNG CANCER OUTCOMES PROJECT (ILCOP)

This presentation will follow the open meeting of the BTS Lung Cancer and Mesothelioma SAG.

3.00pm – 5.00pm

Wesley Room, 4th floor

OPEN MEETING

UK THORACIC SURGERY RESEARCH COLLABORATIVE

The programme will also include open meetings of the BTS Specialist Advisory Groups (SAGs). Further details may be found in the leaflets in the conference bags or by reading the screens in the conference centre.

WEDNESDAY 7 DECEMBER 2011

Time	Details	Location/Floor
10.30am – 11.30am	BTS Occupational and Environmental Lung Disease SAG	Wesley Room/4 th
12.30pm – 1.30pm	BTS CF SAG and Launch of CF Peer Review	Henry Moore Room/4 th
12.45pm – 1.45pm	BTS COPD SAG	Elizabeth Windsor Room/5 th
3.15pm – 4.15pm	BTS Interventional Procedures SAG	Henry Moore Room/4 th

THURSDAY 8 DECEMBER 2011

Time	Details	Location/Floor
10.45am – 11.45am	BTS Sleep Apnoea SAG	Rutherford Room/4 th
11.00am – 12.00pm	BTS TB SAG	Henry Moore Room/4 th
11.30am – 1.30pm	BTS Nurse Advisory Group	Wesley Room/4 th
12.15pm – 1.45pm	BTS ILD and Rare Lung Disease SAG	Rutherford Room/4 th
4.45pm – 5.45pm	BTS Tobacco SAG	Mountbatten Room/6 th

FRIDAY 9 DECEMBER 2011

Time	Details	Location/Floor
10.45am – 11.45am	BTS Respiratory Critical Care SAG	Wesley Room/4 th
12.00pm – 1.00pm	BTS Lung Cancer and Mesothelioma SAG	Elizabeth Windsor Room/5 th
12.15pm – 1.15pm	BTS Infection SAG	Henry Moore Room/4 th
12.15pm – 1.15pm	BTS Asthma SAG	Wesley Room/4 th
12.30pm – 1.30pm	BTS Specialist Trainees Advisory Group	St James's Suite/4 th
12.30pm – 1.30pm	BTS Pulmonary Vascular Disease SAG	Fleet Room/2 nd
2.00pm – 3.00pm	BTS Thoracic Surgery SAG	Wesley Room/4 th

The British Thoracic Society President's Reception and Award Presentations


Thursday 8 December 2011 from 5.45pm to 7.15pm
Benjamin Britten Lounge, 3rd floor, QEII Conference Centre



All participants are warmly invited to join us on this special occasion. The presentations will be made for the annual BTS/BLF/BALR Early Career Investigator Awards, the Medical Student Awards and the BTS Award for Meritorious Service.

FLOOR PLAN OF THE EXHIBITION STANDS

Exhibitors and stand numbers



Whittle & Fleming Rooms, 3rd floor

1	Air Products
7, 8 & 9	AstraZeneca
22	B & D Electromedical
37	Bedfont Scientific Ltd
26	BOC Medical
21	Boehringer Ingelheim GmbH & Pfizer Inc
32	Boston Scientific
31	Brahms GmbH
16	Cellestis Ltd
17, 18, 23 & 24	Chiesi Ltd
6	Chiesi Special Care Division
40	Clement Clarke International
44	Dolby Visisol
3 & 4	Forest Laboratories UK Ltd
27, 28 & 39	GlaxoSmithKline
25	Hitachi Medical Systems
43	Imotech Medical
29 & 30	Merck Sharp & Dohme Ltd
10, 11, 12 & 13	Napp Pharmaceuticals Ltd
34 & 35	Novartis Pharmaceuticals UK Ltd
41	Nutricia UK
14	Olympus KeyMed
5	Orion Pharma (UK) Ltd
33	Oxford Diagnostic Laboratories
2	PARI Medical Ltd
36	PENTAX Lifecare
20	Pfizer Vaccines
38	Pharmaxis Pharmaceuticals Ltd
15	Philips Respirionics
19	ResMed UK
45	Rocket Medical
42	UK Medical

Charity and non-commercial stands

Benjamin Britten Lounge, 3rd floor

C54	Association for Respiratory Technology and Physiology (ARTP)
C53	Association of Chartered Physiotherapists in Respiratory Care (ACPRC)
C52	Association of Respiratory Nurse Specialists (ARNS)
C57	Asthma UK
C60	British Lung Foundation
C48	British Medical Journal
C47	British Thoracic Society
C51	Education for Health
C49	European Respiratory Society
C65	LAM Action
C64	NHS Improvement – Lung
C55	NHS Information Centre
C58	NIHR Respiratory Specialty Group
C56	Primary Ciliary Dyskinesia (PCD) Family Support Group UK
C62	Pulmonary Hypertension Association (PHA) UK
C59	Severe Asthma National Network
C50	Respiratory Education UK
C61	Royal College of Physicians NRAD and ILCOP
C63	TB Alert

Benjamin Britten Lounge, 3rd floor

46	Blackwell
----	-----------

Wednesday 7 December 2011

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd Floor

POSTERVIEWING

Authors present: 10.00am – 11.00am

P1–P11

Pulmonary vascular disease

Discussion of abstracts will take place from 12.45pm to 2.10pm in the St James's Suite, 4th floor

P12–P19

Interferon-gamma assays in TB diagnosis

Discussion of abstracts will take place from 1.00pm to 2.00pm in the Abbey Room, 4th floor

P29–P36

Thinking outside the lung: improving the safety of pleural procedures

Discussion of abstracts will take place from 2.00pm to 3.00pm in the Henry Moore Room, 4th floor

P37–P49

COPD: a systemic disease or a co-morbid condition?

Discussion of abstracts will take place from 2.15pm to 3.45pm in the Abbey Room, 4th floor

P50–P65

Tuberculosis: from diagnosis to management

Discussion of abstracts will take place from 2.15pm to 4.15pm in the St James's Suite, 4th floor

P66–P75

Respiratory critical care

Discussion of abstracts will take place from 2.30pm to 3.45pm in the Elizabeth Windsor Room, 5th floor

P76–P83

Paediatric asthma

Discussion of abstracts will take place from 3.30pm to 4.30pm in the Mountbatten Room, 6th floor

8.45am – 4.00pm

Mountbatten Lounge, 5th Floor

MODERATED POSTERVIEWING

P20–P28

Sleep: clinical studies

Discussion of abstracts will take place from 1.45pm to 3.00pm in the Mountbatten Lounge, 5th floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Lung transplantation

Dr Martin Carby (London)

SCIENTIFIC PROGRAMME

8.30am – 10.15am

Churchill Auditorium, Ground Floor

SYMPOSIUM

TUBERCULOSIS: IMPROVING CLINICAL OUTCOMES THROUGH CUTTING EDGE CARE

Chaired by: Dr Onn Min Kon (London) and Dr Ben Marshall (Southampton)

8.30am Should vitamin D supplements be a standard part of anti-TB therapy?

Dr Adrian Martineau (London)

8.55am Novel diagnostics in TB

Professor Joseph Keane (Dublin)

9.20am Investigating mechanisms of lung destruction in TB to identify new therapeutic approaches

Dr Paul Elkington (London)

9.45am Specific challenges in paediatric TB

Dr James Paton (Glasgow)

8.30am – 10.15am

St James's Suite, 4th Floor

SPOKEN SESSION: S1 – S6

Occupational lung disease

Chaired by: Professor Paul Cullinan (London) and Dr Chris Warburton (Liverpool)

8.35am **S1**

Evidence-based case definition for EAA due to metalworking fluid exposure

CM Barber, CM Burton, DJ Hendrick,

CAC Pickering, AS Robertson,

W Robertson, PS Burge

8.50am **S2**

Occupational exposure, breathlessness and COPD in a general population of older UK men

E Pickles, J Szram, SJ Schofield, APM Woods,

P Cullinan

9.05am **S3**

Work performance and airflow obstruction in a general UK population of older workers

J Szram, SJ Schofield, APM Woods, N Crisp,

D Harris, P Cullinan

9.20am **S4**

Occupational asthma; is this the cause of excess respiratory symptoms and COPD described in bitumen exposed workers?

N Surange, J Hoyle

9.35am **S5**

The prevalence of asthma among cleaners in the United Kingdom

SH Alfajam, C Stenton, T Pless-Molluli, D Howel

9.50am **S6**

Supermarket bakers asthma: a report of three successive rounds of surveillance

J Cannon, J Szram, J Welch, C Sharp,

P Cullinan, M Jones

SCIENTIFIC PROGRAMME

8.30am – 10.15am

Mountbatten Room, 6th Floor

SPOKEN SESSION: S7 – S12

Clinical studies in asthma

Chaired by: Professor Neil Barnes (London) and

Dr Rob Niven (Manchester)

8.35am S7

Adiposity and asthma, pulmonary function and atopy in 11 year old children: a birth cohort study
R Wang, A Custovic, A Simpson, L Lowe, CS Murray

8.50am S8

Sensitivity of impulse oscillometry and spirometry in the assessment of beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in mild-to-moderate asthmatics

PM Short, PA Williamson, BJ Lipworth

9.05am S9

Inhaled and systemic corticosteroid response in moderate-to-severe asthma assessed by extended exhaled nitric oxide and lung function

PA Williamson, PM Short, BJ Lipworth

9.20am S10

Is a high FeNO a marker of non-adherence in difficult asthma?

DM McNicholl, LP McGarvey, LG Heaney

9.35am S11

Inappropriate prescribing of combination inhalers in asthma in Northern Ireland (NI)

J Sweeney, AM Marley, C Patterson, LG Heaney

9.50am S12

Unscheduled healthcare resource utilisation and health-related quality of life before and after Omalizumab initiation in UK clinical practice: the APEX study

N Barnes, A Radwan, F Percival

8.30am – 10.30am

Westminster Suite, 4th Floor

JOINT BTS/BALR SYMPOSIUM

PERSONALISED MEDICINE – SCIENCE FACT OR SCIENCE FICTION? PART I: THE FUTURE

Chaired by: Professor Ann Millar (Bristol) and Professor Terry Tetley (London)

8.30am Grow your own organ: the ultimate goal?

Professor Martin Birchall (London)

9.00am Metabolomics: an alternate tactic

Professor Elaine Holmes (London)

9.30am Gene wide association studies: fulfilling their promise?

Professor William Cookson (London)

10.00am Biologics today and tomorrow

Dr Lynne Murray (MedImmune)

Wednesday 7 December 2011

8.30am – 10.30am

Abbey Room, 4th Floor

SPOKEN SESSION: S13 – S19

Unravelling airway infection in COPD

Chaired by: Dr John Hurst (London) and Professor Sebastian Johnston (London)

8.35am S13

Differentiated human rhinovirus loads in stable COPD and at exacerbation

SN George, AJ Mackay, ARC Patel, RJ Sapsford, DS Garcha, GC Donaldson, JA Wedzicha

8.50am S14

Histone deacetylase activity is reduced in COPD subjects during rhinovirus induced exacerbations

JIM Footitt, P Mallia, MB Trujillo-Torralbo, A Durham, IM Adcock, SL Johnston

9.05am S15

Detection of bacteria in sputum following experimental rhinovirus infection is more common in COPD than controls subjects

JIM Footitt, P Mallia, MB Trujillo-Torralbo, A Jepson, SL Johnston

9.20am S16

Molecular profiling of the airway microbiome in COPD

K Haldar, K Lau, M Bafadhel, C Brightling, M Barer

9.35am S17

Impact of COPD severity and sputum production on antibiotic resistance

SJ Thurston, GC Donaldson, TD McHugh, JA Wedzicha

9.50am S18

A comparison of prevalence and load of airway bacteria in COPD patients with paired stable and exacerbation state samples

DS Garcha, SJ Thurston, ARC Patel, AJ Mackay, JJP Goldring, TD McHugh, GC Donaldson, JA Wedzicha

10.05am S19

Molecular fingerprinting and metagenomic analysis reveals a polymicrobial element in patients with chronic obstructive pulmonary disease

PJ Purcell, A Nelson, A Fisher, JD Perry, A De-Soyza, SP Cummings

8.45am – 10.30am

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S20 – S25

Pulmonary thromboembolism: acute and chronic studies

Chaired by: Dr Robin Condliffe (Sheffield) and Dr Joanna Pepke-Zaba (Cambridge)

Wednesday 7 December 2011

8.50am S20

Time-resolved CT pulmonary angiography contrast transit time in patients with pulmonary embolism – A novel functional CT metric of right heart strain?
ER Swift, S Rajaram, OR Byass, K Chiu, AJ Swift

9.05am S21

Objective and patient reported outcomes of long term management of patients with chronic thromboembolic pulmonary hypertension (CTEPH): a single centre experience
NJ Doughty, J Pepke-Zaba

9.20am S22

Improved symptoms and quality of life after pulmonary endarterectomy (PEA) in patients with chronic thromboembolic disease (CTED) and borderline pulmonary hypertension (PH)
D Taboada, C Treacey, D Jenkins, J Pepke Zaba, K Sheares

9.35am S23

Accuracy of contrast enhanced MR lung perfusion compared to perfusion scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension
S Rajaram, AJ Swift, D Capener, C Hill, C Davies, R Elliot, J Hurdman, R Condliffe, JM Wild, DG Kiely

9.50am S24

Incidence of persistent perfusion defects following pulmonary embolism: impact on pulmonary artery systolic pressure at 6 months
S Fagerbrink, B Mukherjee, D Sirisena, N Salooja, L Howard

10.05am S25

Incidence of surgically treated patients with chronic thromboembolic pulmonary hypertension in the UK during the last decade
CM Treacy, J Colledge, DP Jenkins, K Page, K Sheares, S Tsui, J Dunning, N Screaton, D Gopalan

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.15pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

ADVANCES IN CYSTIC FIBROSIS – LESSONS FOR RESEARCH IN CHRONIC LUNG DISEASES

Chaired by: Dr Diana Bilton (London) and Dr Martin Walshaw (Liverpool)

SCIENTIFIC PROGRAMME

10.30am Modelling chronic respiratory disease: exploring alternative CF models
Professor Joseph Zabner (Iowa)

10.55am Exploring novel innate immune responses
Professor Gerry McElvaney (Dublin)

11.20am Protein dysregulation and repair strategies: advancing knowledge and future directions
Professor Frédéric Becq (Poitiers)

11.45am Improving antibiotic therapy: aerosols and adjuvants
Professor Alan Smyth (Nottingham)

10.30am – 12.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

OPTIMAL MANAGEMENT OF PULMONARY THROMBO-EMBOLISM IN 2011

Chaired by: Professor Paul Corris (Newcastle upon Tyne) and Dr Karen Sheares (Cambridge)

10.30am Making the diagnosis of PTE and the importance of classification and risk stratification
Professor Paul Corris (Newcastle upon Tyne)

10.55am Thrombolysis, catheter disruption and pulmonary embolectomy for pulmonary thrombo-embolism: what is the evidence and what should we do?
Professor Adam Torbicki (Warsaw)

11.20am Navigating your way through thrombophilia
Dr Rhona Maclean (Sheffield)

11.45am The changing face of anticoagulation
Dr Trevor Baglin (Cambridge)

10.30am – 12.15pm

St James's Suite, 4th Floor

SPOKEN SESSION: S26 – S31

Pulmonary rehabilitation: delivery and evaluation of care

Chaired by: Dr William Man (Harefield) and Professor Sally Singh (Leicester)

10.35am S26

Barriers to attendance and adherence at pulmonary rehabilitation
C Hayton, A Clark, AM Wilson

10.50am S27

MRC grade 2: Is there a difference in activity and exercise capacity between COPD and healthy controls?
V Warrington, K Wagg, S Harrison, S Singh

SCIENTIFIC PROGRAMME

11.05am S28

Is a pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery feasible?

A Bradley, J Gillies, K Parker, P Agostini, L Stone-hewer, E Bevan-Smith, E Bishay, M Kalkat, R Steyn, P Rajesh, B Naidu

11.20am S29

Assessing the educational impact of Pulmonary Rehabilitation in non-COPD patients using the Lung Information Needs Questionnaire

RP Fowler, D Ardelean, KI Ingram, AL Clark, PL Marns, SSC Kon, JL Canavan, WD-C Man

11.35am S30

An evaluation of the systemic inflammatory response to endurance walking in patients with COPD: comparison with healthy individuals

JL Canavan, M Moreton-Clack, A Lewko, B Linton-Willoughby, A Jewell, R Garrod

11.50am S31

Energy expenditure and physical activity levels during an eight week pulmonary rehabilitation programme

JL Canavan, KA Ingram, RP Fowler, AL Clark, P Marns, MS Patel, SS Kon, WD-C Man

10.45am – 12.30pm

Abbey Room, 4th Floor

SPOKEN SESSION: S32 – S37

Novel mechanisms driving airway inflammation in asthma

Chaired by: Professor Peter Howarth (Southampton) and Professor Neil Thomson (Glasgow)

10.50am S32

Loss/inhibition of the α V β 5 integrin reduces allergen-induced increases in airway smooth muscle mass in in vivo models of asthma

AL Tatler, AE John, L Jolly, A Habgood, J Porte, AJ Knox, X Huang, D Sheppard, G Jenkins

11.05am S33*

Vitamin D and airway remodelling in pediatric severe therapy resistant asthma

A Sjoukes, A Gupta, T Oates, A Bush, S Saglani

11.20am S34

The adhesion receptor CADMI on mast cells mediates adhesion to lung fibroblasts and smooth muscle

E P Moiseeva, K Roach, ML Leyland, P Bradding

11.35am S35

Rapamycin inhibits IL-33-induced, nuocyte-driven airway inflammation

AS Mirchandani, RJ Salmond, CJ Bain, FY Liew

Wednesday 7 December 2011

11.50am S36

The adhesion receptor CADMI promotes human mast cell viability

EP Moiseeva, ML Leyland, P Bradding

12.05pm S37

Myd88 deficiency influences murine tracheal epithelial metaplasia and submucosal gland abundance

A Giangreco, L Lu, D Mazzatti, B Spencer-Dene, E Nye, V Teixeira, S Janes

*BTS Medical Student Winner

10.45am – 12.30pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S38 – S43

Advances in screening and diagnosis of TB

Chaired by: Dr Sarah Doffman (Brighton) and Dr James Paton (Glasgow)

10.50am S38

Community-based evaluation of immigrant TB screening using interferon gamma release assays and tuberculin skin testing: yields and cost-effectiveness

M Pareek, M Bond, J Shorey, S Seneviratne, A Lalvani, OM Kon

11.05am S39

Migration and tuberculosis – the start of intelligent new entrants screening

ME Kruijshaar, M Lipman, J Moore, I Abubakar

11.20am S40

A cross sectional investigation to determine the background prevalence of latent tuberculosis infection in unselected medical inpatients in a low prevalence region of UK reveals high rates of IGRA positivity

N Varsani, TSC Hinks, DT Godsiff, TC Bull, KL Nash, L McLuckie, A Warley

11.35am S41

Screening for latent TB in HIV: are NICE & BHIVA guidance effective?

S Capocci, C Smith, I Cropley, S Bhagani, MA Johnson, MCI Lipman

11.50am S42

Early identification of mycobacterium tuberculosis (M.tb) and mycobacterium other than tuberculosis (MOTT) by 'cord formation' evaluation in liquid culture

A Elsaghir, S Abdullah, F Sundram, DD Creer

Wednesday 7 December 2011

12.05pm S43

Polyfunctional T cells reveal the spectrum of tuberculosis in HIV co-infection through the identification of immunological correlates of latent and active disease

KM Pollock, D Montamat-Sicotte, G Cooke, M Kapembwa, OM Kon, GP Taylor, A Lavani

11.00am – 1.00pm

Westminster Suite, 4th Floor

JOINT BTS/BALR SYMPOSIUM

PERSONALISED MEDICINE – SCIENCE FACT OR SCIENCE FICTION? PART II: THE PRESENT

Chaired by: Dr Colin Bingle (Sheffield) and Dr Chris Scotton (London)

11.00am Pharmacogenetics in 2011

Professor Ian Hall (Nottingham)

11.35am Treat your own cancer

Dr Martin Sos (Cologne)

12.10pm Bench to bedside: the CFTR story

Dr Cecile Le Camus (Vertex)

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground Floor

SNELL MEMORIAL LECTURE

The changing face of occupational lung disease

Professor Paul Blanc (San Francisco)

Introduced by: Dr Ed Neville (Portsmouth)

12.45pm – 2.10pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P1 – P11

Pulmonary vascular disease

Chaired by: Dr Robin Condliffe (Sheffield) and Dr John Wort (London)

P1 Clinical and economic benefit of cardiopulmonary exercise testing (CPX) in pulmonary hypertension
B Mukherjee, D Sirisena, K Murphy, H Tighe, L Howard

P2 In-Flight hypoxaemia in patients with pulmonary arterial hypertension (PAH)
RM Burns, AJ Peacock, MK Johnson, AC Church

P3 Are inflammatory cytokine levels altered by treatment of pulmonary arterial hypertension?
G Hagan, M Southwood, C Treacy, K Sheares, N Morrell, J Pepke-Zaba

SCIENTIFIC PROGRAMME

- P4** The use of sildenafil to treat pulmonary hypertension associated with sarcoidosis
GJ Keir, AU Wells, SJ Wort
- P5** Pulmonary hypertension in a mouse model with reduced macrophage number (MacLow)
A Zawia, N Arnold, J Pickworth, A Hameed, K Hopkinson, G Miller, A Lawrie
- P6** Managing acute pulmonary embolism in the outpatient setting: initial experiences and outcomes in a UK district general hospital
JP Corcoran, JES Park, C Goode, CWH Davies
- P7** Are we screening survivors of pulmonary embolism (PE) for chronic thromboembolic pulmonary hypertension (CTEPH)?
M Wilczynska, K Taylor
- P8** Use of D-Dimer:CRP ratio compared to D-Dimer alone to predict PE on VQ Scanning
R Berwick, S Navalkisoor, JR Hurst
- P9** Determining the appropriate D-dimer cut off to exclude pulmonary emboli in an ambulatory care setting using different thresholds based on pre-test probability
RM Ladwa, E Bailie, Y Vali, RH Green, JA Bennett, CM Free
- P10** Risks of low molecular weight heparin in suspected pulmonary embolism
L Watkins, S Rafeeq, N McMullan, P Stockton, S Twite, S Agarwal
- P11** Assessment of malignancy in patients with idiopathic pulmonary embolus: an audit
R Som

1.00pm – 2.00pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P12 – P19

Interferon-gamma assays in TB diagnosis

Chaired by: Dr Ibrahim Abubakar (London) and Dr Ben Marshall (Southampton)

P12 Role of Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in blood in the diagnostic work up of active tuberculosis in a high TB prevalence region.
S Kumar, D Gupta, I Verma, SK Jindal, R Agarwal

P13 Interferon-gamma release assay (IGRA) conversion, reversion and implications for the diagnosis of latent tuberculosis infection using a multimodality approach: A retrospective, observational study within a central London TB centre
M H Almond, M O'Donoghue, N Drey, S Seneviratne, A Lavani, M Wickremasinghe, OM Kon

SCIENTIFIC PROGRAMME

- P14** Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in screening for latent tuberculosis infection (LTBI) among HIV-infected adults attending an inner London HIV clinic
RF Miller, T Mahungu, M Young, D Mercey, S Morris-Jones, P Benn
- P15** Does an interferon-gamma release assay change practice in patients referred to clinic for possible latent tuberculosis infection?
JF Tiernan, S Gilhooley, ME Jones, JD Chalmers, C McSparran, I Laurenson, J Stevenson, AT Hill
- P16** TB Infection in the UK indigenous white elderly population: a retrospective study of interferon gamma release assays (IGRAs)
M Gautam, J Darroch, P Davies
- P17** Clinical utility of the Tuberculosis Interferon Gamma Test (IGT) in a low incidence area
JT Donovan, A Yogendran, ID Ramsay, C Giles, RW Lee, AT Scourfield, SR Doffman
- P18** How effective is the recommended staging for latent TB follow-up?
D Thomas, M Jarvis, A Williams
- P19** GeneXpert MTB.Rif assay improves the diagnostic yield of EBUS-TBNA in smear-negative intra-thoracic tuberculous lymphadenopathy
DJ Dhasmana, CJ Bradley, P George, DW Connell, P Molyneaux, A Singanayagam, A Lavani, A Jepson, OM Kon, GS Cooke

1.15pm – 2.15pm Rutherford Room, 4th Floor SYMPOSIUM

PRO-ACTIVE – INTRODUCTION TO A NEW OUTCOME TOOL FOR COPD

Chaired by: Caterina Brindicci (Chiesi) and Professor Michael Polkey (London)

- 1.15pm** The need for an instrument: an academic perspective
Dr Nick Hopkinson (London)
- 1.35pm** The need for an instrument: an industry perspective
Niklas Karlsson (AstraZeneca)
- 1.55pm** PROactive – update on current progress
Dr Thierry Troosters (Leuven, Belgium)

1.30pm – 3.15pm Mountbatten Room, 6th Floor JOINT BTS/BPRS SYMPOSIUM AIR POLLUTION AND CHILDREN'S HEALTH

Chaired by: Professor Jonathan Grigg (London) and Professor John Henderson (Bristol)

Wednesday 7 December 2011

- 1.30pm** How do air pollutants damage children's lungs?
Professor Frank Kelly (London)
- 1.55pm** Improving children's health by reducing indoor air pollution
Dr Nigel Bruce (Liverpool)
- 2.20pm** Does air pollution cause asthma?
Professor John Balmes (Berkeley)
- 2.45pm** Global burden of air pollution in children
Professor Majid Ezzati (London)

1.45pm – 3.00pm Mountbatten Lounge, 5th Floor POSTER DISCUSSION: P20 – P28 Sleep: clinical studies

Chaired by: Dr Joerg Steier (London) and Dr Sophie West (Newcastle upon Tyne)

- P20** Impact of patients' perception of problem driving, symptoms and severity of obstructive sleep apnoea syndrome (OSAS) on outcomes on an advanced office based driving simulator
D Ghosh, SL Jamson, PD Baxter, MW Elliott
- P21** Does time of day affect outcomes on an advanced office based driving simulator in patients with obstructive sleep apnoea syndrome (OSAS)?
D Ghosh, SL Jamson, PD Baxter, MW Elliott
- P22** Do obstructive sleep apnoea (OSA) patients with normal Epworth scores comply with continuous positive airway pressure (CPAP) therapy?
R Pagonda, B Thangakunam, C Mabuto, I Basharet, B Yung, D Mukherjee, K Wadsworth, J Samuel
- P23** 500 consecutive referrals to a DGH sleep service: how useful is the Epworth?
LH White, S Backway, A Kerry, A Stanton, M Juniper
- P24** Prevalence of obstructive sleep apnoea in patients scheduled for bariatric surgery and validation of the STOP-BANG questionnaire as a screening tool
R Kaiser, C Hammond, L Restruck, P Sufi, D Heath
- P25** A novel cost-saving approach to the sleep clinic non-attenders with CPAP machines
AH Shah, P Close, J Oliver, SD West
- P26** The UK Paediatric Sleep Videoconferencing Circuit - from idea to reality!
DS Urquhart, D Kilner
- P27** Undergraduate sleep medicine teaching in UK medical schools – A questionnaire survey
DS Urquhart, J Orme, S Suresh

Wednesday 7 December 2011

- P28** The impact of patient information leaflets in sleep clinic
S Huq, D Price, S Sureshkumar, S Kalidindi, M Walshaw, J Hadcroft

2.00pm – 3.00pm

Henry Moore Room, 4th Floor

POSTER DISCUSSION: P29 – P36

Thinking outside the lung: improving the safety of pleural procedures

Chaired by: Dr Nicholas Maskell (Bristol) and Dr Ed Neville (Portsmouth)

- P29** Securing an intercostal chest drain without sutures
S Kesavan, GD Angelini
- P30** What difference does bedside ultrasound guidance make to pleural fluid aspiration and drainage in a district general hospital setting?
O J Bintcliffe, H Al-Najjar, R K Sinha
- P31** Routine analysis of pleural aspirates for AFB in patients with pleural effusion of unknown cause is of limited use
PK Agarwal, M Ali, J Keane, S Barrett, SO Ansari
- P32** Are junior doctors safe to perform pleural procedures? An audit of junior doctor knowledge and competency of pleural procedures before and after dedicated lecture-based and practical teaching sessions.
SV Ruickbie, G MacDonald, N Walters, A Draper, YE Ong
- P33** Thoracic Ultrasound Training: How are we doing? - A national web- based survey.
A Dwarakanath, TJT Sutherland, S Kumar
- P34** Are nursing staff sufficiently educated and competent in managing patients with a chest drain?
G Fremlin, R Baker, G Walters, T Fletcher
- P35** Primary spontaneous pneumothorax – adherence to guidelines and healthcare economic implications
GD Thomas, FJH Brims
- P36** Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions
D Spyrtos, M Sionidou, T Kontakiotis, P Zarogoulidis, K Zarogoulidis, L Sichletidis

2.00pm – 3.30pm

Westminster Suite, 4th Floor

SPOKEN SESSION: S44 – S48

Cystic fibrosis: bench to bedside

Chaired by: Professor Alan Smyth (Nottingham) and Dr Stephen Turner (Aberdeen)

SCIENTIFIC PROGRAMME

- 2.05pm S44**
 Lung clearance index (LCI) and FEV1 correlate equally with treatment burden as measured by cystic fibrosis questionnaire-revised (CFQ-R)
K O'Neill, JM Bradley, M Tunney, JS Elborn
- 2.20pm S45**
 Clinical efficacy of seasonal influenza vaccination in adults with cystic fibrosis
WG Flight, KJ Mutton, AK Webb, RJ Bright-Thomas, AM Jones
- 2.35pm S46**
 A comparison of three different specimen types for the diagnosis of viral respiratory infections in adults with cystic fibrosis
WG Flight, KJ Mutton, B Isalska, RJ Bright-Thomas, AM Jones
- 2.50pm S47**
 Pseudomonas aeruginosa induces apoptosis in human dendritic cells - a potential mechanism to evade pulmonary immune responses
HK Bayes, T Evans
- 3.05pm S48**
 Mucoidy and the microbiome: community composition in relation to the presence of culturable, mucoid Pseudomonas aeruginosa
MJ Cox, AL Jones, MR Loebinger, RM Duff, NJ Simmonds, JC Davies, R Wilson, EW Alton, WOCM Cookson, D Bilton, MF Moffatt

2.00pm – 3.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

DEVELOPING NEW THERAPIES IN COPD

Chaired by: Professor Wisia Wedzicha (London)

- 2.00pm** Novel targets in airway inflammation
Dr Louise Donnelly (London)
- 2.25pm** Lung remodelling: still an issue
Professor Steven Rennard (Nebraska)
- 2.50pm** Assessment of therapies: the Holy Grail?
Dr John Hurst (London)
- 3.15pm** Very large COPD trials: the future or the past?
Dr Bernd Disse (Boehringer Ingelheim)

2.15pm – 3.45pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P37 – P49

COPD: a systemic disease or a co-morbid condition?

Chaired by: Dr Jonathan Fuld (Cambridge) and Dr Nicholas Hopkinson (London)

SCIENTIFIC PROGRAMME

- P37** Muscle mass in COPD patients receiving angiotensin II receptor blockers and ACE-inhibitors
SSC Kon, MS Patel, AL Clark, KA Ingram, RP Fowler, P Marns, JL Canavan, NS Hopkinson, MI Polkey, WDC Man
- P38** Is nutritional status neglected in COPD patients admitted to hospital?
C Jones, J Suntharalingam
- P39** Nutritional assessments in COPD: the respiratory nurse perspective on current practice across the UK
J Annandale, C Kelly, R Sherrington
- P40** Increased advanced glycation end products in patients with chronic obstructive pulmonary disease (COPD)
M John, S Hussain, S Selvarajah, I Sayers, IP Hall, L Fairclough, CE Bolton
- P41** Cognitive dysfunction in hospitalised patients prior to discharge following acute exacerbation of COPD
JW Dodd, RA Charlton, M Van Den Broek, PW Jones
- P42** The relationship of home activity levels to psychological co-morbidity in COPD
T Stuart, C Rogers, G Balanos, AM Wood
- P43** Assessing the validity of a home activity monitor in patients with COPD
C Rogers, G Balanos, AM Wood
- P44** Validation of a pedometer to measure daily physical activities in COPD patients
AD Alahmari, BS Kowlessar, ARC Patel, AJ Mackay, R Singh, GC Donaldson, JA Wedzicha
- P45** Co-morbidities in alpha-1-antitrypsin deficiency
H Stone, A Pye, RA Stockley
- P46** Gender differences in the prevalence of comorbidities in COPD patients
ARC Patel, GC Donaldson, AJ Mackay, JA Wedzicha, JR Hurst
- P47** The impact of comorbid ischaemic heart disease on exercise capacity in COPD patients
ARC Patel, AD Alahmari, GC Donaldson, B Kowlessar, AJ Mackay, R Singh, JR Hurst, JA Wedzicha
- P48** Should chronic obstructive pulmonary disease be a contra-indication to beta blocker prescription in patients with concomitant heart failure?
DC Lees, M Simpson, E McKay, SJ Owen
- P49** Intra-subject variation in breath profile of exhaled volatile organic compounds (eVOCs) in chronic obstructive pulmonary disease (COPD)
YI Syed, CO Phillips, D Deganello, KE Lewis, T Claypole

Wednesday 7 December 2011

2.15pm – 4.15pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P50 – P65

TB: from diagnosis to management

Chaired by: Dr Marc Lipman (London) and Professor Peter Ormerod (Blackburn)

- P50** A summary of strain typing and clustering of TB in London in 2010 and an analysis of the associated risk factors
EL Hamblion, E Wynne-Edwards, C Anderson, SR Anderson
- P51** Tuberculosis outcome following pre-treatment assessment for directly observed or self administered therapy: still room for improvement?
JC Barrett, S Dart, A Solamalai, C Snook, M Lipman
- P52** Rising paediatric tuberculosis in Greater Manchester – epidemiology and BCG vaccination status of cases
F Sakhinia, J Robinson, R McCann, C Bell, F Child, CS Murray
- P53** Our experience of avoiding unnecessary bronchoscopies by use of sputum induction for the investigation of suspected tuberculosis
T Gorsuch, L Wilson, J L Hoyle
- P54** Impact of a rapid access system for early referral of suspected TB cases
R Verma, J Lee, P Haldar, G Woltmann
- P55** TB risk after new immigrant GP registration: a retrospective cohort analysis
RK Panchal, P Haldar, G Woltmann
- P56** Treatment of multidrug resistant tuberculosis: Where are the guidelines for monitoring?
JL Keal, H Khachi, E Hanzaree, VLC White
- P57** The awareness, perceptions and attitudes among migrants towards TB screening
YYS Ho, D Nazareth, J Gallagher, S Kazmi, PDO Davies
- P58** Indices of TB risk can help stratify recent immigrants registering with a GP for targeted screening
RK Panchal, P Haldar, G Woltmann
- P59** Differing patterns of new immigrant GP registration among ethnic subgroups determine the importance of additional strategies for models of new immigrant screening
RK Panchal, P Haldar, G Woltmann
- P60** Simple measures to improve TB control: applying the cohort review process in London
J White, C Anderson, S Dart, S Tamne, J deKoningh, S Hemming, S Anderson, I Abubakar, M Lipman

Wednesday 7 December 2011

- P61** Karel Styblo comes to town: staff perspectives on TB cohort review
C Anderson, S Tamne, J White, I Abubakar, S Anderson, S Dart, J DeKoningh, M Lipman
- P62** Drug induced hypothyroidism in patients receiving treatment for multi-drug resistant tuberculosis
J Gupta, RAM Breen, HJ Milburn
- P63** The prevalence of viral hepatitis in patients undergoing anti-tuberculous therapy
M Asgheddi, DW Connell, HA Nooredinwand, M Abdullah, M O'Donoghue, L Campbell, A Lalvani, M Wickremasinghe, S Khan, OM Kon
- P64** The effect of wood smoke on the ability of human macrophages to phagocytose and kill *M. tuberculosis*
JE Scriven, DG Fullerton, A Warman, SB Gordon
- P65** Treating tuberculosis in rural South Africa
JN Periselneris

2.30pm – 3.45pm

Elizabeth Windsor Room, 5th Floor

POSTER DISCUSSION: P66 – P75

Respiratory critical care

Chaired by: Dr Nicholas Hart (London) and Dr Matthew Wise (Cardiff)

- P66** Inter-observer reliability of ultrasound to measure rectus femoris cross-sectional area in critically ill patients
B Connolly, Z Puthuchear, H Montgomery, J Moxham, N Hart
- P67** Clinical predictive value of the Medical Research Council Sumscore in critically ill patients
B Connolly, G Jones, A Curtis, P Murphy, N Hart
- P68** A study to investigate the clinical use and outcomes of EZPAP positive pressure device
S Elliott
- P69** A study of the prevalence of hypoxaemia, hypercapnia, hyperoxaemia and acidosis in hospital blood gas specimens (with clinical outcomes)
F Simpson, BR O'Driscoll
- P70** Does meeting the clinical criteria for the systemic inflammatory response syndrome equate to biochemical inflammation following cardiac surgery?
FM Conway, SE Gordon, GJ Quinlan, TW Evans, NS MacCallum
- P71** Relationship between quadriceps rectus femoris cross-sectional area and health related quality of life in patients following critical illness
B Connolly, J Moxham, N Hart

SCIENTIFIC PROGRAMME

- P72** Relationship between quadriceps rectus femoris anatomical cross-sectional area, physiological cross-sectional area and pennation angle in healthy subjects
B Connolly, A Lunt, J Moxham, N Hart
- P73** Epidemiology and long term outcomes of patients with chronic obstructive pulmonary disease admitted to Scottish intensive care units
NI Lone, DA McAllister, KM Rowan, TS Walsh, SH Wild, GD Murray
- P74** Emergency oxygen usage observed by a medical emergency team
J Carr, J Rodrigues, N Duffy, J Earis
- P75** Teaching emergency oxygen prescribing to medical students
J Earis, P Deegan, P Stockton, S McKinnell, R Fewtrell, T Kennedy

3.00pm – 4.30pm

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor and the Mountbatten Lounge, 5th floor (3.15pm – 3.30pm)

3.30pm – 4.30pm

Mountbatten Room, 6th Floor

POSTER DISCUSSION: P76 – P83

Paediatric asthma

Chaired by: Professor Andrew Bush (London) and Professor Michael Shields (Belfast)

- P76** Long-term effectiveness of a staged assessment for problematic severe asthma
J Sharples, A Gupta, L Fleming, CJ Bossley, M Bracken, P Hall, A Hayward, M Puckey, IM Balfour-Lynn, M Rosenthal, A Bush, S Saglani
- P77** Lung clearance index (LCI) in children with severe, therapy resistant asthma (STRA)
S Irving, A Bush, C Bossley, A Gupta, S Saglani
- P78** Lung clearance index in children with acute exacerbation of asthma
HS Sheridan, S Cunningham
- P79** Do children describe the benefits of inhaled asthma therapy in the same way as adults?
FJ Gilchrist, M Brady, K Gallop, DJ Wild, M Tabberer, L Jacques, W Lenney
- P80** A qualitative exploration of the needs and coping strategies of people with severe asthma
EJ Humphreys, DA Campbell, V Knowles, E Wooler, A Caress
- P81** The efficacy of a nurse led, primary care, acute asthma service in reducing short stay hospital admissions
GJ Connett, P Lovegrove, S Lovick, JP Legg

SCIENTIFIC PROGRAMME

- P82** Episodic viral wheeze and multitrigger wheeze – are they really different phenotypes?
E Livingstone, G Noble, G Walsh, S Turner
- P83** Is a single intramuscular dose of triamcinolone and acute bronchodilator sufficient to determine optimal lung function in children with severe therapy resistant asthma?
N Cartledge, S Brown, C Bossley, A Gupta, L Fleming, S Saglani, A Bush

4.15pm – 4.45pm

Churchill Auditorium, Ground Floor

THE PRESIDENT'S ADDRESS

“The Society and the Young Ones: the Speciality and the Special One”

Professor Andrew Greening (Edinburgh)

4.45pm – 5.00pm

Churchill Auditorium, Ground Floor

PRESENTATION OF THE BTS MEDAL

5.00pm – 5.30pm

Churchill Auditorium, Ground Floor

BTS ANNUAL GENERAL MEETING

(BTS members only)

Wednesday 7 December 2011

Thursday 8 December 2011

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 4.00pm

Whittle & Fleming Rooms, 3rd Floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P84–P92

Interstitial lung disease: from bench to bedside and back again

Discussion of abstracts will take place from 12.45pm to 2.10pm in the St James's Suite, 4th floor

P93–P106

Integrated respiratory care

Discussion of abstracts will take place from 1.45pm to 3.30pm in the Abbey Room, 4th floor

P107–P114

Managing asthma: inhaled therapy and beyond

Discussion of abstracts will take place from 2.00pm to 3.00pm in the St James's Suite, 4th floor

P115–P122

Cellular response in the aetiology of COPD

Discussion of abstracts will take place from 3.30pm to 4.30pm in the St James's Suite, 4th floor

P123–P129

Challenges in smoking cessation

Discussion of abstracts will take place from 3.45pm to 4.45pm in the Mountbatten Room, 6th floor

P130–P139

Respiratory physiology: new tools, old concepts

Discussion of abstracts will take place from 4.00pm to 5.15pm in the Abbey Room, 4th floor

P140–P151

Pulmonary rehabilitation: a challenging exercise?

Discussion of abstracts will take place from 4.00pm to 5.30pm in the Elizabeth Windsor Room, 5th floor

P152–P164

Lung cancer: advances in diagnosis and delivery of care

Discussion of abstracts will take place from 4.00pm to 5.45pm in the Westminster Suite, 4th floor

P165–P177

Infections: from vaccination to treatments

Discussion of abstracts will take place from 4.00pm to 5.45pm in the Rutherford Room, 4th floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Pleural disease

Dr Nicholas Maskell (Bristol)

SCIENTIFIC PROGRAMME

8.30am – 10.15am

Churchill Auditorium, Ground Floor

JOINT BTS/BTOG SYMPOSIUM

IS THE EARLIER DIAGNOSIS OF LUNG CANCER FEASIBLE AND WILL IT MAKE ANY DIFFERENCE?

Chaired by: Dr David Baldwin (Nottingham) and Ms Liz Darlison (Leicester)

8.30am Is late diagnosis inevitable? What do patient stories tell us?

Professor Jessica Corner (Southampton)

8.55am Early diagnosis of symptomatic patients: lessons from international comparisons and the NAEDI initiative

Dr Michael Peake (Leicester)

9.20am Experience of an early diagnosis initiative: the Doncaster experience

Dr Trevor Rogers (Doncaster)

9.45am Lung cancer screening: the National Lung Screening Trial

Professor David Lynch (Denver)

8.30am – 10.15am

St James's Suite, 4th Floor

SYMPOSIUM

JOINT BTS/BPRS SYMPOSIUM

THE LONG TERM SEQUELAE OF EARLY LIFE LUNG INSULTS

Chaired by: Dr Charlotte Bolton (Nottingham) and Professor Andrew Bush (London)

8.30am Chronic lung disease of prematurity

Professor Sailesh Kotecha (Cardiff)

8.55am Lung function in the child born extremely preterm – lessons from the EPICure study

Professor Janet Stocks (London)

9.20am The preterm child reaching adulthood

Professor Andrew Bush (London)

9.45am Early life origins of COPD

Professor Peter Burney (London)

8.30am – 10.15am

Westminster Suite, 4th Floor

SPOKEN SESSION: S49 – S54

Cellular studies in obstructive lung disease

Chaired by: Professor Ian Adcock (London) and Professor Linhua Pang (Nottingham)

8.35am **S49**

Increased skeletal muscle-specific microRNA-I in the blood of COPD patients
AVJ Donaldson, A Lewis, A Natanek, WD Man, P Kemp, MI Polkey

SCIENTIFIC PROGRAMME

- 8.50am S50**
Nitrate stress is increased in COPD exacerbations following experimental rhinovirus infection
JIM Footitt, P Mallia, MB Trujillo-Torralbo, A Durham, IM Adcock, SL Johnston
- 9.05am S51**
Reducing intracellular aggregation and improving the secretion of Z α -1 antitrypsin
S Alam, J Wang, S Janciauskiene, R Mahadeva
- 9.20am S52**
Association of microtubule instability with defective phagocytosis in COPD
CMR Thomas, AE Taylor, P Bruijnzeel, JA Wedzicha, PJ Barnes, LE Donnelly
- 9.35am S53**
Alarmins in bronchiolitis obliterans syndrome after lung transplantation
RY Mahida, M Suwara, G Johnson, D Mann, PA Corris, L Borthwick, AJ Fisher
- 9.50am S54**
Polymers of Z α -1-antitrypsin are associated with pulmonary infection post lung transplantation
K Santhanakrishnan, S Alam, J Parmar, R Mahadeva

8.30am – 10.15am

Henry Moore Room, 4th Floor

SPOKEN SESSION: S55 – S60

Clinical and mechanistic studies in thoracic malignancy

Chaired by: Dr Robert Rintoul (Cambridge) and Professor Tariq Sethi (London)

- 8.35am S55**
Cost-effectiveness and quality of life results from the ASTER study: endobronchial and endoscopic ultrasound versus surgical staging in potentially resectable lung cancer
RC Rintoul, JT Annema, KG Tournoy, C Dooms, E Wheaton, V Hughes, A Grant, G Griffith, M Buxton, L Sharples
- 8.50am S56**
EBUS-TBNA prevents mediastinoscopies in patients with isolated mediastinal lymphadenopathy: A prospective clinical trial and cost minimisation analysis
N Navani, DR Lawrence, S Kolvekar, D McAsey, R Omar, S Morris, SM Janes
- 9.05am S57**
Gene expression profiling of endobronchial ultrasound-derived cytological aspirates from hilar and mediastinal lymph nodes in NSCLC
RW Lee, E McClean, A Quinn, R Breen, D Cousins, G Santis

Thursday 8 December 2011

- 9.20am S58**
Beta catenin determines tracheal cell fate and squamous lung cancer progression by modulating intercellular adhesiveness
A Giangreco, L Lu, C Vickers, E Ilieva, K Groot, J George, A Nicholson, E Sage, F Watt, S Janes
- 9.35am S59**
Chemo-immunotherapy of mesothelioma - depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model
HJ Steer, A Cleaver, A Nowak, B Robinson, R Lake
- 9.50am S60**
Mesenchymal stem cells expressing TRAIL induce apoptosis in malignant pleural mesothelioma
E Sage, K Kolluri, A Giangreco, S Janes

8.30am – 10.15am

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S61 – S66

Pleural infection and pneumonia

Chaired by: Dr Nicholas Maskell (Bristol) and Dr Mark Woodhead (Manchester)

- 8.35am S61**
RAPID score – the development of a validated clinical score in pleural infection, to identify at presentation those at risk of poor outcome
NM Rahman, BC Kahan, R Miller, NA Maskell
- 8.50am S62**
Appearances of empyema on computed tomography – analysis of the MIST 2 cohort
JM Franklin, J Purcell-Jones, EJ Helm, R Benamore, NM Rahman, FV Gleeson
- 9.05am S63**
Telehealth in acute community acquired pneumonia: proof of concept and provisional evaluation of impact on hospital length of stay
S Selvaraj, E Davies, C Humphries, KS Srinivasan, H Moudgil
- 9.20am S64**
Understanding better the pathophysiology of aspiration pneumonia
A Vaishnavi, I Satia, D Balasubramanian, R Sundar
- 9.35am S65**
Early supported discharge scheme (ESDS) for pneumonia and lower respiratory tract infection (LRTI) - are there enough suitable patients?
A Collins, S Wilks, D Wootton, A Wright, L Davies, J Hadcroft, S Gordon

Thursday 8 December 2011

9.50am S66

Is hospital readmission an appropriate outcome measure for community-acquired pneumonia?

J Brettell, MA Woodhead

8.45am – 10.30am

Mountbatten Room, 6th Floor

SYMPOSIUM

SARCOIDOSIS

Chaired by: Professor Seamas Donnelly (Dublin) and Dr Toby Maher (London)

8.45am The pathogenesis of sarcoidosis: how genes shape the disease process

Dr Ling-Pei Ho (Oxford)

9.10am Pathogens and sarcoidosis

Professor Seamas Donnelly (Dublin)

9.35am Staging and monitoring pulmonary sarcoidosis: useful and useless viables

Professor Athol Wells (London)

10.00am The changing face of sarcoid therapies

Professor Marc Judson (Charleston)

8.45am – 10.30am

Rutherford Room, 4th Floor

SPOKEN SESSION: S67 – S72

Linking mechanisms to prognosis in pulmonary arterial hypertension

Chaired by: Professor Nicholas Morrell (Cambridge) and Professor Andrew Peacock (Glasgow)

8.50am S67

Characterisation of the endothelial outgrowth cell

M Toshner, ML Ormiston, B Dunmore, J Waters, E McKinney, A Rana, N Morrell

9.05am S68

Inhibition of p38 mitogen activated protein kinase (MAPK) prevents the development of experimental pulmonary hypertension

AC Church, R Wadsworth, G Bryson, DJ Welsh, AJ Peacock

9.20am S69

Serum osteoprotegerin predicts mortality in a prospective study on incident cases of pulmonary arterial hypertension

R Condliffe, J Pickworth, K Hopkinson, A Hameed, S Walker, C Elliot, S Francis, C Newman, D Crossman, A Morton, D Kiely, A Lawrie

9.35am S70

Diagnostic utility and prognostic value of quantitative cardiac MR indices in patients with suspected pulmonary hypertension

AJ Swift, S Rajaram, R Condliffe, D Capener, C Hill, C Davies, J Hurdman, C Elliot, JM Wild, DG Kiely

SCIENTIFIC PROGRAMME

9.50am S71

Influence of age on clinical phenotypes of incident idiopathic pulmonary arterial hypertension. Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland

Y Ling, MK Johnson, D Kiely, R Condliffe, C Elliot, S Gibbs, L Howard, J Pepke-Zaba, K Sheares, P Corris, A Fisher, J Lordan, S Gaine, G Coghlan, J Wort, M Gatzoulis, AJ Peacock

10.05am S72

Prediction of survival in pulmonary arterial hypertension using survival equations. Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland

Y Ling, MK Johnson, D Kiely, R Condliffe, C Elliot, S Gibbs, L Howard, J Pepke-Zaba, K Sheares, P Corris, A Fisher, J Lordan, S Gaine, G Coghlan, J Wort, M Gatzoulis, AJ Peacock

8.45am – 10.30am

Abbey Room, 4th Floor

SPOKEN SESSION: S73 – S78

Cell pathways in lung inflammation and injury

Chaired by: Dr Alison Condliffe (Cambridge) and Dr Gisli Jenkins (Nottingham)

8.50am S73

Macrophages as vehicles for delivering cell therapy to injured lung

K McNulty, CJ Scotton, EK Sage, RC Chambers, SM Janes

9.05am S74

Increased plasma levels of syndecan-1 and sFlt-1 during cardiopulmonary bypass surgery: associations with sRAGE

J Zhang, BC Creagh-Brown, S Mumby, MJ Griffiths, A Burke-Gaffney

9.20am S75

Do 'clinically relevant' tidal volumes really cause ventilator-induced lung injury in mice?

MR Wilson, BV Patel, M Takata

9.35am S76

Proteinase 3 activity in sputum from alpha-1-antitrypsin deficient subjects

NJ Sinden, M Ungurs, R Edgar, P Bharadwa, RA Stockley

9.50am S77

Comparing the degree of inhibition of TNF- α and IL-6 by p38 inhibitors in monocyte derived macrophages (MDMs)

RA Noble, S Patel, I Kilty

SCIENTIFIC PROGRAMME

10.05am S78

Differentiation of monocytes to pro-inflammatory forms is influenced by cigarette smoke and HLA type in COPD
PR Newby, C Schmutz, CR Buckley, RA Stockley, AM Wood

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.30am – 12.15pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

PLENARY SCIENTIFIC SYMPOSIUM

Chaired by: Professor Andrew Fisher (Newcastle upon Tyne) and Professor Moira Whyte (Sheffield)

10.30am Integrins in lung fibrosis: all roads lead to Rho?
Dr Gisli Jenkins (Nottingham)

10.55am Is sunshine the cure for all inflammatory disease?
Dr David Thickett (Birmingham)

11.20am Host-pathogen interactions during pneumococcal pneumonia
Dr Jeremy Brown (London)

11.45am Turning off the fire alarm
Professor Ian Sabroe (Sheffield)

10.30am – 12.15pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S79 – S84

Severe asthma in children and adults

Chaired by: Dr Liam Heaney (Belfast) and Dr Colin Wallis (London)

10.35am S79

Specific functional antibody deficiency is associated with a reduction lung function in the severe asthma population
H Wardman, R Niven, G McCumesky, LJ Holmes, D Menzies, G Tavernier

10.50am S80

Localisation of the site of fixed airflow obstruction in moderate to severe asthma using hyperpolarised helium-3 magnetic resonance imaging
S Gonem, I Ball, S Corkill, D Desai, A Singapuri, P Gustafsson, J Owers-Bradley, C Brightling, S Siddiqui

11.05am S81

Refractory asthma in the UK: a follow-up analysis
J Sweeney, CE Brightling, A Menzies-Gow, RM Niven, LG Heaney

Thursday 8 December 2011

11.20am S82

Fungal sensitisation in children with severe therapy resistant asthma
S Castanhinha, A Gupta, M Maglione, S Koo, C Bossley, L Fleming, A Bush, S Saglani

11.35am S83

Repeatability and inter-relationships of small airway biomarkers
S Gonem, I Ball, S Corkill, D Desai, A Singapuri, P Gustafsson, J Owers-Bradley, C Brightling, S Siddiqui

11.50am S84

Can clinicians accurately predict non-adherence to medication in patients with difficult asthma? A comparison between clinical judgement and prescription issue data
AC Murphy, S Belingheri, CE Brightling, AJ Wardlaw, ID Pavord, P Bradding, RH Green

11.00am – 12.15pm

Abbey Room, 4th Floor

SYMPOSIUM

BLF SUPPORT OF ASBESTOS RELATED DISEASE RESEARCH

Chaired by: Professor Stephen Spiro (London)

11.05am The BLF's Asbestos-related Disease Research Initiative
Dr Sam Janes (London)

11.20am Current asbestos exposures and resulting mesothelioma risks in the UK population
Professor Julian Peto (London)

11.35am Rational targeting of Inhibitor of Apoptosis Proteins (IAPs) for effective therapy of malignant pleural mesothelioma
Dr David Waugh (Belfast)

11.50am GADD34: a potential drug target in malignant mesothelioma
Dr Lucy Dalton (Cambridge)

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor; and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

12.30pm – 1.15pm

Churchill Auditorium, Ground Floor

THE BTS LECTURE

Mechanisms in the development of emphysema

Professor Rubin Tudor (Colorado)
Introduced by: Professor Andrew Greening (Edinburgh)

Thursday 8 December 2011

12.30pm – 1.45pm

Westminster Suite, 4th Floor

OPEN MEETING

BTS/SIGN Asthma Guideline

An update on progress of the Asthma Guidelines and work in relation to patient information.

1.30pm – 2.45pm

Henry Moore Room, 4th Floor

POSTER DISCUSSION: P84 – P92

ILD: from bench to bedside and back again

Chaired by: Dr Helen Parfrey (Cambridge) and Professor Moira Whyte (Sheffield)

P84 BTS National Interstitial Lung Diseases (ILD) Survey 2010-11

OJ Dempsey, S Welham, N Hirani

P85 Mortality trends in asbestosis, extrinsic allergic alveolitis and sarcoidosis in England and Wales

A Hanley, V Navaratnam, RB Hubbard

P86 The assessment of health related quality of life in sarcoidosis with the King's Sarcoidosis Questionnaire (KSQ)

AS Patel, R Siebert, D Creamer, G Larkin, B Gray, AU Wells, IJ Higginson, SS Birring

P87 The needs and experiences of Progressive Idiopathic Fibrotic Interstitial Lung Disease patients, informal caregivers and health professionals - A qualitative study

S Bajwah, J Koffman, IJ Higginson, JR Ross, AU Wells, SS Birring, A Patel, J Riley

P88 Thalidomide as treatment for IPF associated cough

G Saini, T McKeever, S Johnson, G Jenkins

P89 Ambulatory oxygen assessments in COPD and pulmonary fibrosis

K Heslop, C Stenton, C Irving

P90 Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation

AG Rossi, R Duffin, C Haslett, AE Leitch

P91 Are cases of granulomatous common variable immunodeficiency misdiagnosed as sarcoidosis in routine clinical practice?

P Oppong, S Banik, D Derry

P92 C-reactive protein as a predictive indicator of treatment and disease progression in patients with sarcoidosis: a retrospective observational cohort study in the West of Ireland

MJ McDonnell, I Saleem, R Rutherford, A O'Regan, JJ Gilmartin

SCIENTIFIC PROGRAMME

1.45pm – 3.30pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P93 – P106

Integrated respiratory care

Chaired by: Professor Tony Davison (Southend on Sea) and Ms Jane Scullion (Leicester)

P93 Hospital admission avoidance for people with exacerbations of chronic obstructive pulmonary disease (COPD) through collaborative working between Suffolk COPD Services and East of England Ambulance Service

LJ Pearce, M Broad, TB Pulimood, CM Laroche

P94 Transforming acute care in COPD: findings from a national programme of service improvement

C Thompson, P Duncan, C Blackaby, Z Lord, O Okosi, H Wall, A Porter

P95 Cost effectiveness of overnight face-to-face nurse led COPD service

D Green, O Hampson, S Agarwal, S Church

P96 A comparison between community based models of COPD care

PT Flood-Page

P97 Optimising management and improving outcomes in chronic obstructive pulmonary disease by integrating care

EJ Cetti, E Vijaykumar

P98 Improving diagnosis and management of COPD: Learning from a programme of national improvement projects

C Blackaby, Z Lord, C Thompson, A Porter, P Duncan, O Okosi, H Wall

P99* 30-day COPD readmissions relate to disease severity and demographic factors rather than simply organisation and delivery of hospital care

J Hare, E Thompson, K Bodger, P Walker, M Pearson

P100 Designing and implementing a COPD discharge care bundle

NS Hopkinson, C Englebrechtsen, N Cooley, K Kennie, M Lim, T Woodcock, A Lavery, S Wilson, SL Elkin, C Caneja, C Falzon, H Burgess, D Bell, D Lai

P101 A survey of emergency oxygen guideline implementation amongst all 15 UK Ambulance Services in early 2011

FP Moore, AG Davison, J Smith, BR O'Driscoll

P102 A survey of home oxygen provision across London

AC Davidson, S Williams, N Baxter, E Morris, L Restrict

SCIENTIFIC PROGRAMME

- P103** The practice of prescription of long term oxygen therapy to patients who continue to smoke
CKY Lee, J Noble, DA Wales, RM Jones
- P104** Southampton City: Finding The Missing Millions and Reducing Admissions Through Medical Intelligence
SC Bourne, T Wilkinson, H Kruk, K Austin, J Watson, N James
- P105** Direct Access Pulmonary Function Testing for Primary Care
KE Backler, L Leech, M Purdon, D Roberts, Z Lord, RC Buttery
- P106** Reduction of inappropriate oxygen prescriptions by a home oxygen service
AY Yates, CC Chamberlain, HGB Bakere

***BTS Medical Student Highly Commended**

1.45pm – 3.30pm

Mountbatten Room, 6th Floor

SYMPOSIUM

THE AIRWAYS MICROBIOME

Chaired by: Professor Ken Bruce (London) and Professor Stuart Elborn (Belfast)

- 1.45pm** Molecular methodologies for the identification of microorganisms in the airways
Dr Alan Walker (Cambridge)
- 2.10pm** The sputum microbiome in CF; the impact of exacerbations
Professor Stuart Elborn (Belfast)
- 2.35pm** The significance of microbial ecology of the respiratory tract in COPD
Dr Jeremy Brown (London)
- 3.00pm** Where do these bugs come from and what do they mean?
Professor Ken Bruce (London)

1.45pm – 3.30pm

Elizabeth Windsor Room, 5th Floor

SPOKEN SESSION: S85 – S90

Lung cancer: advances in treatment

Chaired by: Dr David Baldwin (Nottingham) and Dr Pallav Shah (London)

- 1.50pm S85**
British Thoracic Oncology Group Trial, BTOG2: randomised phase III clinical trial of gemcitabine combined with cisplatin 50mg/m² (GC50) versus cisplatin 80mg/m² (GC80) versus carboplatin AUC 6 (GCb6) in advanced NSCLC
D Ferry, LJ Billingham, HW Jarrett, D Dunlop, J Thompson, M Kumar, G Skailes, M Nicolson, R Shah, P Leonard, A Chetiyawardana, P Wells, C Lewanski, P Woll, B Crosse, M Hill, S Pirrie, KJ O'Byrne

Thursday 8 December 2011

- 2.05pm S86**
Quality of life in advanced non-small cell lung cancer; effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients
LJ Billingham, P Gaunt, HW Jarrett, D Dunlop, J Thompson, KJ O'Byrne, M Kumar, G Skailes, M Nicolson, R Shah, P Leonard, A Chetiyawardana, P Wells, C Lewanski, P Woll, B Crosse, M Hill, D Ferry
- 2.20pm S87**
Delivered dose intensity of gemcitabine 1250mg/m² with cisplatin at 80mg/m² (GC80) and 50mg/m² (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes
D Dunlop, D Ferry, HW Jarrett, LJ Billingham, J Thompson, M Kumar, G Skailes, M Nicolson, R Shah, P Leonard, A Chetiyawardana, P Wells, C Lewanski, P Woll, B Crosse, KJ O'Byrne
- 2.35pm S88**
Day case cisplatin delivery for advanced NSCLC patients: faster, cheaper, more desirable
H Jarrett, M Hill, LJ Billingham, KJ O'Byrne, D Ferry
- S89 - WITHDRAWN**
A meta-analysis of limited resection versus lobectomy for stage I non-small cell lung cancer
M Matsui, H Takagi, H Yamamoto, S Goto, T Umemoto
- 2.50pm S90**
Nurse specialist input is independently associated with anti-cancer treatment in lung cancer
P Beckett, I Woolhouse, R Stanley, LJ Tata, MD Peake, L Darlinson

2.00pm – 3.00pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P107 – P114

Managing asthma: inhaled therapy and beyond

Chaired by: Dr Donna McShane (Cambridge) and Professor Ian Pavord (Leicester)

- P107** Effectiveness of omalizumab on asthma control and lung function in severe allergic asthma patients in the Czech Republic
V Sedláč

Thursday 8 December 2011

- P108** Omlaizumab for severe allergic asthma: cost-effective or priceless?
J Miles, D Green
- P109** Intravenous aminophylline in the treatment of severe asthma - do we need ECG monitoring?
JGGB Penge, J Hull, K Guha, A Menzies-Gow
- P110** Fluticasone propionate/formoterol fumarate combination therapy is more efficacious in improving lung function than its individual components in patients with asthma
D Price, A Papi, K Kaiser, B Grothe, M Lomax, T McIver
- P111** Fluticasone propionate/formoterol fumarate combination therapy is superior to fluticasone propionate alone in improving asthma control
D Price, A Papi, M Tamm, K Kaiser, B Grothe, M Lomax, T McIver
- P112** Fluticasone propionate/formoterol fumarate combination therapy reduces the risk of exacerbations compared with its individual components in patients with asthma
S Dissanayake, J Sastre, A Papi, K Kaiser, B Grothe, M Lomax, T McIver
- P113** The cost-effectiveness of step down from high dose fluticasone/salmeterol dry powder or suspension formulations in asthma applied to the UK setting
PL Paggiaro, G Buseghin, G Nicolini, S Patel, S Iannazzo, O Zaniolo, A Papi
- P114** Difficult asthma - the Plymouth experience
B Castell, D Pike, M Masoli

2.00pm – 3.30pm

Westminster Suite, 4th Floor

SYMPOSIUM: T1-T6

BTS/BLF/BALR EARLY CAREER

INVESTIGATOR AWARD SYMPOSIUM

Chaired by: Professor Andrew Fisher (Newcastle upon Tyne) and Professor David Lomas (Cambridge)

Judging panel: Professor Andrew Fisher (Newcastle upon Tyne), Dr Sam Janes (London), Professor David Lomas (Cambridge) and Professor Ann Millar (Bristol)

- T1** Matrix metalloproteinase -driven tissue destruction in human tuberculosis (TB) is mediated by Th-17 cytokines and the PI3K/p110a/p70S6K cascade
S Singh, UK Singh, PT Elkington, JS Friedland
- T2** Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis
JD Chalmers, DC Kilpatrick, BJ McHugh, MP Smith, JRW Govan, C Doherty, M Matsushita, SP Hart, T Sethi, AT Hill

SCIENTIFIC PROGRAMME

- T3** Measuring eosinophil kinetics in humans
N Farahi, AM Condliffe, NR Singh, S Heard, RP Simmonds, CK Solanki, K Solanki, KK Balan, AM Peters, ER Chilvers
- T4** Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with cystic fibrosis
G Davies, JC Davies, DR Gill, SC Hyde, C Boyd, JA Innes, DJ Porteous, SH Cheng, RK Scheule, T Higgins, U Griesenbach, EFW Alton
- T5** The KCa3.1 K⁺ channel mediates wound healing in human myofibroblasts
KM Roach, W Coward, C Feghali-Bostwick, SM Duffy, P Bradding
- T6** TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension
AG Hameed, ND Arnold, J Pickworth, JC Chamberlain, CMH Newman, DC Crossman, SE Francis, A Lawrie

2.00pm – 3.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

SLEEP DISORDERS AND THE BRAIN

Chaired by: Dr Mark Elliott (Leeds) and Professor Adrian Williams (London)

- 2.00pm** Narcolepsy – beyond sleepiness
Dr Paul Reading (Middlesbrough)
- 2.25pm** Things that go bump in the night
Dr Paul Cooper (Salford)
- 2.50pm** Restless legs and periodic leg movement disorder
Dr Dev Banerjee (Birmingham)
- 3.15pm** Cerebral vascular function in sleep-disordered breathing – a link to brain pathology?
Professor Douglas Corfield (Manchester)

2.00pm – 3.45pm

Rutherford Room, 4th Floor

SPOKEN SESSION: S91 – S96

COPD: systemic manifestations and cardiovascular disease

Chaired by: Dr Charlotte Bolton (Nottingham) and Dr William Man (Harefield)

- 2.05pm S91** Aspergillus fumigatus sensitisation in patients with chronic obstructive pulmonary disease
M Bafadhel, J Agbetile, A Fairs, D Desai, M Pancholi, V Mistry, ID Pavord, AJ Wardlaw, CH Pashley, CE Brightling

SCIENTIFIC PROGRAMME

- 2.20pm S92**
Cognitive function and cerebral white matter tract microstructure in COPD
JW Dodd, M Van Den Broek, PW Jones, RA Charlton
- 2.35pm S93**
The development of a novel scale to screen and measure anxiety in patients with chronic obstructive pulmonary disease (COPD)
TG Willgoss, AM Yohannes, J Goldbart, F Fatoye
- 2.50pm S94**
Ultrasound measurement of quadriceps wasting in early chronic obstructive pulmonary disease and its relationship with daily physical activity
D Shrikishna, R Tanner, JM Seymour, M Patel, BA Connolly, ZA Puthuchear, SLF Walsh, SA Bloch, PS Sidhu, N Hart, J Moxham, MI Polkey, NS Hopkinson
- 3.05pm S95**
Effect of pulmonary rehabilitation on cardiovascular risk factors in COPD
SSC Kon, AL Clark, KA Ingram, RP Fowler, P Marns, JL Canavan, MS Patel, MI Polkey, WDC Man
- 3.20pm S96**
Survival after the first myocardial infarction is shorter in patients with COPD compared to the general population
JK Quint, E Herrett, A Timmis, H Hemingway, L Smeeth

3.15pm – 4.15pm
COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

- 3.30pm – 4.30pm**
St James's Suite, 4th Floor
POSTER DISCUSSION: P115 – P122
Cellular responses in the aetiology of COPD
Chaired by: Dr John Hurst (London) and Dr Sarah Walmsley (Sheffield)
- P115**
Chronic diesel exhaust particle (DEP) exposure differentially alters monocyte differentiation and function in healthy controls compared to COPD.
N Chaudhuri, H Jary, S Lea, N Khan, LC Parker, D Singh, I Sabroe
- P116**
Testing antioxidant and anti-inflammatory therapies in a complex lung tissue model
TS Singh, FR Razali, MN North, TW Wilkinson, BLN Nicholas

Thursday 8 December 2011

- P117**
3D cryo-electron microscopic analysis of the disease mechanism of a I-antitrypsin deficiency
B Gooptu, Y Chaban, JA Irving, DK Clare, DA Lomas, E Orlova, HR Saibil
- P118**
The role of the retinoic acid pathway in human lung regeneration
J-P Ng-Blichfeldt, M Griffiths, U Griesenbach, B Allen, M Hind
- P119**
Changes in airway and systemic IL-18 levels at exacerbation in COPD patients
AJ Mackay, GC Donaldson, ARC Patel, R Singh, JR Hurst, JA Wedzicha
- P120**
Comparison of cellular inflammation and TLR expression profiles between healthy and COPD subjects
A Keys, T Wilkinson, KJ Staples, M North, S Pink, S Wilson, I Kilty, R Djukanovic, B Nicholas
- P121**
Differential responses of M1 and M2 monocyte-derived macrophage phenotypes in COPD
AJN Ward, KK Chana, CM Thomas, PS Fenwick, LE Donnelly
- P122**
No abstract assigned to this number

3.30pm – 5.15pm

Henry Moore Room, 4th Floor

SPOKEN SESSION: S97 – S102

BMP signalling in pulmonary hypertension

Chaired by: Dr Luke Howard (London) and Dr Allan Lawrie (Sheffield)

- 3.35pm S97**
BMPR2 R899X knock-in mice developed age-related pulmonary hypertension
L Long, X Yang, NW Morrell, M Southwood
- 3.50pm S98**
BMPR-II mutations do not predispose to pulmonary arterial hypertension in a mouse model of schistosomiasis
A Crosby, E Soon, F Jones, M Southwood, B Dunmore, D Dunne, NW Morrell
- 4.05pm S99**
The anti-malarial drug and lysosomal inhibitor, chloroquine, increases cell surface expression of BMPR-II
Bj Dunmore, L Long, XD Yang, A Crosby, NW Morrell
- 4.20pm S100**
The bone morphogenetic protein type II receptor is critical for venous angiogenesis in zebrafish
JE Cannon, CR Bradshaw, JC Smith, NW Morrell

Thursday 8 December 2011

4.35pm **S101**

Heterozygous loss of BMPR-II predisposes to inflammatory cytokine secretion and pulmonary vascular smooth muscle proliferation
E Soon, A Crosby, M Southwood, J Pepke-Zaba, P Upton, NW Morrell

4.50pm **S102**

The crosstalk of PDE inhibitor with BMP signalling pathway in human pulmonary arterial smooth muscle cells
J Yang, X Li, C Wu, N Morrell

3.45pm – 4.45pm

Mountbatten Room, 6th Floor

POSTER DISCUSSION: P123 – P129

Challenges in smoking cessation

Chaired by: Dr Keir Lewis (Swansea) and Dr Louise Restrick (London)

- P123** A retrospective cohort study of the long term effectiveness of smoking cessation counselling
AC Ling, DD Elward, S Barry
- P124** Children unite to stop smoking in cars
I Jarrold, K Huntly, T Turkel
- P125** Stop smoking as treatment for COPD - quit-interventions of higher intensity and duration are required
J Browne, N Aslam, E Jones, B Flint, J Dzingai, G Fabris, J Billett, L Restrick, M Stern
- P126** Does a personalised and non-clinical explanation of lung health trigger the impulse in smokers to make a quit attempt?
JL Roberts, I Houghton
- P127** Improving smoking cessation advice through the implementation of a quality improvement intervention
L Hodgson, A Fairhurst, P Thorburn, AF Frew, SR Doffman
- P128** Smoking cessation educational poster campaign
J Ryder, L Davies, J Bibby
- P129** Report of a respiratory health check in a self-selected group of male prisoners in Suffolk
LJ Pearce, E Cecil, C Phillips, TB Pulimood, CM Laroche

4.00pm - 5.15pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P130 – P139

Respiratory physiology: new tools, old concepts

Chaired by: Mr Martyn Bucknall (London) and Dr Karl Sylvester (Cambridge)

SCIENTIFIC PROGRAMME

- P130** Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients
P Tzani, M Aiello, D Elia, L Boracchia, E Marangio, D Olivieri, E Clini, A Chetta
- P131** CT emphysema score, dynamic hyperinflation and ventilatory efficiency during exercise in patients with COPD
D Elia, N Sverzellati, P Tzani, M Aiello, V Vecchio, E Marangio, A Chetta
- P132** Comparative study of the curvilinear ultrasound probe (CUP) vs. the linear ultrasound probe (LUP) to measure rectus femoris cross sectional area (RFcsa).
S Mandal, B Connolly, E Suh, J Moxham, N Hart
- P133** Lung clearance index is a reproducible and sensitive measure of airways disease in bronchiectasis
S Rowan, J Bradley, M Ennis, A Horsley, N Bell, P Gustafsson, JS Elborn
- P134** Validating structured light plethysmography (SLP) as a non-invasive method of measuring lung function when compared to spirometry
S Alimohamed, K Prosser, C Weerasuriya, R Iles, J Cameron, J Lasenby, C Fogarty
- P135** Maximum Inspiratory Flow measured directly with an Inspiratory Flow Meter compared with measurements from Flow Volume loop traces
MCP Apps, M Skipper, J Skipper, S Basford, V Bryant, J Saines, T Andrews
- P136** Comparison between primary care and secondary care spirometry
KE Backler, L Leech, RC Buttery
- P137** Interpretation of plethysmography in healthy young children
JC Kirkby, R Bonner, S Lum, P Bates, V Morgan, R Strunk, F Kirkham, S Sonnappa, J Stocks
- P138** Evaluation of the need for a comprehensive assessment of lung function pre operatively in the morbidly obese
A Renton, DA Lonsdale, GV Miller, JS White
- P139** The use of venturi masks with oxygen concentrators
JCT Pepperell, C Fraser, G McClue

4.00pm – 5.30pm

Elizabeth Windsor Room, 5th Floor

POSTER DISCUSSION: P140 – P151

Pulmonary rehabilitation: a challenging exercise?

Chaired by: Dr Rupert Jones (Plymouth) and Dr Michael Steiner (Leicester)

SCIENTIFIC PROGRAMME

- PI40** Uptake and completion of pulmonary rehabilitation – the influence of referral source
AL Clark, KA Ingram, RP Fowler, P Marns, SSC Kon, JL Canavan, WD-C Man
- PI41** Unwarranted variation in chronic obstructive pulmonary disease care: provision of pulmonary rehabilitation for Londoners
M Buxton, S Prigmore, K Barnes, A Coombes, S Williams, L Restrict
- PI42** Pedometer and activity monitor step count reliability compared to visual during walking in patients with chronic respiratory disease
LJ Turner, L Houchen, S Singh
- PI43** Exploration of patient activity levels following thoracotomy and lung resection
P Agostini, H Cieslik, B Naidu, S Singh
- PI44** Evaluation of multidisciplinary Pulmonary Rehabilitation education delivered by either DVD or spoken talk
S Ward, L Sewell, S Singh, S Singh
- PI45** Effect of pulmonary rehabilitation on waist circumference and waist-hip ratio
KA Ingram, RP Fowler, AL Clark, PL Marns, MS Patel, SSC Kon, JL Canavan, WDC Man
- PI46** Validation of the COPD assessment test (CAT) in pulmonary rehabilitation: application to a cohort of mixed pulmonary diseases
P Lachapelle, M Brosseau, M Houle-Péloquin, C Poirier
- PI47** Outcomes of pulmonary rehabilitation in severe asthma
J Agbetile, S Singh, P Bradding, I Pavord, R Green
- PI48** The adaptation and evaluation of the Living Well with COPD programme for pulmonary rehabilitation
D Earley, J MacMahon, J Bourbeau, JM Bradley, B O'Neill
- PI49** Piloting and evaluating post-pulmonary rehabilitation (PR) long term exercise (LTE) for COPD patients
SE Roberts, G Kettle, S Rogers, A Segal, S Purcell, G Fabris, H Broomfield, M Calonge-Contreras, J Billet, L Restrict, M Stern
- PI50** Use of ambulatory oxygen therapy in pulmonary rehabilitation
D Anderson, S Ferrer Valls, S Church, S Agarwal
- PI51** Cost of pulmonary rehabilitation is offset by reduction in health care utilization
S Kibe, D Frost, S Hart

Thursday 8 December 2011

4.00pm – 5.45pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

THE ROLE OF INFECTION IN ASTHMA PATHOGENESIS

Chaired by: Professor Madeleine Ennis (Belfast) and Dr Bernard Higgins (Newcastle upon Tyne)

- 4.00pm** The hygiene hypothesis – where are we now?
Professor Erika von Mutius (Munich)
- 4.25pm** Modelling interactions of viruses in asthma
Professor Donna Davies (Southampton)
- 4.50pm** Asthma and fungi
Dr Robert Niven (Manchester)
- 5.15pm** Asthma and bacteria – cause or effect?
Dr Dominick Shaw (Nottingham)

4.00pm – 5.45pm

Westminster Suite, 4th Floor

POSTER DISCUSSION: PI52 – PI64

Lung cancer: advances in diagnosis and delivery of care

Chaired by: Dr Paul Beckett (Leeds) and Dr Sam Janes (London)

- PI52** The National Lung Cancer Audit – Year 6 completeness and outcomes
P Beckett, I Woolhouse, R Stanley, A Yelland, MD Peake
- PI53** Measuring variation in decision making within lung cancer multidisciplinary team (MDT) meetings - a pilot study
JW Donaldson, M Ellis, R Rintoul, DR Baldwin
- PI54** The improving lung cancer outcomes project: a study of the feasibility of a national reciprocal peer review and facilitated quality improvement programme
S Jimenez, L Martin, E Aveling, G Martin, I Woolhouse
- PI55** GP education of the early symptoms of lung cancer: does it improve our earlier diagnosis or staging of lung cancer?
SJ Cooper, S Mandal
- PI56** NAEDI Lung Cancer Awareness Campaign in London
A Safa, A Berry, H Ali, J Car, EF Bowen
- PI57** Follow up of pulmonary nodules: following the Fleischner Radiology Guidelines
S Selvaraj, L Parry, K Garbett, J McAdam, TR Naicker, KS Srinivasan, H Moudgil
- PI58** End of life care for lung cancer; can we identify those in need of support
SM Jones, J Gallagher, T Sweeney, E Pugh, A McIver, V Kelly, MJ Walshaw, M Ledson
- PI59** Rate of chest- x-rays (CXRs) twelve months prior diagnosis of lung cancer
A Dwarakanath, MEJ Callister

Thursday 8 December 2011

- P160** Turning round lung cancer care in Liverpool: a 15 year audit
A Nazir, TA Aljemali, SM Kazmi, D Nazareth, K Mohan, C Smyth, M Ledson, M Walshaw
- P161** Combined I8F-FDG PET/CT as part of a surveillance programme of patients with newly diagnosed pre-invasive endobronchial lesions detects synchronous lung cancers
LJE Smith, I Kayani, J Bomanji, AM Groves, B Carroll, N Navani, JP George, SM Janes
- P162** Comparison of clinical characteristics and outcomes of patients with PET positive versus PET negative solitary pulmonary nodules managed by a Lung MDT
P Malhotra, N Lovell, PK Plant, MEJ Callister, S Karthik, A Scarsbrook
- P163** Factors influencing histological confirmation of diagnosis in lung cancer patients
S Chandramouli, M Cheema
- P164** EGFR mutation prevalence in patients with non-small cell lung cancer: an audit of testing within the North of England Cancer Network
NE Chamberlin, AC Ward

4.00pm – 5.45pm

Rutherford Room, 4th Floor

POSTER DISCUSSION: P165 – P177

Infections: from vaccination to treatments

Chaired by: Dr Jeremy Hull (Oxford) and Dr Mike McKean (Newcastle upon Tyne)

- P165** Non-tuberculosis mycobacterium infection in cystic fibrosis lung disease; effects on bacterial community
R Sattar
- P166** Temporal dynamics of polymicrobial communities in the lower respiratory tract of patients with cystic fibrosis
A Nelson, SJ Bourke, JD Perry, A De-Soyza, SP Cummings
- P167** Screening for viral upper respiratory tract infection in pulmonary exacerbations in cystic fibrosis
RJ José, S Hassan, M Butler, D Watson, L Kuitert
- P168** Eradication of *Burkholderia cepacia* in CF: time for a coordinated approach?
A Horsley, J Govan, AM Jones
- P169** Characteristics and survival of patients without cystic fibrosis (CF), isolating mucoid *P. aeruginosa* (mPA) in sputum samples
R Ahmed, M Denton, I Clifton, D Peckham
- P170** A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK
A Bentley, I Filipovic, K Gooch, K Buesch

SCIENTIFIC PROGRAMME

- P171** Impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood pneumonia seen in hospital in the North East of England
MA Elemraid, KM Eastham, SP Rushton, MDF Shirley, DA Spencer, MF Thomas, F Hampton, R Gorton, K Pollard, AR Gennery, JE Clark
- P172** Changes in pneumococcal serotype distribution of paediatric empyema in the age of pneumococcal conjugate vaccines
MF Thomas, CL Sheppard, M Guiver, RC George, C Simmister, D Cliff, R Gorton, MA Elemraid, JE Clark, SP Rushton, JY Paton, DA Spencer
- P173** Comparison of primary pleural drainage strategies in paediatric empyema
MF Thomas, C Simmister, D Cliff, MA Elemraid, JE Clark, SP Rushton, R Gorton, JY Paton, DA Spencer
- P174** Emergence of pneumococcal serotype 19A as a cause of severe complicated pneumonia with empyema in children in England
DA Spencer, MF Thomas, CL Sheppard, M Guiver, RC George, R Gorton, JY Paton, C Simmister, D Cliff, MA Elemraid, JE Clark, SP Rushton
- P175** Mantoux or gamma interferon (IGRA) – which test is best in children?
C Mount, M Helbert, C Bell, C Murray, F Child
- P176** Does BCG protect against atopic diseases only for a limited time period?
MF Linehan, RM Niven, DN Baxter, TL Frank
- P177** Evolution of lung function in primary ciliary dyskinesia: a two centre retrospective study
M Maglione, A Bush, C Hogg, S Montella, F Santamaria

5.45pm – 7.15pm

Benjamin Britten Lounge, 3rd Floor

**THE PRESIDENT'S RECEPTION –
EARLY CAREER INVESTIGATOR AWARDS,
MEDICAL STUDENT AWARDS AND THE
BTS AWARD FOR MERITORIOUS SERVICE**

SCIENTIFIC PROGRAMME

8.00am – 9.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms, 3rd floor

8.45am – 2.00pm

Whittle & Fleming Rooms, 3rd Floor

POSTER VIEWING

Authors present: 10.00am – 11.00am

P178–P190

Improving the investigation of suspected respiratory disease

Discussion of abstracts will take place from 1.00pm to 2.45pm in the Abbey Room, 4th floor

P200–P208

To wheeze or not to wheeze: is it all asthma?

Discussion of abstracts will take place from 1.30pm to 2.45pm in the Henry Moore Room, 4th floor

P209–P223a

COPD: exacerbations, survival and end of life care

Discussion of abstracts will take place from 1.30pm to 3.30pm in the Westminster Suite, 4th floor

P224–P233

Models of care delivery

Discussion of abstracts will take place from 1.45pm to 3.00pm in the St James's Suite, 4th floor

P234–P243

Improving delivery of care in cystic fibrosis

Discussion of abstracts will take place from 2.00pm to 3.15pm in the Rutherford Room, 4th floor

P244–P251

Acute and chronic respiratory infections

Discussion of abstracts will take place from 2.00pm to 3.15pm in the Elizabeth Windsor Room, 5th floor

P252–P265

COPD and drugs: new and old concepts

Discussion of abstracts will take place from 3.00pm to 4.45pm in the Abbey Room, 4th floor

P266–P276

NIV: COPD, neuromuscular disease and obesity

Discussion of abstracts will take place from 3.30pm to 5.00pm in the Mountbatten Room, 6th floor

8.45am – 2.30pm

Mountbatten Lounge, 5th Floor

MODERATED POSTER VIEWING

P191–P199

Lung cancer: clinical studies

Discussion of abstracts will take place from 1.30pm to 2.30pm in the Mountbatten Lounge, 5th floor

8.15am – 8.45am

Fleet Room, 2nd Floor

THE BTS JOURNAL CLUB

Pulmonary hypertension

Dr Robin Condliffe (Sheffield)

Friday 9 December 2011

8.30am – 10.00am

Churchill Auditorium, Ground Floor

SYMPOSIUM

THE OUTCOMES STRATEGY FOR COPD AND ASTHMA – 'TURNING THE STRATEGY INTO REALITY'

Chaired by: Professor Sue Hill (Chief Scientific Officer, Department of Health) and Dr Robert Winter (National Clinical Director for Respiratory Disease, Department of Health)

8.30am From policy to practice – translating strategy into local delivery
Professor Sue Hill (Chief Scientific Officer, Department of Health) and SHA Respiratory Leads

9.05am Driving quality through data – using data to challenge practice at a local level
Dr Robert Winter (National Clinical Director for Respiratory Disease, Department of Health) and SHA Respiratory Leads

9.40am Research priorities to drive improvement in care and outcomes
Speaker to be confirmed

8.30am – 10.15am

Mountbatten Room, 6th Floor

SYMPOSIUM

RESECTION RATES

Chaired by: Mr John Duffy (Nottingham) and Dr Richard Harrison (Stockton on Tees)

8.30am Lung cancer resection rates in the USA: why are they higher than UK rates?
Dr Keith Naunheim (St Louis)

9.00am UK lung cancer resection rates: a national perspective
Professor Henrik Møller (London)

9.25am UK lung cancer resection rates: a national perspective from the Society of Cardiothoracic Surgeons
Mr Richard Page (Liverpool)

9.50am The role of the multi-disciplinary team in improving lung cancer resection rates in the UK
Mr David Waller (Leicester)

8.30am – 10.15am

Westminster Suite, 4th Floor

SPOKEN SESSION: S103 – S108

Clinical studies in bronchiectasis

Chaired by: Dr Adam Hill (Edinburgh) and Dr Michael Loebinger (London)

8.35am S103 Microbial community composition in the lungs of patients with cystic fibrosis and non-CF bronchiectasis
GG Einarsson, E Klem, AA Fodor, L Wei, M Drain, MC Wolfgang, JS Elborn, MM Tunney

Friday 9 December 2011

- 8.50am S104**
The culture microbiome in the lungs of patients with COPD
GG Einarsson, D Comer, MM Tunney, J S Elborn
- 9.05am S105**
Longitudinal microbiology of adult non-CF bronchiectasis
WA Haja Sahabudeen, DL Smith
- 9.20am S106**
A randomised double blind 13 week crossover trial of hypertonic saline (HTS) (6%) versus isotonic saline (ITS) (0.9%) in patients with bronchiectasis
JM Bradley, K Treacy, B O'Neill, F McCourt, L Green, E Gardner, JS Elborn
- 9.35am S107**
The influence of viral symptoms in infective exacerbations of non-cystic fibrosis bronchiectasis
MP Smith, CJ Doherty, JRW Govan, K Templeton, AT Hill
- 9.50am S108**
Expert consensus on diagnostic criteria and tertiary service requirements for bronchiectasis
J Holme, S Bianchi, I Clifton, A De-Soyza, F Edenborough, D Peckham, O Pirzada, P Walker, M Walshaw, R Niven

8.30am – 10.15am

Henry Moore Room, 4th Floor

SPOKEN SESSION: S109 – S114

ILD mechanisms

Chaired by: Professor Rachel Chambers (London) and Dr David Thickett (Birmingham)

- 8.35am S109**
Contribution of aberrant monocyte-natural killer T (NKT) cell axis to immune-pathology in sarcoidosis
AP Crawshaw, WL Kok, L Denney, L-P Ho
- 8.50am S110**
Targeted deletion of Gα_q/Gα₁₁ in surfactant protein C-positive epithelial cells reduces TGFβ activation and results in inflammation and alveolar airspace enlargement
AE John, A Habgood, J Porte, A Tatler, L Jolly, S Offermanns, RG Jenkins
- 9.05am S111**
The role of TNF-related apoptosis inducing ligand (TRAIL) in pulmonary fibrosis
EE McGrath, A Lawrie, H Marriott, PF Mercer, SS Cross, RC Chambers, DH Dockrell, MKB Whyte

SCIENTIFIC PROGRAMME

- 9.20am S112**
TNF-RI ubiquitous scaffolding and signalling protein (TRUSS) is a regulator of TNF-alpha induced NF-kappa-B activation
AJ Langton, I Horan, S Farrow, DW Riches, ER Chilvers, H Parfrey
- 9.35am S113**
The Influenza virus activates TGFβ via an αVβ6-integrin mediated pathway
AS Stavrou, LJ Jolly, JP Porte, PW Weinreb, AT Tatler, AJ John, AK Knox, SV Violet, TH Hussel, SK Kuchipudi, SD Dunham, GJ Jenkins
- 9.50am S114**
Lymphatic vessel distribution in fibrotic lung diseases
EA Renzoni, E Weber, F Sozio, A Rossi, AU Wells

8.30am – 10.15am

Abbey Room, 4th Floor

SPOKEN SESSION: S115 – S120

Respiratory muscles, exercise and ventilation

Chaired by: Professor John Gibson (Newcastle upon Tyne) and Professor John Moxham (London)

- 8.35am S115**
The Effect of Posture on the 2nd Intercostal Space Surface Parasternal Electromyogram (EMGpara): Validating A Novel Clinical Tool to Measure Neural Respiratory Drive
MC Ramsay, E-S Suh, S Mandal, P Murphy, J Steier, A Simonds, N Hart
- 8.50am S116**
Parasternal muscle electromyography (EMGpara) reflects observed changes in dynamic hyperinflation during acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
E Suh, M Ramsay, S Mandal, E Boleat, B Christian, K Henderson, P Murphy, J Moxham, N Hart
- 9.05am S117**
Respiratory muscle fatigue following exercise in patients with interstitial lung disease
D Elia, JL Kelly, D Martolini, E Renzoni, AK Boutou, A Chetta, MI Polkey, NS Hopkinson
- 9.20am S118**
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI
H Marshall, MH Deppe, J Parra-Robles, S Hillis, C Billings, SR Miller, JH Watson, J Wolber, DA Lipson, R Lawson, JM Wild
- 9.35am S119**
UK HOT-HMV Trial: acceptability and tolerability of high pressure domiciliary non-invasive ventilation (NIV) in COPD
PB Murphy, J Moxham, MI Polkey, N Hart

SCIENTIFIC PROGRAMME

9.50am S120

Reference values for the incremental shuttle walking test in a healthy population
SL Harrison, NJ Greening, L Houchen, JEA Williams, M Morgan, M Steiner, SJ Singh

8.45am – 10.15am

Elizabeth Windsor Room, 5th Floor

BTS/UKRRC SYMPOSIUM

MRC/ABPI COPD CONSORTIUM

Chaired by: Professor Chris Brightling (Leicester)

8.45am Phenotyping COPD

Dr David Singh (Manchester)

9.05am Mechanisms, impact and therapeutic targeting of bacterial colonisation in COPD

Professor Peter Barnes (London)

9.25am Lung injury and repair in COPD

Professor Alan Knox (Nottingham)

9.45am Targeting skeletal muscle mass and function in COPD

Professor Michael Polkey (London)

8.45am – 10.30am

St James's Suite, 4th Floor

SPOKEN SESSION: S121 – S126

Mast cells, smooth muscle and inflammation in asthma

Chaired by: Professor Ian Hall (Nottingham) and Professor Ashley Woodcock (Manchester)

8.50am S121

Mediator profiling of severe asthma phenotypes
D Desai, CJ Newby, P Haldar, S Shah, S Gupta, M Bafadhel, A Singapuri, S Siddiqui, J Woods, A Herath, I K Anderson, P Bradding, RH Green, AJ Wardlaw, ID Pavord, RD May, CE Brightling

9.05am S122

Sputum cytokine profiles in asthma and the impact of smoking—a factor analysis
M Spears, C Dewet, C McSharry, R Chaudhuri, I Donnelly, L Jolly, E Cameron, NC Thomson

9.20am S123

The effect of rhinovirus infection on cough receptors on human sensory nerve and human primary bronchial epithelial cells
H Abdullah, SL Cosby, L Heaney, L McGarvey

9.35am S124

RAGE is expressed by human airway smooth muscle cells and expression is increased in asthma
L Di Candia, E Gomez, J Challiss, CE Brightling, R Saunders

Friday 9 December 2011

9.50am S125

Potential interactions of CRACM ion channels with the calcium activated potassium channel KCa3.1 in human lung mast cells
I Ashmole, M Patel, SM Duffy, M Leyland, P Bradding

10.05am S126

The cell adhesion receptor CADMI regulates other adhesion receptors in human mast cells
EP Moiseeva, ML Leyland, P Bradding

10.00am – 11.00am

COFFEE/TEA will be served in the Whittle & Fleming Rooms and Benjamin Britten Lounge, 3rd floor

10.15am – 12.00pm

Henry Moore Room, 4th Floor

SPOKEN SESSION: S127 – S132

Lung infections: mechanisms of disease

Chaired by: Professor David Dockrell (Sheffield) and Professor John Simpson (Newcastle upon Tyne)

10.20am S127

Anti-protein serological responses to Streptococcus Pneumoniae, in diverse populations
RJ Wilson, JM Cohen, C Hyams, WJ vanWamel, C de Vogel, A van Belkum, SB Gordon, JS Brown

10.35am S128

Highly invasive capsular serotypes of Streptococcus pneumoniae bind high levels of Factor H and are resistant to complement and phagocytosis
C Hyams, K Trzcinski, DM Weinberger, M Lipsitch, JS Brown

10.50am S129

Neutrophil function and advancing age: the effects of Simvastatin in health and during pneumonia
E Sapay, H Greenwood, J Hazeldine, G Walton, D Thickett, JM Lord, RA Stockley

11.05am S130

HIV-1 infection of macrophages dysregulates pro-inflammatory host responses to Mycobacterium tuberculosis through inhibition of IL10
GS Tomlinson, PTG Elkington, L Bell, NF Walker, J Tsang, J Brown, R Breen, M Lipman, DR Katz, RF Miller, BM Chain, M Noursadeghi

11.20am S131

Human macrophage model of biomass smoke exposure shows impaired ingestion of S. pneumoniae
AN Aljurayyan, DG Fullerton, S Barrett, SB Gordon

Friday 9 December 2011

11.35am S132

Investigating the role of Pellino 1, an E3 ubiquitin ligase, in modulating signalling pathways controlling the inflammatory response.

JA Bennett, LR Prince, CA Stokes, LC Parker, MK Whyte, I Sabroe

10.30am – 11.15am

Elizabeth Windsor Room, 5th Floor

UPDATE SESSION

NIHR RESPIRATORY FUNDING OPPORTUNITIES

Dr David King (Director, NIHR Central Commissioning Facility)

10.30am – 12.00pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

PHYSIOLOGY OF THE ELITE ATHLETE: THE LEAD UP TO LONDON 2012

Chaired by: Professor Richard Casaburi (Los Angeles) and Dr Michael Steiner (Leicester)

10.30am Exercise physiology in the elite performance athlete

Professor Ron Maughan (Loughborough)

10.55am The management of asthma in elite athletes

Dr Louis-Philippe Boulet (Québec)

11.30am Exercise and ageing. What can we learn from master athletes?

Professor Stephen Harridge (London)

10.30am – 12.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

SECONDARY PULMONARY HYPERTENSION

Chaired by: Dr David Kiely (Sheffield) and Professor Andrew Peacock (Glasgow)

10.30am COPD and pulmonary hypertension

Professor Ardeschir Ghofrani (Giessen)

10.55am Pulmonary hypertension and left heart disease

Professor Jean-Luc Vachiéry (Brussels)

11.20am Interstitial lung disease and secondary pulmonary hypertension

Dr John Wort (London)

11.45am Will generics affect the provision of specialist care?

Dr Luke Howard (London)

10.30am – 12.15pm

Westminster Suite, 4th Floor

SPOKEN SESSION: S133 – S138

ILD: clinical studies

Chaired by: Dr Nik Hirani (Edinburgh) and Dr Lisa Spencer (Liverpool)

SCIENTIFIC PROGRAMME

10.35am S133

The assessment of health related quality of life in interstitial lung disease with the King's brief interstitial lung disease questionnaire (K-BILD)

AS Patel, R Siegert, K Brignall, G Keir, S Bajwah, SR Desai, AU Wells, IJ Higginson, SS Birring

10.50am S134

High prevalence of ischaemic heart disease (IHD) in patients meeting clinico-radiological profile for idiopathic pulmonary fibrosis (IPF)

LEE Schomberg, A Draper, I Vlahos, A Devaraj, A Nair, F Chua

11.05am S135

A retrospective multi-centre study of the effects of allogeneic haematopoietic stem cell transplantation on pulmonary function

RT Dharmagunawardena, RM Pearce, J Lee, JF Apperley, T Littlewood, KM Wilson, K Orchard, G Jackson, JA Snowden, K Kirkland, G Cook, R Hubbard, J Brown

11.20am S136

The association between cough reflex sensitivity and serum angiotensin-converting enzyme level in patients with sarcoidosis

A Sinha, KK Lee, AS Patel, GF Rafferty, AU Wells, SS Birring

11.35am S137

The natural history of IPF in patients eligible for clinical trials versus patients not eligible

P Macfarlane, ZH Hoo, RLS Hammersley, CM McErlean, S Anpalakhan, GA Stewart, WA Wallace, JT Murchison, AJ Simpson, N Hirani

11.50am S138

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole

L Shulgina, A Cahn, E Chilvers, H Parfrey, A Clark, E Wilson, O Twentyman, T Davison, J Curtin, A Wilson

10.30am – 12.30pm

Abbey Room, 4th Floor

SPOKEN SESSION: S139 – S144a

Pathophysiology and management of cough

Chaired by: Dr Surinder Birring (London) and Dr Omar Usmani (London)

10.35am S139

Cough responses to tussive agents in health and disease

S Khalid, R Dockry, K Holt, H Sumner, D Valdramidou, MA Birrell, MG Belvisi, A Woodcock, JA Smith

SCIENTIFIC PROGRAMME

- 10.50am S140**
Predictors of 24-hour cough frequency in acute cough
KK Lee, S Matos, DH Evans, ID Pavord, SS Birring
- 11.05am S141**
TRPA1 expression and characterisation in patients with chronic cough
S Faruqi, A Campbell, AH Morice
- 11.20am S142**
Investigating patterns in twenty-four hours of coughing
RJ Dockry, K Sunger, P Marsden, A Kelsall, S Decalmer, W Powley, R Murdoch, A Woodcock, JA Smith
- 11.35am S143**
The sensations provoking cough: a qualitative investigation
F Solari, K Sunger, J Yorke, A Caress, JA Smith
- 11.50am S144**
Acute cough: a longitudinal observational study
KK Lee, S Matos, DH Evans, ID Pavord, SS Birring
- 12.05pm S144a**
Endogenous inhibition of experimentally induced cough in healthy subjects
EC Young, LA Houghton, KJ Holt, AA Woodcock, JA Smith

10.45am – 12.30pm St James's Suite, 4th Floor SYMPOSIUM

'LATE BREAKING NEWS' SYMPOSIUM – THE BEST OF BRITISH AUDITS

Chaired by: *Dr Christine Bucknall (Glasgow)*

- 10.45am** Introduction
Dr Christine Bucknall (Glasgow)
- 10.50am** National adult NIV audit
Dr Craig Davidson (London)
- 11.10am** National bronchiectasis audit
Dr Adam Hill (Edinburgh)
- 11.30am** ERS COPD audit update
Professor Michael Roberts (London)
- 11.50am** Making improvement a reality following audit
Mrs Catherine Blackaby (NHS Improvement – Lung) and Dr James Calvert (Bristol)
- 12.30pm** BTS audit and quality improvement – future plans
Dr Christine Bucknall (Glasgow)

12.15pm – 2.00pm

LUNCH will be available to purchase in the Cafe in the Pickwick Suite, 1st floor, and the Snack Bar in the Whittle & Fleming Rooms, 3rd floor

Friday 9 December 2011

12.30pm – 1.15pm Churchill Auditorium, Ground Floor THE MORAN CAMPBELL LECTURE Lung physiology and advances in COPD research

Professor Richard Casaburi (Los Angeles)

Introduced by: Professor Michael Morgan (Leicester)

12.30pm – 1.15pm Rutherford Room, 4th Floor OPEN MEETING COMPREHENSIVE CLINICAL RESEARCH NETWORKS

Chaired by: *Professor Peter Calverley (Liverpool)*

- 12.30pm** Wading through the jargon! How to get more involved in UK-CRN trials
Professor Peter Calverley (Liverpool)

- 12.45pm** A recruitment success story from the North East
Dr Tony de Soyza (Newcastle upon Tyne)

- 1.00pm** Question and answer session

1.00pm – 2.45pm Abbey Room, 4th Floor POSTER DISCUSSION: P178 – P190 Improving the investigation of suspected respiratory disease

Chaired by: *Dr Mohammed Munavvar (Preston) and Dr Suveer Singh (London)*

- P178** The effect of BAL induced inflammation on nasal innate defence – reduction in experimental human pneumococcal carriage
AD Wright, JF Gritzfeld, S El Batrawy, L Roche, A Collins, SB Gordon
- P179** The changing numbers and indications of mediastinoscopy procedures performed following the introduction of endobronchial ultrasound at a UK tertiary centre
M Bahir, R Breen, A Quinn, J King, G Santis
- P180** Electromagnetic navigation bronchoscopy as a diagnostic method in respiratory medicine – early clinical experiences
S George, C Priegnitz, N Anduleit, W Randerath
- P181** Complications from CT guided lung biopsies and risk factors for pneumothorax
Z Sheikh, E Woo, T Meagher
- P182** Utility of PET/CT reporting in lung cancer
SM Kazmi, S Sureshkumar, A Nazir, D Nazareth, J Greenwood, M Ledson, M Walshaw
- P183** Comparison of patient satisfaction between endobronchial ultrasound and flexible bronchoscopy performed under conscious sedation: a prospective study
S Huq, C Smyth, S Kazmi, T Giles, M Walshaw, S Binukrishnan, K Mohan

Friday 9 December 2011

- P184** Identifying learning strategies used by respiratory trainees in bronchoscopy
S Wiscombe
- P185** An evaluative study of breath sounds teaching
CF Ramsay
- P186** The reliability of the respiratory physical examination
M Newnham, E Jones, D Wall, R Mukherjee
- P187** Does greater physician involvement with interventional procedure coding improve coding outcome?
ARL Medford, A Pillai
- P188** Impact of ward based chest ultrasound on the radiology department
H Lockman, NJ Withers
- P189** Evaluation of the role of cardio-pulmonary exercise testing in the diagnosis of unexplained breathlessness
JER Thing, B Mukherjee, K Murphy, H Tighe, L Howard
- P190** Long-term outcome of bronchial artery embolisation (BAE) for massive haemoptysis
A Adlakha, R Rupta, A Sebastian, P Tait, J Jackson, P Ind

1.30pm – 2.30pm

Mountbatten Lounge, 5th Floor

POSTER DISCUSSION: P191 – P199

Lung cancer: clinical studies

Chaired by: Mr Eric Lim (London) and Dr Michael Peake (Leicester)

- P191** A meta-analysis of adjusted and unadjusted observational studies of sleeve lobectomy versus pneumonectomy for non-small cell lung cancer
H Yamamoto, H Takagi, S Goto, M Matsui, T Umemoto
- P192** Short-term outcome of attempted curative resection for lung cancer in elderly patients
A Nazir, S M Kazmi, D Nazareth, J Greenwood, M Ledson, M Walshaw
- P193** Assessment of performance status in lung cancer – do oncologists and respiratory physicians agree?
C Addy, J Suntharalingam, E De Winton, V Masani, G Taylor
- P194** Why do lung cancer patients still die in hospital?
Mark Weir, L Magowan, M Doherty, R Sharkey, M Mc Closkey, M Kelly, JG Daly
- P195** Outcomes in emergency admissions with lung cancer: a one-year perspective from a teaching hospital
HK Morgan, L Hodgson, E Baldock, SR Doffman

SCIENTIFIC PROGRAMME

- P196** The cost effectiveness of PET scans in the radical treatment of lung cancer patients in a district general hospital
C Wotton, K Allen, V Masani
- P197** PET-FDG staging for lung cancer: outcome of high uptake FDG at extrathoracic sites
S Selvaraj, K Garbett, J McAdam, TR Naicker, KS Srinivasan, H Moudgil
- P198** Is there a role for MRI cranial imaging in patients with non-small cell lung cancer being considered for radical treatment?
D Laws, K Adeniji, N Ranaweera
- P199** A study of symptoms and pathways to treatment in lung cancer patients
U Darnedde, R Banham, Z Tasigiannopoulos, T Roques, A Wilson, A Clark, C Martin

1.30pm – 2.45pm

Henry Moore Room, 4th Floor

POSTER DISCUSSION: P200 – P208

To wheeze, or not to wheeze: is it all asthma?

Chaired by: Dr Bernard Higgins (Newcastle upon Tyne) and Dr Andrew Menzies-Gow (London)

- P200** Use of hypertonic saline in bronchoprovocation for the diagnosis of bronchial asthma
SM Abdullah Al Mamun
- P201** No abstract assigned to this number
- P202** Impact study of 243 indirect bronchial provocation tests with mannitol in the diagnosis and management of asthma.
IA Du Rand, L O'Reilly, D Wilson
- P203** Correlation of Nijmegen score and hospital anxiety/depression (HAD) score in dysfunctional breathlessness
A Dwarakanath, V Davison, CM Taylor, AG Fennerty
- P204** The burden of repeated asthma admissions and associations with psychiatric comorbidity
H Burke, Z Pond, C Duffus, RJ Kurukulaarachy
- P205** Managing the challenges of recruitment of patients with asthma to randomised controlled trials.
D Morrison, E Cameron, G Braganza, NC Thomson, R Chaudhuri, FS Mair
- P206** Psychological comorbidity in vocal cord dysfunction
E Gregson, S Campbell, S Lillie, R Stacey, J Haines, S Fowler, A Vyas
- P207** Does the Nijmegen correlate to the D12 when used as an outcome measure in patients with breathing pattern dysfunction?
R Johnston, F Shaw, A Menzies Gow, L Flude
- P208** Obesity augments circulating neutrophil levels in asthma
MC Pynn, G Davies, CA Thornton, A Bryant, R Jones

SCIENTIFIC PROGRAMME

1.30pm – 3.15pm

Mountbatten Room, 6th Floor

SYMPOSIUM

WALKING THE TRANSLATIONAL PATHWAY TO NEW IPF THERAPIES

Chaired by: Professor David Lynch (Denver) and Professor Athol Wells (London)

- 1.30pm** Key mediators in the pathogenesis of IPF
Dr Thomas Wynn (Bethesda)
- 1.55pm** Moving from targets to treatments
Dr Andrew Blanchard (GlaxoSmithKline)
- 2.20pm** IPF clinical studies: trials and tribulations
Professor Richard Hubbard (Nottingham)
- 2.45pm** Getting new treatments to patients: what are the service implications?
Dr Nik Hirani (Edinburgh)

1.30pm – 3.30pm

Westminster Suite, 4th Floor

POSTER DISCUSSION: P209 – P223a

COPD: exacerbations, survival and end of life care

Chaired by: Dr Sarah Elkin (London) and Dr Hilary Pinnock (Whitstable)

- P209** Risk factors for respiratory exacerbations in the BOLD study
L Gnatiuc, S Coton, S Buist, B Kato, P Mejza, P Burney
- P210** Which symptoms prompt patients with an exacerbation of COPD to persevere, self-treat or seek care? A comparison with health professionals
JS Wilson, JJ Sittlington, E McCrum-Gardner, F Kee, JS Elborn
- P211** Exacerbation frequency and maintenance treatment of COPD in UK clinical practice
M Thomas, A Radwan, C Stonham, S Marshall
- P212** The DECAF score: predicting in-hospital mortality in acute exacerbations of COPD
J Steer, GJ Gibson, SC Bourke
- P213** Longitudinal changes in the rate and mean age of incidence and prevalence of COPD in the UK, 2000-2009
G James, I Petersen, G Donaldson, W Wedzicha
- P214** Acute exacerbations of COPD - a review of resuscitation status and associations with prognostic factors in hospital admissions
B Rudran, L Idris, C Childs, F Riccio, S Loganathan, TJ Shaw
- P215** The effect of oxygen prescription at hospital discharge on re-admission rates in chronic obstructive pulmonary disease (COPD)
R Mukherjee, M Kotska, JA Brebner, R Rashid, B Chakraborty, Y Khan, P Sweeney, PS Burge

Friday 9 December 2011

- P216** Recruiting COPD inpatients to clinical research: recent experience from interventional and observational studies
AW Hitchings, JW Dodd, PW Jones, EH Baker
- P217** Factors affecting patient satisfaction in a COPD research cohort
BS Kowlessar, ARC Patel, GC Donaldson, AJ Mackay, JR Hurst, JA Wedzicha
- P218** Recording of COPD mortality must improve if it is to be a robust outcome measure
S Ansari, M Ali, DJ Powrie, KG Lingam, AG Davison
- P219** Ten year mortality in a primary care COPD cohort: multidimensional index BOD more discriminant than GOLD staging
NP Keaney, K Ansari, J Munby, M Price, A Kay, IK Taylor
- P220** Transfer factor and arterial oxygen partial pressure are predictors of survival in hospital outpatients with COPD
AK Boutou, D Shrikrishna, RJ Tanner, C Smith, JL Kelly, G Coissi, MI Polkey, NS Hopkinson
- P221** Advance care planning in chronic obstructive pulmonary disease: a qualitative study of patients' views
A MacPherson, C Walshe, V O'Donnell, A Vyas
- P222** Multi-disciplinary team attitudes towards end-of-life care in severe COPD
B Turnpenny, K Shepherd, R Barraclough, C Haskins
- P223** End of life discussion in pulmonary rehabilitation: too scary or worth a try?
S Robinson, L Wilson, M Qayoom, S Dawson, L Killeen, T Shturova, IS Patel
- P223a** Increasing the quality of COPD case finding, diagnosis and management through a primary care financial incentive scheme in inner London
M Calonge Contreras, J Billett, L Restricks, K Sennett, C Cooper, M Stern

1.45pm – 3.00pm

St James's Suite, 4th Floor

POSTER DISCUSSION: P224 – P233

Models of care delivery

Chaired by: Dr Martin Allen (Stoke on Trent) and Dr Michael Ward (Sutton-in-Ashfield)

- P224** The impact of implementing a collaborative antimicrobial ward round model within the Respiratory Directorate of a large university teaching hospital
SE Oliver, E Hughes, P Lal, DC Lees, RP Cooke, B Chakrabarti

Friday 9 December 2011

- P225** The post pandemic influenza experience in a busy district general hospital
R Taylor, A Graham, N Martin
- P226** Managing suspected pulmonary embolism in an ambulatory setting: The Leicester experience.
RM Ladwa, E Bailie, Y Vali, RH Green, JA Bennett, CM Free
- P227** Development of a preliminary questionnaire for the identification of vocal cord dysfunction
VW Cheng, B Chesworth, S Lillie, J Haines, P Constantinou, SJ Fowler
- P228** An audit of the effectiveness of competency based spirometry training
J Shakespeare, K Storey, D Parr
- P229** Factors affecting inhaler choice and adherence in urban Liverpool
G Tack, E Tjia-Leong, L Davies, CJ Warburton
- P230** Do we need a 'two week rule' referral pathway for lung cancer?
MH Ali, Berry A, J Van Griethuysen, H Peters, A Jameel, G Haji, F Shora, MP Berry, EF Bowen
- P231** 'Safety-net' for abnormal chest radiographs with a low index of suspicion for malignancy
C Wall, P Arora, PM Turkington, R Chisholm, PM Turkington
- P232** Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community
S Ghosh, NO Kelly, J Smith, J Dexter, C Carroll-Hawkins, W Robertson
- P233** Judicious use of oximetry can help deliver cost effective sleep service
CL Collins, B Balakrishnan, J Madieros

1.45pm – 3.30pm

Churchill Auditorium, Ground Floor

SYMPOSIUM

PATHOPHYSIOLOGY OF CRITICAL CARE-ACQUIRED WEAKNESS

Chaired by: Dr Stephen Brett (London) and Dr Nicholas Hart (London)

- 1.45pm** Clinical aspects of critical care-acquired weakness: epidemiology, aetiology and consequences
Dr Tarek Sharshar (Paris)
- 2.10pm** Sepsis and mitochondrial function
Professor Mervyn Singer (London)
- 2.35pm** Muscle signalling and protein turnover
Professor Michael Rennie (Nottingham)
- 3.00pm** An unplanned ICU experience
Dr Laura Price (London)

SCIENTIFIC PROGRAMME

2.00pm – 3.15pm

Rutherford Room, 4th Floor

POSTER DISCUSSION: P234 – P243

Improving delivery of care in cystic fibrosis

Chaired by: Dr Mary Carroll (Southampton) and Professor Stuart Elborn (Belfast)

- P234** The importance of appropriate reference equations for spirometry: lessons learned from the cystic fibrosis gene therapy 'run-in' study
G Davies, AJ Simpson, KJ Bayfield, MJ McGovern, MA Embley, HS Sheridan, C Saunders, MH Dewar, S Cunningham, EFWF Alton, JA Innes, JC Davies
- P235** A UK registry study of prophylactic antibiotic use for *Staphylococcus aureus* in children with cystic fibrosis
DKH Lo, MH Hurley, A Prayle, AR Smyth
- P236** Cystic fibrosis deaths in US and UK: comparisons of registry and routine data
F Chowdhury, MJ Wildman, E Gunn, D Bilton
- P237** Does desaturation on exercise predict nocturnal hypoxia in children with cystic fibrosis?
J Keating, N Collins, M Rosenthal, A McKee, D Urquhart
- P238** Prescription issue data as a measure of adherence with nebulised therapy in an adult cystic fibrosis centre
PI Wilson, SP Range, AC Murphy
- P239** Radiation exposure in adults with cystic fibrosis
P Milburn-McNulty, D Nazareth, M Ledson, J Greenwood, MJ Walshaw
- P240** Pneumothorax management in cystic fibrosis patients
J Gallagher, S Chandramouli, D Nazareth, K Mohan, M Ledson, MJ Walshaw, J Greenwood
- P241** Accucheck (TM) measurement of blood glucose correlates with true lab glucose measurement in children screened for cystic fibrosis related diabetes
AJ Fall, A Mallinson, A Mill, DS Urquhart
- P242** Bone density and testosterone levels in male cystic fibrosis patients
B Marson, C Valsalakumari, L Speight, J Platts, L George, RI Ketchell, J Duckers
- P243** Anxiety and depression in adolescents and adults with cystic fibrosis
V Fainardi, E Iacinti, F Longo, MC Tripodi, G Pisi

2.00pm – 3.15pm

Elizabeth Windsor Room, 5th Floor

POSTER DISCUSSION: P244 – P251

Acute and chronic respiratory infections

Chaired by: Dr Jeremy Brown (London) and Dr Michael Loebinger (London)

SCIENTIFIC PROGRAMME

- P244** Risk stratification of flu in post-pandemic winter 2010
CM Orton, E Wong, P De, W McAllister
- P245** Can clinical, radiological or laboratory parameters differentiate H1N1 associated pneumonia from community acquired pneumonia?
GE Hayes, CD Sheldon, BD Patel
- P246** Airway and systemic inflammation in stable and exacerbated bronchiectasis: a pilot study
R Chitkara, H Batchelor, Rj Sapsford, S Workman, ARC Patel, AJ Mackay, B Grimbacher, JR Hurst
- P247** The respiratory phenotype of the BBS4 null mouse lung
M Cho, P Beales, M Hind, R Quinlan
- P248** Associations of depression, fatigue and quality of life in adult non-CF bronchiectasis
H Batchelor, S Brill, JS Brown, JR Hurst
- P249** Assessment of health related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis using a new disease-specific tool for measuring HRQoL: the Quality of Life-Bronchiectasis (QOL-B) questionnaire
AR McCullough, CM Hughes, M Tunney, JS Elborn, JM Bradley
- P250** Mycoplasma pneumonia. Presenting features and diagnosis in our district general hospital in 2010
KS Caldwell, R Johns, L Teare, HS Jenkins
- P251** Junior doctors' interpretation of CXRs is more consistent than consultants in the context of possible pneumonia
B Singh, J Curtis, SB Gordon, PJ Diggle, DG Wootton

3.00pm – 4.45pm

Abbey Room, 4th Floor

POSTER DISCUSSION: P252 – P265

COPD and drugs: new and old concepts

Chaired by: Dr Charlotte Bolton (Nottingham) and Professor Peter Calverley (Liverpool)

- P252** Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial
A D'Urzo, JA van Noord, C Martin, R Horton, D Banerji, Y Lu, VKT Alagappan, T Overend
- P253** NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24-hours: the GLOW1 trial
T D'Urzo, G Ferguson, C Martin, VKT Alagappan, D Banerji, Y Lu, R Horton, T Overend

Friday 9 December 2011

- P254** NVA237 once daily improves exercise endurance in patients with COPD from the first dose: the GLOW3 trial
D Singh, K Beeh, A Drollmann, L Di Scala, R Smith
- P255** ATTAIN: twice-daily acclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease
D Singh, PW Jones, ED Bateman, A Agusti, R Lamarca, G de Miquel, C Caracta, E Garcia Gil
- P256** Acclidinium bromide: a phase IIb, dose-finding study
D Singh, H Magnussen, A Kirsten, S Mindt-Pruefert, C Caracta, D Jarreta, E Garcia Gil
- P257** Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD
PM Short, PA Williamson, BJ Lipworth
- P258** Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD
SM Abdullah Al Mamun, S Rahman
- P259** Effects of metformin on clinical outcome in patients hospitalised for COPD exacerbations: a retrospective cohort study
AW Hitchings, L Hayes, G Picton, L Turner, R Cull, S Aslam, JRH Archer, SA Srivastava, EH Baker
- P260** Oral nutritional supplements in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis
PF Collins, RJ Stratton, M Elia
- P261** Does the provision of a rescue pack keep patients with chronic obstructive pulmonary disease (COPD) at home?
LEE Schomberg, JL Garner, JW Porter, K Bahadur, L Ross, CA Kosky, AC Davidson
- P262** Oramorph for breathlessness: in pursuit of guidelines and patient information for use in COPD
A Williamson, L Restrict, C Potter, S Purcell, S Roberts, B Coleman, M Stern
- P263** Cannabis use, respiratory symptoms and lung function, in a north Edinburgh primary care population
PT Reid, J McKenzie, L Copeland, R Elton, J Macleod, JR Robertson
- P264** The prevalence of β -blocker prescription in COPD patients
ARC Patel, GC Donaldson, AJ Mackay, JA Wedzicha, JR Hurst
- P265** A randomised control trial to investigate the effectiveness of PLB in the clinical setting
SE Roberts, FM Schreuder, T Watson, M Stern

Friday 9 December 2011

3.30pm – 5.00pm

Mountbatten Room, 6th Floor

POSTER DISCUSSION: P266 – P276

NIV: COPD, neuromuscular disease and obesity

Chaired by: Dr Stephen Bourke (North Shields) and Dr Mark Elliott (Leeds)

- P266** Late ventilation is associated with high in-hospital mortality in patients hospitalised with acute exacerbations of COPD
J Steer, GJ Gibson, SC Bourke
- P267** Association of the length of non-invasive ventilation (NIV) with arterial bicarbonate level in COPD patients with acute hypercapnic respiratory failure (AHRF)
A Thomas, B Beauchamp, L Dyal, B Chakraborty, D Banerjee, E Gallagher, R Mukherjee
- P268** Can we improve “door-to-mask” times for patients with chronic obstructive pulmonary disease (COPD) Requiring Non-Invasive Ventilation (NIV)?
S Mandal, TQ Howes, CM Roberts
- P269** Feasibility and acceptability of non-invasive ventilation (NIV) as an aid to exercise in patients admitted with acute exacerbation of chronic respiratory disease
F Dyer, F Bazari, C Jolley, L Flude, V Lord, MI Polkey, NS Hopkinson
- P270** Motor neurone disease (MND); a survey of deaths in the era of non-invasive ventilation
SK Banerjee, MG Davies, IE Smith
- P271** Impact of structured referral and follow up pathways on access to ventilatory support for people with motor neurone disease (MND)
SK Banerjee, MG Davies, IE Smith
- P272** A 7 year retrospective evaluation of initiation of long term non-invasive ventilatory support for motor neurone disease
J Palmer, P Hughes
- P273** Outcome after prolonged invasive mechanical ventilation in myotonic dystrophy
SK Banerjee, V Licence, N Oscroft, MG Davies, T Quinnell, J Shneerson, IE Smith
- P274** Seasonal variation in initiation and discontinuation of domiciliary non-invasive ventilation: a 12-month cohort study
Y Khatun, PB Murphy, AC Davidson, N Hart
- P275** An afferent reservoir enables the Nippy I to deliver any gas
R Richards
- P276** The value of vital capacity and daytime pulse oximetry to predict hypercapnia in obese patients
E Boleat, S Mandal, E Suh, N Hart

SCIENTIFIC PROGRAMME

3.00pm – 4.30pm

COFFEE/TEA will be served in the Benjamin Britten Lounge, 3rd floor

SPEAKERS' BIOGRAPHICAL DETAILS

Dr Trevor Baglin is a Consultant Haematologist at Addenbrooke's Hospital in Cambridge. He is President of the British Society for Haemostasis and Thrombosis, and Chairman of the International Society for Thrombosis and Haemostasis Sub-committee for Control of Anticoagulation. His major clinical and research interest is venous thromboembolism.

Dr David Baldwin became a Consultant at Nottingham University Hospitals in 1996. He is interested in lung cancer epidemiology, the diagnostic pathway and early diagnosis of lung cancer and has published on these topics. He is Lead Respiratory Physician on the UK CT lung cancer screening trial (UKLS). Locally he is a keen provider of interventional respiratory procedures. He is Lead Clinician for the Nottingham Lung Cancer Centre. He is Honorary Secretary of BTS and was Clinical Lead on the NICE Lung Cancer Guideline (published in 2011). He enjoys time with his family and is a keen windsurfer.

Dr John R Balmes is a Professor of Medicine at the University of California, San Francisco where he is the Chief of the Division of Occupational and Environmental Medicine at San Francisco General Hospital and Attending Physician in Pulmonary and Critical Care Medicine. He is also Professor of Environmental Health Sciences in the School of Public Health at the University of California, Berkeley. Dr Balmes has been conducting research on the respiratory effects of air pollutants for over 25 years.

Dr Dev Banerjee is a Consultant in Respiratory and Sleep Medicine at Birmingham Heartlands Hospital and a Senior Research Fellow at the Aston Brain Centre, Aston University. He qualified from Leeds University, and underwent specialist training in respiratory medicine in the West Midlands, before training further in sleep medicine at the Royal Prince Alfred Hospital, University of Sydney (2003 – 2004). He currently leads an eight-bedded PSG sleep unit and clinic in Birmingham. His specialist clinical and research areas of interest include obesity and sleep apnoea, cardiovascular event prevention in OSA (the SAVE trial), driving and sleepiness, narcolepsy, parasomnias, insomnia and restless legs/periodic leg movements. He also acts as a medico-legal expert witness in sleep/automatism and is a member of the Expert Witness Institute and Society of Expert Witnesses.

Professor Peter Barnes is Head of Respiratory Medicine at Imperial College London. He has published over 1000 peer-review papers on asthma, COPD and related topics and has been the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007.

Professor Frédéric Becq is Professor of Physiology and Director of the Institute of Cellular Physiology and Biology at the University of Poitiers/CNRS. His research interests are in cystic fibrosis, ionic channels, molecular

pharmacology and drug discovery. He is a member of the ERS and of the ECFS, and a member of the Scientific Committee of the University of Poitiers and of the Scientific Committee of Vaincre La Mucoviscidose.

Dr Diana Bilton is a Consultant at the Royal Brompton Hospital and Honorary Senior Lecturer at Imperial College. She specialises in cystic fibrosis and non-CF bronchiectasis. Dr Bilton has served on the Non-CF Bronchiectasis Guidelines Committee as well as the BTS Infection Specialist Advisory Group. She Chairs the Medical Advisory Group of the CF Trust. Dr Bilton has research interests in new treatments of both CF and non-CF bronchiectasis.

Dr Colin Bingle is a Reader in the Academic Unit of Respiratory Medicine in the Department of Infection and Immunity at the University of Sheffield. His research interests are focused on cellular differentiation and regulation of gene expression in the lung and encompass the fields of comparative genomics, the genetics of complex diseases, immunology and host defence.

Dr Paul D Blanc is Professor and Endowed Chair in Occupational and Environmental Medicine at the University of California San Francisco. He received his BA from Goddard College in Vermont, where he first became interested in health and the environment. He has authored numerous scholarly publications as well as *How Everyday Products Make People Sick* (UC Press, 2009).

Dr Andy Blanchard is a Research Director at GlaxoSmithKline where he has spent 15 years working as both a bench scientist and manager of pre-clinical research groups of up to 25 people. His focus has been on identifying biological mechanisms and specific drug targets for therapeutic intervention in a number of disease areas and currently is exploring translational approaches to this process in fibrotic disease.

Dr Charlotte Bolton is Associate Clinical Professor in Respiratory Medicine, within the Respiratory BRU at the University of Nottingham. Her research and clinical interests include pulmonary rehabilitation and the systemic manifestations of chronic respiratory disease including COPD, cystic fibrosis and in children born preterm.

Dr Louis-Philippe Boulet is a Respiriologist at the Institut universitaire de Cardiologie et de Pneumologie de Québec (Québec Heart and Lung Institute) and Professor of Medicine at Laval University, Québec City, Canada. He currently holds a chair in knowledge transfer, education and prevention of respiratory and cardiovascular health at Laval University. He is the Chair of the Canadian Thoracic Society (CTS) Respiratory Guidelines Committee and is an active committee member of many national and international Medical Societies, including the World Allergy Organisation (WAO), Global Alliance against Chronic Respiratory Diseases (GARD), and various CTS, American Thoracic

SPEAKERS' BIOGRAPHICAL DETAILS

Society and European Thoracic Societies Task Forces. He is the Chair of the Dissemination and Implementation Committee of the GINA (Global Initiative on Asthma) International Asthma Guidelines. He did his postgraduate studies at Laval University and completed a fellowship at McMaster University (Hamilton, Canada). He is a former President of the Canadian Thoracic Society and member of the Board of directors of the American Thoracic Society and the American College of Chest Physicians. Dr Boulet is the founder and honorary member of the Quebec Asthma and COPD Network. He is a member of the editorial board of the Canadian Respiratory Journal, CHEST, and invited associate editor of the European Respiratory Journal. In addition to his clinical and teaching tasks, he has an extensive research programme on asthma, respiratory allergy, high-level athletes' respiratory health, occupational asthma and guidelines implementation and knowledge transfer. He has published more than 350 peer-reviewed manuscripts, more than 500 abstracts and 32 books and book chapters on respiratory diseases.

Professor Chris Brightling is a Wellcome Senior Clinical Fellow and Honorary Consultant Respiratory Physician at Glenfield Hospital in Leicester. He has published over 100 peer-reviewed papers. His research is focussed on understanding the pathophysiology and improving the clinical management of airway disease including asthma, chronic obstructive pulmonary disease and chronic cough. In particular he has major interests in the utilisation of inflammatory markers and imaging in the management of airway diseases and the role of mast cell-airway smooth muscle interactions in asthma. He is a member of the BTS/SIGN guideline committee, the ATS/ERS severe asthma guideline group and the WHO severe asthma strategy group. He is an associate editor for *Chest* and is on the editorial board of other specialist respiratory journals. He is the coordinator of the European Union consortium AirPROM and the MRC/ABPI consortium COPD MAP.

Dr Jeremy Brown is a Clinician Scientist and a Reader in Respiratory Infection in the Centre for Respiratory Research at University College London. His main research interest is the molecular pathogenesis of *Streptococcus pneumoniae* pneumonia, and his clinical interest is pneumonia, infections in the immunocompromised host and bronchiectasis.

Dr Nigel G Bruce is a Reader in Public Health and Consultant with WHO (Department of Public Health and the Environment, Geneva), in the Department of Public Health and Policy at the University of Liverpool. He trained in medicine at Cambridge (UK) and the London Hospital and completed professional training in general practice before embarking on a career in epidemiology and public health. He gained an MSc in Epidemiology in 1985 and a PhD in 1991. He moved to the University of Liverpool in 1992, where he was Head of the Division of Public Health from 2007 to 2009. Research interests include environment and child health, in particular the

impact of indoor/household air pollution on respiratory illness in children and adults and on adverse pregnancy outcomes, together with the development and evaluation of interventions and policy for improving access to clean, safe household energy. Since October 2009, Dr Bruce has been working on secondment with WHO (Geneva) leading the programme of work linking household energy, air pollution, health and climate change.

Professor Peter Burney is Professor of Respiratory Epidemiology and Public Health Medicine at Imperial College, London, and has been the Honorary Director of the Department of Health's Social Medicine and Health Services Research Programme since 1996. His interests are mainly in the epidemiology of asthma and COPD. He started the European Community Respiratory Health Survey (ECRHS) in the late 1980s and currently co-ordinates the Burden of Obstructive Lung Disease (BOLD) programme. He is a principal investigator with the MRC-HPA Centre for Environment and Health and co-chairs the Global Burden of Disease group on chronic respiratory disease.

Professor Andrew Bush is Professor of Paediatric Respiriology, Imperial School of Medicine at the National Heart and Lung Institute, and Consultant Paediatric Chest Physician, Royal Brompton Hospital. He is currently Joint Editor in Chief of *Thorax*. His research interests include the invasive and non-invasive assessment of airway inflammation, therapy resistant asthma, and airway remodelling in inflammatory airway diseases. He has published nearly 350 peer review papers, and numerous chapters and invited reviews; he has supervised or co-supervised 24 MD and PhD degrees. He recently co-edited the 8th Edition of Kendig's *Respiratory Disorders in Children*, and the 3rd Edition of *Cystic Fibrosis*. Most importantly, he is the grandfather of Dylan, the most beautiful and talented two year old in the world.

Dr Martin Carby is a Consultant Respiratory and Transplant Physician at The Royal Brompton and Harefield NHS Foundation Trust. He has extensive experience in interventional bronchoscopy in the setting of lung transplantation and a specific research interest in the treatment of fungal infections. He is also the hospital tutor for core medical training and simulation enhanced learning and a member of the respiratory medicine speciality training committee for North West Thames. He is an invited speaker at this year's annual meeting of the International Society of Heart and Lung Transplantation.

Dr Richard Casaburi is Associate Chief for Research and Professor of Medicine, Division of Respiratory Physiology and Medicine, Harbor-UCLA Medical Center, in Torrance, California. He is also Medical Director of the Rehabilitation Clinical Trials Center, a laboratory dedicated to COPD research. Dr Casaburi holds the Grancell/Burns Chair in the Rehabilitative Sciences at the Los Angeles Biomedical Research Institute. He has

SPEAKERS' BIOGRAPHICAL DETAILS

published over 200 papers focused on COPD, pulmonary rehabilitation, and exercise physiology.

Dr Robin Condliffe is a Consultant Respiratory Physician in the Royal Hallamshire Hospital, Sheffield. He received training in pulmonary vascular medicine in Sheffield and Papworth. He has published on the diagnosis and outcomes of PH in leading journals including AJRCCM and ERJ for which he is also a regular reviewer. He is on the working party for the 5th world PH guidelines, due 2013.

Dr Paul Cooper is a Consultant Neurologist at the Manchester Centre for Clinical Neurosciences. He has a particular interest in epilepsy, and the assessment of blackouts and "funny turns"; and specialises in the complex interactions between epilepsy and psychiatric and psychological illness. Dr Cooper helped develop a multidisciplinary Sleep Service, and is now one of five consultants providing a regular Sleep Clinic.

Professor Douglas Corfield is Professor of Medical Sciences, School of Medicine, Manchester University. His research interests lie in the neurophysiology of the brain/lung axis in humans: specifically to understand how the brain controls and perceives breathing and how changes in breathing affect brain function. As a medical educationalist, he leads the first two years of the MBChB at Manchester and has a particular interest in the vertical integration of the basic sciences in undergraduate medical curricula.

Professor Paul A Corris is Professor of Thoracic Medicine at Newcastle University and the Newcastle upon Tyne Hospitals NHS Foundation Trust. He directs the National Pulmonary Vascular Service (Newcastle) and the Cardiothoracic Transplant Unit. He is the Co Lead for Respiratory Medicine in the North East SHA. He is immediate past President of the British Thoracic Society, a past President of the International Society for Heart and Lung Transplantation and a past Chair of the BTS Scientific Committee. He sits on the editorial boards of *Transplantation* and the *Journal of Heart and Lung Transplantation*, and was an Associate Editor of *Thorax*.

Liz Darlison is currently a Consultant Nurse at the University Hospitals of Leicester NHS Trust leading the development of Mesothelioma UK, the National Macmillan Mesothelioma Resource Centre. She is a member of the National Lung Cancer Forum for Nurses committee and represents nursing on a variety of national and professional committees. Ms Darlison is a co-founder and current committee member of the International Thoracic Oncology Nursing Forum. She is a module leader and regularly lectures within the Royal Marsden School of Nursing and Rehabilitation and is an Honorary Lecturer at De Montfort University, Leicester.

Professor Donna Davies is Head of the Academic Unit of Clinical and Experimental Sciences and Professor

of Respiratory Cell and Molecular Biology in the Faculty of Medicine at the University of Southampton. She has pioneered the use of in vitro models to study mechanisms of asthma and COPD, taking advantage of methodologies that could not be used ethically in vivo. In 2003, together with Stephen Holgate and Ratko Djukanovic, she co-founded, 'Synairgen', a University spin-out company whose focus is on development of new treatments for chronic lung diseases where there is an unmet medical need.

Dr Louise E Donnelly is a Reader in Respiratory Cell Biology, Airway Diseases, at the National Heart and Lung Institute, Imperial College London. Her research interest is focussed on the cellular profile in inflammatory lung diseases including asthma and COPD. In particular, her work investigates how inflammatory cells are altered in the disease state and how these changes can be exploited in the development of novel therapeutic strategies. To this end, Dr Donnelly's group have established a number of human primary cell systems to investigate mechanisms of aberrant inflammation.

Professor Seamas Donnelly of St Vincent's University Hospital and University College Dublin (UCD), represents the classical researcher in translational medicine, identifying key regulators of the inflammatory response and translating these observations to inflammatory respiratory diseases. He was recently awarded an honorary Professorship by the University of Edinburgh. He is co-applicant on the Wellcome Trust Dublin Clinical Research Facility, and is an SFI PI Programme grant holder with significant additional funding having been obtained from the Wellcome Trust, The European Union and national and international charitable funding agencies.

Mr John Duffy is a Consultant Thoracic Surgeon at Nottingham City Hospital, having previously trained in London, Birmingham and Nottingham. He is currently Co-chair of the Thoracic Surgery Sub-group of the Society for Cardiothoracic Surgery and is Chair of the BTS Thoracic Surgery Specialist Advisory Group.

Dr Paul Elkington is a Senior Lecturer in Respiratory Infection at Imperial College and Consultant in Respiratory Medicine at the Hammersmith Hospital. His research interest is in how tuberculosis causes lung damage, focusing on matrix metalloproteinases (MMPs), with the ultimate aim of introducing MMP inhibitors to reduce TB morbidity and mortality.

Dr Mark Elliott is a Consultant Physician in Respiratory and General Medicine at St James's University Hospital, Leeds. He qualified from the University of Cambridge and Royal London Hospital in 1982. He trained in London and in 1993 was appointed as Consultant Physician at St James's University Hospital, Leeds. Dr Elliott has been responsible for developing the home sleep and assisted ventilation service, for acute in hospital NIV and weaning of patients with prolonged

SPEAKERS' BIOGRAPHICAL DETAILS

ventilator dependence. He has research interests in acute and chronic non invasive ventilation and sleep related abnormalities of breathing.

Professor Madeleine Ennis is Professor of Immunopharmacology in the Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences at the Queen's University of Belfast. Her research interests range from asthma to COPD with particular emphasis on how inflammatory cell function changes with disease.

Professor Andrew Fisher is Professor of Respiratory Transplant Medicine in the Institute of Cellular Medicine at Newcastle University. He trained in Nottingham as an undergraduate and completed post-graduate specialist training in the Northern Deanery where he developed a clinical and research interest in lung transplantation. His research work spans basic mechanisms to clinical trials. He is the Academic Director of the newly opened Institute of Transplantation at the Freeman Hospital, the UK's first comprehensive multi-organ transplant facility.

Professor Andrew Greening is Consultant Physician at Lothian University Hospitals Division, Western General Hospital, Edinburgh, and Honorary Professor of Pulmonary Disease, School of Clinical and Molecular Medicine, University of Edinburgh. Current clinical and research interests include asthma control and non-invasive assessment of airways inflammation, and gene therapy for Cystic Fibrosis.

Professor Jonathan Grigg is Professor of Paediatric Respiratory and Environmental Medicine at Barts and the London School of Medicine and Dentistry, Queen Mary University London. He qualified in 1982 from the Royal London Hospital. His research training included a three year clinical fellowship at the Royal Postgraduate Medical School, a one year fellowship at the Department of Paediatric Leukocyte Biology, Texas Children's Hospital, and a three year fellowship at the Department of Thoracic Medicine, Royal Children's Hospital Melbourne. On return to the UK, he was appointed Senior Lecturer in Paediatric Respiratory Medicine at the University of Leicester, then moved to Barts and the London in 2006. His current research interests include; the effect of air pollution on pulmonary innate immunity, RCT's of preschool wheeze therapies, the management of difficult asthma in school-age children, and children's environmental health.

Professor Ian Hall is Professor of Molecular Medicine, and Dean of the Faculty of Medicine and Health Sciences at the University of Nottingham. He completed his clinical studies at the University of Oxford before moving to Nottingham for specialist training and an initial period in research. Subsequently he was an MRC travelling fellow at the University of Pennsylvania and National Asthma Campaign Senior Research Fellow back in Nottingham. He runs a specialist asthma

clinic at the Nottingham University Hospitals NHS Trust. Projects in his laboratory focus upon genetic approaches to the study of airway diseases with a special emphasis on asthma and COPD, and studies on cell signalling mechanisms in cells relevant to airway pathology. He chairs the MRC's Clinical Training and Career Development Panel and is a member of the MRC's Training and Career Group. He is a member of Sub-panel 1: Clinical Medicine in the 2014 Research Excellence Framework.

Dr Richard Harrison is a Consultant Respiratory Physician in the Department of Respiratory Medicine at the University Hospital of North Tees. He trained in Liverpool and Southampton. Dr Harrison has a particular interest in invasive investigational techniques in lung cancer: EBUS and medical thoracoscopy.

Dr Nicholas Hart is a Clinical Research Consultant within Guy's and St Thomas' Foundation Trust and Kings College London Comprehensive Biomedical Research Centre and Director of Respiratory Research and Development within King's Health Partner's Academic Health Science Centre. In addition to providing clinical support for critical care, he provides support to the Lane Fox Respiratory Unit, which is the regional weaning and non-invasive ventilation unit specialising in providing long-term support for patients with neuromuscular, skeletal deformities, chronic obstructive airways disease and obesity-related respiratory failure. Dr Hart's research is focused on the reduction of respiratory morbidity with the specific aims of reducing dyspnoea, increasing exercise capacity and enhancing health-related quality of life in patients with chronic respiratory disease and patients during and after critical illness. A research programme of translational physiological research has developed focusing on two major areas: (1) advanced physiological monitoring and ventilatory strategies and (2) muscle wasting, weakness and rehabilitation. These areas of research have been mapped onto patients with COPD, critical illness and obesity. Dr Hart is chief investigator of two UK multicentre clinical trials as well as leading the development of translational skeletal muscle biology programme. Dr Hart's own current and collaborative research projects are funded by National Institute of Health Research, Medical Research Council, British Lung Foundation, Guy's and St Thomas' Charity and a number of unrestricted grants from industry partners.

Professor John Henderson is Professor of Paediatric Respiratory Medicine at the University of Bristol and Bristol Royal Hospital for Children and co-Director of the Avon Longitudinal Study of Parents and Children (ALSPAC). His research interests are in the genetic and environmental influences on the development of asthma and allergy in children.

Dr Bernard Higgins is a Consultant Respiratory Physician in Newcastle, having previously trained in

SPEAKERS' BIOGRAPHICAL DETAILS

Manchester, Edinburgh and Nottingham. He has a particular interest in asthma, co-Chairs the British Asthma Guideline Steering Group and has recently completed a term as Chair of the BTS Asthma Specialist Advisory Group.

Dr Nik Hirani is a Senior Clinical Lecturer and Honorary Consultant at the Edinburgh Royal Infirmary and PI in the University of Edinburgh MRC Centre for Inflammation Research. He chairs the BTS Interstitial Lung Disease Specialist Advisory Group and the NICE IPF Guideline Group. He has a research interest in translational studies in lung fibrosis and oxygen-regulated mechanisms in lung injury and fibrosis.

Dr Ling-Pei Ho qualified in medicine from Glasgow University, and held an MRC Training Fellowship and DH National Clinician Scientist Award before her current position as HEFCE Senior Clinical Lecturer and Consultant in Respiratory Medicine. She started the Oxford Sarcoidosis-ILD Clinic in 2005, and leads the Lung Immune Regulation Group at the Weatherall Institute of Molecular Medicine, Oxford. Her work combines molecular and cellular immunology, and focuses on how immune responses in the lungs are regulated to prevent immune-pathology. Her group has a strong commitment to translational research particularly in sarcoidosis.

Dr Luke Howard is a Consultant Chest Physician at the National Pulmonary Hypertension Service at Hammersmith Hospital, which actively monitors over 500 patients with pulmonary hypertension, and is an Honorary Clinical Senior Lecturer at the National Heart and Lung Institute, Imperial College London. He has research interests in exercise physiology and clinical trials in pulmonary hypertension.

Professor Richard Hubbard is a Chest Physician and Epidemiologist in Nottingham. He is currently the British Lung Foundation Professor of Respiratory Epidemiology. His main clinical interest is the care of people with interstitial lung disease and the short and long term respiratory complications of bone marrow transplantation. Currently his main research projects relate to the aetiology and natural history of idiopathic pulmonary fibrosis and access to care for people with lung cancer, but Professor Hubbard is also interested in the epidemiology of allergic disease and provision of care for all people with lung disease.

Dr John Hurst graduated from the University of Edinburgh in 1997 and is currently a Clinical Senior Lecturer at University College London Medical School, and Honorary Consultant in Respiratory and Acute Medicine at the Royal Free Hampstead NHS Trust, London UK. His clinical and research interests are in COPD and bronchiectasis, and specifically studying the mechanisms responsible for high-risk patients and time periods for exacerbations of these diseases. He has acted as Associate Editor for *Thorax* and peer reviews for general and specialist journals.

Professor Marc A Judson is a Professor of Medicine and Chief of the Division of Pulmonary and Critical Care Medicine at Albany Medical College in Albany, New York. His major area of clinical and research interest concerns sarcoidosis. Dr Judson has published more than 150 medical articles and book chapters and more than half of them have concerned sarcoidosis. He has participated in more than 40 sarcoidosis research studies. He is an Associate Editor of *Respiratory Medicine* and is on the Editorial Board of *Chest*.

Dr Joseph Keane is a Consultant Respiratory Physician in St James's Hospital, and Associate Professor of Medicine in Trinity College Dublin. His research interests include the host response to tuberculosis; and developing improved diagnostic tests for this disease. He is the director of the TB service in St James's, which is the designated supra-regional centre for tuberculosis.

Professor Frank J Kelly holds the Chair in Environmental Health at King's College London, where he is Director of the Analytical and Environmental Science Division. His other positions of responsibility are Director of the Environmental Research Group and Deputy Director of the MRC-HPA Centre for Environment and Health. From these dual positions he is able to combine his two main research interests, namely free radical/antioxidant biochemistry, and the impact of atmospheric pollution on human health. In addition to his academic work, Professor Kelly is past President of the European Society for Free Radical Research and past Chairman of the British Association for Lung Research. He is also involved with providing policy support to the WHO on air pollution issues and is a member of the Committee on the Medical Effects of Air Pollution (COMEAP).

Dr David King took up the role of Director of the NIHR Central Commissioning Facility in June 2008, moving from the Department of Health, where he had worked on the implementation of a number of the new NIHR funding schemes, including Research Centres and Units, CLAHRCs and Programme Grants for Applied Research. Prior to that, Dr King worked as an R&D Manager in an NHS Trust for five years and also spent eleven years at the Medical Research Council's Head Office, including one year on secondment to the Wellcome Trust. Dr King has a first degree in biochemistry, a PhD in cancer research and an MBA.

Professor Alan Knox is a Professor of Respiratory Medicine at Nottingham University and Director of the Nottingham Respiratory Biomedical Research Unit. He is Respiratory Lead for the Trent Comprehensive Local Research Network. Professor Knox is currently on the editorial advisory boards of *Thorax* and *AJP (Lung)*, having previously been executive editor of *Thorax*. His main research interests are in the molecular pathophysiology of lung diseases (asthma, COPD, pulmonary hypertension, idiopathic pulmonary fibrosis, cystic fibrosis) and translational research in these areas.

SPEAKERS' BIOGRAPHICAL DETAILS

Dr Onn Min Kon is Lead Clinician for the TB service at Imperial College Healthcare NHS Trust. He is an Honorary Senior Lecturer in the National Heart and Lung Institute, Imperial College and has research interests in tuberculosis and airway diseases. He is Lead Clinician for the North West London TB sector and a member of the BTS Tuberculosis Specialist Advisory Group.

Professor Sailesh Kotecha has been Professor and Head of Child Health in Cardiff since 2005. His group's interests lie in understanding the molecular and cellular causes that lead to the development of chronic lung disease of prematurity (CLD) in preterm babies. In particular his group's research has focussed on delineating the processes that lead to the development and resolution of pulmonary inflammation as well as the role of ante- and post-natal infection. His group have recently started to link these studies to longer term cardio-respiratory physiological outcomes including the response of pulmonary arteries to hypoxia in preterm and growth retarded.

Dr David Lynch is Professor and Co-Director in the Division of Radiology at National Jewish Health, Denver, Colorado. As a member of the Executive Committee of the National Lung Screening Trial, he has been involved with every phase of the study. He has participated in numerous multi-center studies related to thoracic imaging.

Professor William MacNee received his medical degree and MD from the University of Glasgow and trained thereafter in the Royal Infirmary of Edinburgh/University of Edinburgh Medical School. He was the recipient of an MRC travelling fellowship in the University of British Columbia, St Paul's Hospital Vancouver. Currently he is Professor of Respiratory and Environmental Medicine, University of Edinburgh, and Honorary Consultant Physician, Lothian Health. He is a past Chair of the Scientific Committee of the European Respiratory Society (ERS) and past ERS President. He has served on the British Thoracic Society COPD guideline committee, was co chair of the ERS/ATS COPD guidelines committee and was a past member of the GOLD executive committee. He has been an associate editor of the *European Respiratory Journal* and the *American Journal of Respiratory and Critical Care Medicine*. His primary research interests are in pathological mechanisms of the lung and systemic effects of COPD, and he also has an interest in the mechanisms of the harmful effects of environmental pollutants. Professor MacNee has published over 260 peer reviewed papers, and edited several books on COPD.

Dr Toby Maher is a Consultant Respiratory Physician working on the Interstitial Lung Disease Unit at the Royal Brompton Hospital. Prior to this, he was a Wellcome Trust Clinical Research Fellow at the Centre for Respiratory Research, University College London. His research interests include; biomarker discovery, clinical trials in fibrosing lung disease and studying the role of

prostanoids, apoptosis and cellular senescence in the pathogenesis of IPF.

Dr Adrian Martineau is Senior Lecturer in Respiratory Infection and Immunity at Barts and The London School of Medicine and Dentistry, Queen Mary University of London. His research focuses on immunomodulatory actions of vitamin D in respiratory disease.

Dr Nick Maskell is a Senior Lecturer and Consultant Respiratory Physician at the University of Bristol and North Bristol NHS Trust. His research interests relate to translational studies in all aspects of pleural disease and he runs the Bristol Pleural CTU. He is the CI for three UK-CRN portfolio pleural studies. He undertook his DM thesis in Oxford prior to taking up his consultant post at North Bristol in 2003. In addition to clinical research, Dr Maskell is the lead clinician for pleural disease at NBT and runs a specialist pleural disease service. He was chairman of the British Thoracic Society guidelines committee with guidelines published in 2010.

Professor Ron Maughan is a Professor at Loughborough University, England. His research interests are in the physiology, biochemistry and nutrition of exercise performance, with an interest in both the basic science of exercise and the applied aspects that relate to health and to performance in sport.

Professor Ann Millar is Professor of Respiratory Medicine at the University of Bristol, having trained in London and Liverpool. She has clinical interests in diffuse parenchymal lung disease, acute lung injury and the immunocompromised lung. Professor Millar's research interests are in the mechanism regulating the outcome of acute and chronic lung injury.

Professor Henrik Møller is Professor of Cancer Epidemiology in King's College London School of Medicine and the National Lead for Analysis and Research in the National Cancer Intelligence Network. He is Director of the Thames Cancer Registry, which covers the 12 million population in London, Kent, Surrey and Sussex and which forms part of the overall network of cancer registries in England. Previously, Professor Møller was the Director of a research unit in the Danish National Research Foundation 1995-1999, Scientist and Acting Unit Chief at the International Agency for Research on Cancer 1992-1995, and Cancer Epidemiologist at the Danish Cancer Registry 1986-1992. He has published widely in cancer epidemiology and health services research. Further information on the work of the Thames Cancer Registry is available via www.tcr.org.uk.

Dr Lynne A Murray had a PhD from Imperial College London in Immunology and Pathology and received post-doctoral training at UCLA. Following this, Dr Murray moved into industry and worked at Centocor/ J&J in the US in chemokine and fibrosis research. Dr Murray

SPEAKERS' BIOGRAPHICAL DETAILS

became Director of Pharmacology at Promedior, a start-up developing therapeutics to treat fibrosis. Now in MedImmune in Cambridge, UK, Dr Murray is focusing on MedImmune's fibrosis research efforts, both internally and with external collaborators. Dr Murray's research interests span the underlying pathways promoting the effects of injury, inflammation and underlying immune conditions on lung remodelling; as well as how these mechanisms can translate across multiple organs and disease indications. She has authored multiple papers and book chapters in lung and fibrosis research.

Dr Keith S Naunheim is the Vallee and Melba Willman Professor of Surgery and Chief of Thoracic Surgery at Saint Louis University School of Medicine. He is the immediate past president of the Southern Thoracic Surgical Association and has served on the American Board of Thoracic Surgery.

Dr Rob Niven is a Senior Lecturer and Consultant Respiratory Physician at the University of Manchester and University Hospital of South Manchester. As a clinician he runs a supra-regional service for severe asthma. He has assessed over 600 severe asthma patients, with around 50% of these referrals being for patients on maintenance oral steroids. He is a core member of the UK National Severe Asthma Network, with over 650 patients entered onto a national database, with Manchester being the leading site.

As a researcher Dr Niven has published over 70 peer reviewed papers and authored five book chapters. Areas of interest have included occupational lung disease, environmental epidemiology and more recently clinical practice in severe asthma. He has innovated research into clinical practice in the fields of hypertonic saline for bronchiectasis as a therapy, awareness and diagnosis of dysfunctional breathing patterns, the role of antifungal therapy in severe asthma with fungal sensitisation and has been a chief investigator in the UK in the Bronchial thermoplasty trials.

In addition he is a keen educator and leads the final year exams for the South Manchester site as well as being active in all aspects of education at undergraduate level.

Mr Richard D Page has been a Consultant Thoracic Surgeon at Liverpool Heart and Chest Hospital since 1994. He is the thoracic surgical audit lead for the Society for Cardiothoracic Surgery for GB and Ireland.

Professor Andrew Peacock is Consultant Cardiopulmonary Physician and the Director of the Scottish Pulmonary Vascular Unit, which looks after all the patients with pulmonary hypertension in Scotland (population 5 million). He is also Professor in Medicine at the University of Glasgow (Respiratory Medicine). His laboratory studies the effects of hypoxia on pulmonary vascular-cell proliferation and on the physiological responses of the human pulmonary circulation. He has

been involved in many of the clinical trials of new therapies for pulmonary hypertension in the last years, and has spent time developing new end points in the assessment of patients with pulmonary vascular disease. He is Chairman of the Pulmonary Circulation Group of the European Respiratory Society and the Pulmonary Hypertension Physicians UK and is the author of more than 150 papers, reviews and chapters on pulmonary vascular disease. He is co-editor with Robert Naeije and Lew Rubin of *Pulmonary Circulation (3rd Edition): diseases and their treatments*.

Dr Michael D Peake is a Consultant and Senior Lecturer in Respiratory Medicine at Glenfield Hospital, Leicester. He is also: Clinical Lead, National Cancer Intelligence Network and the National Lung Cancer Audit; Associate Director of the Clinical Effectiveness and Evaluation Unit, Royal College of Physicians; National Lead for Lung Cancer and National Awareness and Early Diagnosis Initiative in NHS Improvement; co-chair of the Department of Health's Lung Cancer and Mesothelioma Advisory Group, and Clinical Outcomes Group; a member of the steering group of the British Thoracic Oncology Group; vice-chair of Mesothelioma UK, and the National Clinical Audit Advisory Group.

Professor Michael Polkey is Consultant Physician in the Department of Sleep and Ventilation at the Royal Brompton Hospital and Professor of Respiratory Medicine at the National Heart and Lung Institute, London. His research interests include mechanisms of respiratory failure, systemic aspects of COPD and lung volume reduction surgery.

Dr Laura Price is a Specialist Registrar in Respiratory and Intensive Care Medicine in London. She is currently working towards a PhD in pulmonary hypertension at The Royal Brompton Hospital. In December 2008, she developed severe Guillain Barre Syndrome, which required a three month period of invasive ventilation on ICU followed by prolonged rehabilitation. She has made a good recovery and has returned to work full time.

Dr Paul Reading completed his neurological training in Edinburgh and Newcastle before recently moving to the James Cook University Hospital, Middlesbrough, to take up a new neurology post. He has been running a regular Neurology Sleep Clinic for 10 years. His particular interests are narcolepsy, abnormal sleep in neurodegenerative disease, and parasomnias. He is President Elect of the British Sleep Society, the largest body in the UK for professionals involved in sleep medicine and science.

Dr Stephen I Rennard is Larson Professor of Medicine in the Pulmonary and Critical Care Medicine Section of the Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Nebraska. His research includes clinical investigation in COPD and mechanistic study of lung tissue repair and remodeling.

SPEAKERS' BIOGRAPHICAL DETAILS

Professor Michael J Rennie is Emeritus Professor in the School of Biomedical Sciences at the University of Nottingham. Until September 2011, he was Professor of Clinical Physiology at the School of Graduate Entry Medicine and Health. Professor Rennie's research interests for the last 40 years have been human metabolism, especially muscle metabolism and what goes wrong in ageing, immobilisation and disease to cause muscle wasting. His work has been supported by major medical charities, including the US NIH, MRC and BBSRC.

Dr Trevor Rogers graduated from, and did early medical training, in Bristol then specialised in respiratory medicine in Sheffield, obtaining an MD. He has been a Consultant at Doncaster Royal Infirmary since 1995, since when he has become particularly interested in lung cancer. Current research has mainly concerned how symptoms and primary care interventions affect presentation.

Professor Ian Sabroe is a chest physician who specialises in severe asthma and pulmonary arterial hypertension. His particular research interest is how inflammation is initiated in the lung in response to infections and lung damage, why it might fail to resolve in disease, and whether it matters at all. He was until 2009 an MRC Senior Clinical Fellow, and is now Professor of Inflammation Biology at the University of Sheffield.

Dr Chris Scotton is a Principal Research Fellow at the Centre for Respiratory Research, University College London. He obtained his PhD in 2001 while working at Cancer Research UK, followed by a Marie Curie postdoctoral fellowship in Milan. Dr Scotton moved to UCL in 2004, where he is currently funded by an MRC Career Development Award. His research focuses on the interaction between coagulation and innate immune mechanisms in the lung, with a major interest in the interstitial lung diseases. Through a variety of international collaborations and links with the pharmaceutical industry, he is investigating novel opportunities for intervention in this disease area, including regenerative medicine approaches. As of 2010, he is also the Meetings Secretary for the British Association for Lung Research.

Dr Tarek Sharshar trained in neurology and intensive care medicine in Paris, France. He completed a PhD in clinical physiology at Imperial College London. He is now a Senior Consultant in the Department of Intensive Care Medicine at the teaching Raymond Poincaré Hospital and Professor at The University of Versailles. He is supervising research on neurological complications of critical illness as well as neuroendocrine and brain dysfunctions related to septic shock, notably in collaboration with the Institut de Pasteur, Mc Gill University and Leuven University.

Dr Dominick Shaw is an Associate Clinical Professor and Honorary Consultant at Nottingham University and Nottingham City Hospital. He runs a difficult asthma clinic, and his main area of research is the non-invasive

assessment of airway inflammation in asthma. He also has projects using hyperpolarised MRI in asthma models.

Professor Mervyn Singer is Professor of Intensive Care Medicine at University College London and an NIHR Senior Investigator. His main interests are haemodynamics, tissue oxygenation, sepsis and multiple organ failure (and particularly the role of mitochondrial dysfunction in its genesis).

Professor Dave Singh is Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester and Medicines Evaluation Unit. After graduating in medicine from Cambridge University, he trained in respiratory medicine and clinical pharmacology in Manchester. This included experience of phase one and two studies, with a special interest in inflammation, leading to an MD from the University of Manchester. His research interests are the pharmacotherapy of asthma and COPD, with studies spanning from basic pharmacology to clinical trials.

Professor Alan Smyth is Professor of Child Health at the University of Nottingham and Honorary Consultant in Paediatric Respiratory Medicine at Nottingham University Hospitals NHS Trust. He is Director of the Nottingham Children and Young Person's Cystic Fibrosis Clinic, which provides care for 160 children. He also sees children with asthma, TB, HIV, specialist respiratory problems and general paediatric problems. Professor Smyth is a member of the Nottingham Respiratory Biomedical Research Unit. He has a major research interest in novel ways of treating infection in cystic fibrosis, and his group have ongoing projects looking at inhibition of bacterial communication. By way of contrast the group are also looking at more effective ways of communicating with sick children. Professor Smyth is Director of MCRN East, under the Medicines for Children Programme and Co-ordinating Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group. When not working, he loves cycling, runs half marathons (increasingly slowly) and tries to keep up with his children.

Dr Michael Steiner is a Consultant Respiratory Physician at Glenfield Hospital, University Hospitals of Leicester NHS Trust. His clinical and research interests are in the field of rehabilitation and chronic care in COPD. He has particular expertise in exercise performance, physical training and rehabilitation, nutrition and skeletal muscle dysfunction in COPD and other long term conditions.

Professor Janet Stocks is Professor of Respiratory Physiology, Head of Portex Unit of Paediatric Anaesthesia, Pain Research, Critical Care, Respiratory Medicine, Physiology and Physiotherapy at UCL, Institute of Child Health, London, UK. Professor Stocks' research has focused on elucidating the early determinants of lung function, including the impact of respiratory disease and the detrimental effects of factors such as preterm delivery, intrauterine growth retardation and

SPEAKERS' BIOGRAPHICAL DETAILS

maternal smoking on subsequent lung health. She is currently chairing the ERS Global Lungs Initiative (www.lungfunction.org) to develop improved all-age spirometry equations that are applicable globally.

Professor Terry Tetley is Professor of Lung Cell Biology at the National Heart and Lung Institute, Imperial College London. Her research has focused on mechanisms of pulmonary inflammation and lung disease due to inhalation of airborne particles, including environmental particulate air pollution, asbestos, cigarette smoke, engineered nanoparticles and microbial material.

Dr David Thickett is a Reader in Respiratory Medicine at the Centre for Translational Inflammation Research, School of Clinical and Experimental Medicine in Birmingham. His research interests involve translational and clinical studies in acute lung injury, sepsis, interstitial lung disease and COPD as well as basic science studies in lung epithelial cell biology. He is Director of the Birmingham Respiratory Academic Training programme.

Dr Adam Torbicki is Head of the Department of Chest Medicine at the Institute of Tuberculosis and Lung Diseases in Warsaw, Poland. His research interests are related to pulmonary circulation. He is Co-ordinator of the European Guidelines in Pulmonary Embolism 2008, and former Chairman of the ESC Working Group on Pulmonary Circulation. Dr Torbicki is currently Vice-President of the ESC.

Dr Rubin M Tudor is Hart Family Professor of Medicine and Director of the Programme in Translational Lung Research at the University of Colorado, Denver. Dr Tudor's research focuses on defining the molecular pathogenetic mechanisms of COPD and of pulmonary hypertension. His work has contributed to the development of the concept of alveolar cell and molecular maintenance programme, the role of cell death, ceramide and cellular stress responses, and cellular ageing in the pathogenesis of emphysema. His work in the pathogenesis of pulmonary hypertension led to identification of genetic instability in the pulmonary vascular lesions, the concept of apoptosis resistance and "cancer-like" features in the disease, and development of the only model of severe pulmonary hypertension in rodents with endothelial cell proliferation.

Dr Erika von Mutius is Professor of Paediatrics at the Dr von Hauner University Children's Hospital in Munich, Germany. She is a paediatrician, allergologist and epidemiologist, and Head of the Asthma and Allergy Department. Her research interests have been focused on the epidemiology of paediatric respiratory and allergic diseases for many years.

Dr Alan Walker is a microbiologist by training with specific interests in the bacteria that inhabit the gastrointestinal and respiratory tracts of mammalian hosts, particularly in humans and mice. After receiving

a BSc (Hons) in Microbiology from the University of Aberdeen, he studied for his PhD at the Rowett Institute of Nutrition and Health in Aberdeen and at the University of Dundee. He currently works as a Staff Scientist at the Wellcome Trust Sanger Institute, where state of the art sequencing facilities are used to better characterise host-associated microbial communities and shed light on the roles these microbes play both in health and in diseases such as cystic fibrosis.

Mr David Waller has been Consultant Thoracic Surgeon at Glenfield Hospital, Leicester since 1997. His appointments include: NCRI Lung CSG and mesothelioma subgroup chair; BTOG steering committee; Executive of the Society for Cardiothoracic Surgery; BTS/SCTS Lung Cancer Guidelines committee and Regional Training Programme Director. Mr Waller's publications include work on lung multi disciplinary teams and resection rates.

Professor Wisia Wedzicha is Professor of Respiratory Medicine at the UCL Medical School, University College London and the Royal Free Hospital. She qualified from Somerville College, Oxford University and St Bartholomew's Hospital Medical College, London University. She has a major interest in the causes, mechanisms and impact of COPD exacerbations and in the role of bacterial and viral infection at COPD exacerbation. She directs an active research group into COPD exacerbations and has published extensively on this topic. She chairs the Department of Health Home Oxygen Clinical User Group. She was a member of the Guideline Development Group for the revision of the NICE COPD Guidelines, and is a member of the Programme Board for the COPD National Clinical Strategy. Until June 2010, Professor Wedzicha was Editor in Chief of *Thorax*. She is a member of the *BMJ* and *AJRCCM* advisory boards and on the editorial board of a number of international journals. She is Guidelines Director for the ERS and also Publications Director.

Professor Moira Whyte is Professor of Respiratory Medicine and Head of the Department of Infection and Immunity at the University of Sheffield. Her research group have interests in basic mechanisms of innate immunity, particularly in the regulation of inflammatory cell apoptosis, and in the role of inflammation in interstitial lung diseases and airways disease.

Professor Adrian J Williams has had a long interest in sleep medicine, dating back to research into the sudden infant death syndrome conducted at Harvard University. Subsequently he was appointed as a Chest Physician at UCLA and developed what was to become the largest sleep service within the Veterans Administration while at the same time co-directing the UCLA Sleep Disorders Centre. He was one of the early clinicians boarded in Sleep Medicine and has published widely in that field including early contributions to the use of oximetry in the diagnosis of obstructive sleep apnoea, the use of non-invasive ventilation in COPD and the recognition

SPEAKERS' BIOGRAPHICAL DETAILS

that systemic hypertension could in part be related to obstructive sleep apnoea. In the UK he has helped develop the Guy's and St Thomas' Sleep Disorders Centre into one of the most active in the UK clinically and research. His current interests are focused on the parasomnias and their management as well as continued interest in oximetry in the setting of non-respiratory disorders such as periodic limb movement disorder.

Dr S John Wort is a HEFCE Clinical Senior Lecturer in Pulmonary Hypertension and Intensive Care Medicine at Imperial College London and the Royal Brompton Hospital. His research interests include endothelin-1 biology, pulmonary hypertension associated with respiratory diseases and the role of inflammation in the pathogenesis of pulmonary arterial hypertension.

Dr Thomas A Wynn is Scientific Director of the NIH-Oxford-Cambridge Scholars Programme, and Chief of the Immunopathogenesis Section, Programme in Barrier Immunity and Repair and The Laboratory of Parasitic Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health in Bethesda, USA.

EXHIBITORS' INFORMATION

Air Products Healthcare

Stand number I

Air Products is one of the world's leading homecare providers, serving more than 350,000 patients in 14 countries across the globe. Our services are contributing to a modern healthcare system in the UK by improving patients' quality of life and helping reduce hospitalisations, co-morbidities and other secondary effects. Our objective is to support patients and clinicians in their undertaking of oxygen therapy by offering dedicated support, equipment servicing and maintenance. The support we give to patients and clinicians, combined with relieving the burden of managing and maintaining equipment, allows clinicians to focus on patient care.

Tel: +44 (0)800 373 580 (Homecare Helpline)

Website: www.airproducts.co.uk/homecare

The Association for Respiratory Technology and Physiology

Stand number C54

The Association for Respiratory Technology and Physiology (ARTP) is the sole professional organisation in the UK for practitioners working in respiratory and sleep physiology. ARTP provides nationally, professionally recognised qualifications in lung function testing/spirometry. An important function of the ARTP is the provision for CPD and the writing of standards/guidelines. ARTP organises an Annual Conference and training courses including blood gas sampling, interpretation, respiratory muscle assessment, sleep disorders and cardiopulmonary exercise testing. ARTP co-ordinates spirometry training centres throughout the UK and also write/publish textbooks in lung function testing and physiology. ARTP Sleep represents practitioners working in sleep medicine.

Tel: +44 (0)845 226 3062

Email: admin@artp.org.uk

Website: www.artp.org.uk

The Association of Chartered Physiotherapists in Respiratory Care

Stand number C53

The Association of Chartered Physiotherapists in Respiratory Care (ACPRC) is a national body of physiotherapists interested in respiratory care, formed in November 1980, now with over 800 members. It is one of the larger clinical interest groups within the Chartered Society of Physiotherapy. Through our well-established national and international links with hospitals offering a respiratory physiotherapy service and links with other respiratory organisations (such as BTS, ERS, BLF, ICS, APCP) we facilitate the exchange of information, ideas and research findings to our members. Our aim is to promote best practice in respiratory physiotherapy for the benefit of patients.

Tel: +44 (0)7740 117 902

Email: secretary@acprc.org.uk

Website: www.acprc.org.uk

The Association of Respiratory Nurse Specialists

Stand number C52

The Association of Respiratory Nurse Specialists (ARNS), established in 1997, is the primary nursing forum for respiratory nurse specialists lead by respiratory nurses, to promote a higher level of respiratory nursing practice through leadership, education and professional development. ARNS works to influence the direction of respiratory nursing care, engaging with national and international stakeholders and government agencies, to deliver evidence based practice within the rapidly changing health-care environment.

Tel: +44 (0)7740 117 902

Email: info@arns.co.uk

Website: www.arns.co.uk

Asthma UK

Stand number C57

Asthma UK is the charity dedicated to improving the health and well-being of the millions of people with asthma in the UK. We work with people with asthma, healthcare professionals and researchers to develop and share expertise to help people increase their understanding and reduce the effect of asthma on their lives. Plus:

You can contact the Asthma UK Adviceline team of asthma nurse specialists on:

Tel: +44 (0)800 121 6244 (Monday-Friday 9am-5pm)

Our Supporter Care Team deals with queries about membership, donations and information, plus any general queries about Asthma UK:

Tel: +44 (0)800 121 6255 (Monday-Friday 9am-5pm)

Email: info@asthma.org.uk

Website: asthma.org.uk

AstraZeneca

Stand numbers 7, 8 & 9

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies, investing \$5.2 billion in medicines research and development in 2009, and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

Tel: +44 (0)1582 836 000

Website: www.AstraZeneca.co.uk

B&D Electromedical

Stand number 22

B & D Electromedical was founded in 1988 and is renowned for excellence in customer service and quality of innovation. Based in Stratford-upon-Avon, Warwickshire, we are the only UK based company to design and manufacture homecare ventilators and bi-level devices.

2011 is a particularly significant year as we have extended our product range beyond the ever-popular Nippy ventilation range – to include the Nippy Clearway.

EXHIBITORS' INFORMATION

The Nippy Clearway is an airway clearance device that combines a robust, intuitive platform with automatic technology to enhance airway clearance options for respiratory clinicians. The Nippy Clearway is a portable mechanical insufflator-exsufflator (MiE), but it also provides mode options for Intermittent Positive Pressure Breathing (IPPB), airway vibration and short-term ventilation.

The launch of the Nippy Clearway has also provided a platform for B&D Electromedical to develop a global business beyond the UK and Ireland. We are now trading in nine other countries. This means that our customers in the UK are even more important, as their feedback and suggestions for our product development now influence our global product offering.

Tel: +44 (0)1789 293 460
Email: sales@nippyventilator.com
Website: www.nippyventilator.com

Bedfont Scientific Ltd **Stand number 37**

Established in 1976, Bedfont Scientific are market leaders in exhaled breath gas monitoring instruments, including the Smokerlyzer range of carbon monoxide monitors used in smoking cessation programmes and the NObreath for measuring exhaled nitric oxide to provide accurate analysis of airway inflammation.

Visit Bedfont on stand number 37 at the British Thoracic Society Winter Meeting, or please contact Bedfont direct for more information on their product range.

Tel: +44 (0)1622 851122
Email: info@bedfont.com
Website: www.bedfont.com

Blackwell **Stand number 46**

Blackwell has been supplying specialist publications and academic books for over 130 years. With 50 shops around the UK, two dedicated medical bookshops and medical departments in all of our major outlets, Blackwell is the largest medical book supplier and retailer in the UK.

We provide a specialist service to everyone in the medical profession, offering a wide range of books, publications, medical instruments and training materials. We are a contracted supplier to the NHS and Department of Health.

Tel: 020 7611 2160
Email: exhibitions@blackwell.co.uk
Website: www.blackwell.co.uk

BOC Healthcare **Stand number 26**

BOC Healthcare is a leading supplier of medical gases globally and in the UK. Our Home Oxygen Service provides the best oxygen therapy and full support for patients of all ages with a wide variety of respiratory conditions (breathing problems). We currently supply oxygen therapy to approximately 14,000 patients living in the East and North East of England. BOC Healthcare is also involved in providing superior associated services to respiratory deficient patients such as Oxygen Assessment and Pulmonary Rehabilitation. These services for patients of all ages and suffering from a variety of breathing

conditions are supported by the latest innovative equipment and clinical assistance. To find out more please visit stand 26.

Tel: +44 (0)800 136 603
Email: healthcare.home-uk@boc.co.uk
Website: www.bochealthcare.co.uk/homeoxygeneservices/

Boehringer Ingelheim GmbH and Pfizer Inc **Stand number 21**

Boehringer Ingelheim is one of the 20 leading pharmaceutical corporations in the world. As leader in COPD treatment, the company is committed to delivering high-quality respiratory care through the discovery of new respiratory medicines (SPIRIVA®) and delivery systems (RESPIMAT®), thus providing benefit for patients and healthcare providers.

Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known brands. Our innovative products improve the quality of life of people the world over and helps them enjoy longer, healthier, and more productive lives.

Tel: +44 (0)1344 424 600 (Boehringer Ingelheim)
Tel: +00 1 212 733 2323 (Pfizer)
Websites: www.boehringer-ingelheim.com
 www.pfizer.com

Boston Scientific **Stand number 32**

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of \$7.806 billion in 2010. For more than 30 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The company's products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery.

For enquiries relating to Bronchial Thermoplasty please call Andrew Moss:

Tel: +44 (0)1442 411 690
Website: www.bostonscientific.com.

BRAHMS GmbH **Stand number 31**

BRAHMS GmbH, part of Thermo Fisher Scientific, specializes in innovative products which facilitate earlier diagnosis of diseases and better control of therapy, thus enabling doctors to provide more efficient and economic patient care. Major fields of activity are diagnosis of infectious and thyroid diseases, cardiology and pneumology as well as sepsis, tumours, and Down's syndrome.

Tel: +44 (0)1223 811083
Email: UKBOTInfo@thermo.com
Websites: http://www.thermoscientific.com
 http://www.brahms-uk.com

The British Lung Foundation **Stand number C60**

The British Lung Foundation (BLF) is the only UK charity working for everyone affected by lung disease. We focus

our resources on providing support for people affected by lung disease. The BLF works in a variety of ways, including funding world-class research, campaigning to bring about positive change in lung health and improving treatment, care and support for people affected by lung disease.

Tel: +44 (0)20 7688 5555
Helpline: +44 (0)8458 50 50 20
Email: enquiries@blf-uk.org
Website: www.lunguk.org

Cellestis **Stand number 16**

QuantiFERON®-TB Gold In-Tube (QFT™), a simple blood test, is the first major advance in TB diagnosis since the introduction of the tuberculin skin test (TST) over 100 years ago. As a modern alternative to the TST, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation. In many cases, results can be available within 24 hours.

Tel: +00 49 6151 428 590
Website: www.cellestis.com

Chiesi Limited **Stand numbers 17, 18, 23 & 24**

Chiesi Limited is a research focused, international company, developing and bringing innovative pharmaceutical solutions, which aim to relieve symptoms and improve the quality of human life. Chiesi is established in the areas of respiratory, cardiovascular and musculoskeletal medicine, with a research pipeline focused in the treatment of respiratory disease. It is an organisation that combines commitment and results with integrity, operating in a socially and environmentally responsible manner.

Tel: +44 (0)161 488 5555
Email: info@chiesi.uk.com
Website: www.chiesi.uk.com

Chiesi Limited **Stand number 6**

Since their foundation in 1995, Chiesi Limited (previously known as Trinity) set out to carve a niche for itself through its range of modified-release drugs in the therapeutic areas of cardiology, musculoskeletal and respiratory medicine. It did so with entrepreneurial flair and the company soon earned an established place in the UK marketplace with a range of ethical, branded products. In 1999, the company was acquired by the Chiesi Group, an international pharmaceutical company headquartered in Parma, Italy. Since the acquisition, the company has expanded its therapeutic franchises to cover neonatology, respiratory, cardiovascular, musculoskeletal and gastrointestinal medicine. The Chiesi Group remains a family owned and managed business despite having grown to be an organisation with over 3,550 employees operating in many countries across the globe.

EXHIBITORS' INFORMATION

Chiesi's stated aims are to bring innovative solutions to their therapeutic areas of expertise which includes uncommon diseases such as cystic fibrosis and neonatal respiratory distress syndrome, as well as developing advanced drug delivery technologies. The Chiesi Group has several R&D facilities in Europe and the USA. One of its key R&D innovations is the unique Modulite® technology which overcomes many of the technical barriers associated with the formulation of CFC-free inhalers. In 2010 the company received the Research and Development Award under the UK-Italy Business Awards programme for its outstanding investments in research and development in the United Kingdom, which was dedicated to the research of drug delivery technologies.

Tel: +44 (0)161 488 5555
Email: info@chiesi.uk.com
Website: www.chiesi.uk.com

Clement Clarke International **Stand number 40**

Clement Clarke International has been the major force in the manufacturing of innovative medical instrumentation worldwide since 1917. Today's range of respiratory medical devices covers diagnosis, monitoring and the treatment of many respiratory conditions. From the beginning of Peak Flow Measurement, CCI have been involved with the widely acclaimed "Mini-Wright" Peak Flow Meter, supported by hundreds of published papers and is recognised in the industry as the "Gold Standard" for Expiratory Flow Measurement.

Tel: +44 (0) 1279 414969
Email: resp@clement-clarke.com
Website: www.clement-clarke.com

Dolby Vivisol **Stand number 44**

Providing home oxygen and other respiratory services is our daily commitment at Dolby Vivisol. Our UK operations in the South of England and Scotland aim to support healthcare professionals in offering a top-class and personalised service to your patients. Dolby Vivisol have many years of experience throughout the UK and Europe, supporting research and innovation to provide benefits to patients we support. From the flexibility built in our systems to the adoption of new technology, we deliver a high quality of care for the patient.

Tel: +44 (0)800 833 531
Email: info@dolbyvivisol.com
Website: www.dolbyvivisol.com

Education for Health **Stand number C51**

Education for Health is the UK's leading education charity for health professionals working with patients with long term conditions and our education has been shown to measurably improve services and health outcomes. We believe that education should be at the heart of service improvement and not as an add on. We find ourselves being asked to set the standard for effective education and asked to partner with health organisations across the globe to pioneer best practice learning experiences to materially and substantially benefit patient care. We would welcome any opportunity to share this unique information, knowledge and

EXHIBITORS' INFORMATION

expertise. Historically our distance learning programmes have been paper based but in 2010 we have harnessed the enormous potential of the internet and digital technologies by developing dynamic, interactive e-learning programmes. Our educational programmes are run throughout the UK and internationally and are accredited by the Open University.

Tel: +44 (0)1926 836 849
E-mail: r.clarke@educationforhealth.org
Website: www.educationforhealth.org

The European Respiratory Society

Stand number C49

Founded in 1990, the European Respiratory Society (ERS) is a not-for-profit, international medical organisation. It is the largest society in Europe in its field, with more than 10,000 members in over 100 countries. The ERS aims to alleviate suffering from respiratory disease and to promote lung health through research, clinical education, advocacy and public awareness. The ERS is dedicated to raising awareness of lung health and improving prevention, management and treatment of lung disease.

Tel: +41 21 213 01 01
Email: ersinfo@ersnet.org
Website: www.ersnet.org

Forest Laboratories UK Ltd

Stand numbers 3 & 4

Forest Laboratories UK Ltd has recently launched Nebusal™ (Sterile 7% hypertonic sodium chloride solution) for use in mobilisation of secretions in the lower respiratory tract in patients such as those with cystic fibrosis (CF), bronchiectasis, chronic obstructive pulmonary disease (COPD) and severe asthma. Forest also markets Colomycin (Colistimethate sodium) as a treatment option within cystic fibrosis, within the UK and Ireland.

Tel: +44 (0)1322 421 800

GlaxoSmithKline

Stand numbers 27, 28 & 39

We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

We are one of the world's leading research-based pharmaceutical and healthcare companies. Headquartered in the UK, we are a global organisation with offices in over 100 countries and major research centres in the UK, USA, Belgium and China. But being a leader brings responsibility. This means that we care about the impact that we have on the people and places touched by our mission to improve health around the world.

It also means that we must help developing countries where debilitating disease affects millions of people and access to life-changing medicines and vaccines is a problem. To meet this challenge, we are committed to providing discounted medicines where they are needed the most.

We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

We produce medicines that treat major disease areas such as asthma, anti-virals, infections, mental health, diabetes, cardiovascular and digestive conditions. In addition, we are a leader in the important area of vaccines and are developing new treatments for cancer.

Tel: +44 (0)800 221 441
Email: customercontactuk@gsk.com
Website: www.gsk.co.uk

Hitachi Medical Systems

Stand number 25

EBUS guided TBNA – The new generation complementary to EUS-FNA.

Hitachi's innovative Endobronchial Ultrasound System (EBUS) combines high resolution ultrasound with high definition video imaging which together play a vital role in delivering accurate information for precise tumour staging. Safe, accurate and significantly less invasive for complete mediastinal staging.

Tel: +44 (0)844 800 4294
Website: www.hitachi-medical-systems.com

Imotech Medical

Stand number 43

Imotech Medical supply a full range of clinical solutions for pulmonary physicians, being the sole UK distributor of premium Fujifilm flexible HD endoscopy products, with new ranges of innovative products for both rigid endoscopy, ultrasound and associated therapeutic treatments.

Imotech Medical will also be launching new HD EBUS and bronchoscopy systems along with a unique funding package solution that could enable cost effective updating/replacement of equipment in these financially difficult times. Visit us at Stand 43 to find out more.

Tel: +44 (0)1594 844 770
Email: mark.hibbert@imotechmedical.com
Website: www.imotechmedical.com

LAM Action

Stand number C65

LAM Action is the UK charity for patients with lymphangioleiomyomatosis (LAM). Its primary aims are:

- To provide support and information for LAM patients and their families
- To educate health professionals about LAM and advance research into LAM

LAM is a rare multi-system disease, diagnosed mainly in women of childbearing age. It mainly affects the lungs, causing excessive growth of smooth muscle cells which progressively destroys lung tissue and erodes lung function. Currently, there is no cure for LAM and no effective treatment, so for many patients lung transplantation is the only means of survival.

Tel: +44 (0)115 823 1934
Website: www.lamaction.org

EXHIBITORS' INFORMATION

Merck Sharp & Dohme Limited

Stand numbers 29 & 30

Today's MSD is a global healthcare leader who is working to help the world be well.

Through our medicines, vaccines, biologic therapies, and consumer and animal products, we collaborate with human and animal health professionals across the UK and in more than 140 countries to deliver innovative health solutions. Beyond this, we have a commitment to increasing access to healthcare through far-reaching programmes that donate and deliver our products to people who need them.

Tel: +44 (0)1992 467 272

Website: www.msd-uk.co.uk

Napp

Stand numbers 10, 11, 12 & 13

With a strong heritage in the area of pain management, Napp has built a reputation for provision of medicines that utilise innovative delivery mechanisms to help patients manage their symptoms. Building on this experience, we plan to expand into the field of respiratory medicine. Napp is committed to the long-term support of respiratory medicine and ongoing improvement of patient care through investment in the education and development of healthcare professionals.

Tel: +44 (0)1223 424 444

Email: enquiries@napp.co.uk

Website: www.napp.co.uk

NHS Improvement Lung

Stand number C64

NHS Improvement's strength and expertise lies in practical service improvement. It has over a decade of experience in clinical patient pathway re-design in cancer, diagnostics, heart, lung and stroke and demonstrates some of the most leading edge improvement work in England which supports improved patient experience and outcomes. Working closely with the Department of Health, Trusts, clinical networks, other health sector partners, professional bodies and charities, over the past year it has tested, implemented, sustained and spread quantifiable improvements with over 250 sites across the country as well as providing an improvement tool to over 800 GP practices.

Tel: +44 (0)116 222 5184

Email: info@improvement.nhs.uk

Website: www.improvement.nhs.uk

The NHS Information Centre for Health and Social Care

Stand number C55

The NHS Information Centre is England's national, authoritative source of health and social care information for frontline decision makers. Working with a wide range of health and social care providers, the organisation collects data, analyses it and publishes the facts and figures that help the NHS and social care services run effectively. The NHS Information Centre produces a wide range of statistical publications across a number of areas that include the National Lung Cancer Audit. To find out more about this year's audit come and speak to us at stand number C55.

Tel: +44 (0)845 300 6016

Email: enquiries@ic.nhs.uk

Website: www.ic.nhs.uk

Novartis

Stand numbers 34 & 35

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products.

Employing over 3,500 people across nine sites, Novartis Pharmaceuticals UK Limited is involved in development, manufacturing, packaging, customer service and marketing for products used in the UK and worldwide.

This includes Novartis respiratory medicines, which currently help those living with Chronic Obstructive Pulmonary Disease (COPD), Asthma and Cystic Fibrosis. Novartis is committed to respiratory medicine. The Respiratory Research Centre at Horsham in West Sussex is the Novartis worldwide headquarters for respiratory research, employing over 500 scientists, in a £42 million purpose-built centre.

Tel: +44 (0)1276 692 255

Website: www.novartis.co.uk

Nutricia UK

Stand number 41

Nutricia specialises in the delivery of advanced medical nutrition for the very young, the old and the sick. As well as being the largest specialist nutrition company in Europe, Nutricia is the market leader in the UK.

One of Nutricia's latest innovations is a disease targeted nutritional supplement which has been shown to enhance physical capacity when combined with exercise in COPD patients.

Nutricia are part of a working group, represented by the Association of Respiratory Nurse Specialists, Education for Health and Respiratory Dietician Network. Together they will be launching Respiratory Healthcare Professionals – Nutritional COPD Guidelines.

Tel: +44 (0)1225 711 688

Website: www.nutricia.co.uk

Olympus KeyMed

Stand number 14

A wholly-owned subsidiary of the Olympus Corporation of Japan, Olympus KeyMed is an important part of the global Olympus network, with specific responsibility for the development and manufacture of medical equipment and industrial products for distribution worldwide.

During the BTS Winter Meeting, the latest technology from Olympus will be featured on its stand, including linear and radial endobronchial ultrasound, a range of flexible bronchoscopes, Autofluorescence Imaging, Narrow Band Imaging, a unique autoclavable semi-rigid thoracoscope, comprehensive range of bronchoscopy accessories and the IBV Valve System, a new minimally invasive treatment for diseased lung in emphysematous patients or damaged lung resulting in air leaks.

Tel: +44 (0)1702 616 333

Website: www.olympus.co.uk

EXHIBITORS' INFORMATION

Orion Pharma (UK) Ltd

Stand number 5

Orion Pharma (UK) Ltd is a wholly owned subsidiary of Orion Corporation, which is a pharmaceutical company based in Finland and listed on the Nasdaq OMX Helsinki stock exchange. Our principal role is to represent Orion's pharmaceutical products in the UK. Our key focus is on Prescription Only Medicines (POM) for human healthcare, which include therapy areas such as respiratory, central nervous system (CNS), and both female and male health.

In the spirit of the values which are common to all units and employees of the Orion Group, we endeavour to provide innovative medicinal treatments and best quality service to patients, healthcare professionals and the community in the UK.

Tel: +44 (0)1635 520 300

Website: www.orionpharma.co.uk

Oxford Diagnostic Laboratories

Stand number 33

TB Screening Just Got Easier:

Visit Oxford Diagnostic Laboratories on stand number 33 to learn about the most simple, reliable and cost effective TB Testing Service available in the UK.

Oxford Diagnostic Laboratories is the only national service laboratory dedicated to running the T-SPOT®.TB IGRA for accurate detection of tuberculosis.

Oxford Diagnostic Laboratories offer a Simple 3-Step Process: Collect the blood sample; Send the blood sample; Report the test results.

Tel: +44 (0)1235 433 164

Email: odl@oxfordimmunotec.com

Website: www.tbtestingservices.com

PARI Medical Ltd

Stand number 2

PARI is a leading manufacturer of nebuliser systems, with offices worldwide. For more than 100 years PARI has been developing solutions for people suffering from respiratory diseases in the form of high-quality, reliable nebuliser devices.

PARI represent the 'Gold Standard' in inhalation therapy, based on solid evidence:

- First choice nebuliser for clinical trials worldwide
- 67 studies published using PARI nebulisers, with outstanding results

The PARI product range also includes hypertonic saline for inhalation and a spacer device, treating an enormous variety of respiratory conditions. Precisely targeted and optimised for different age groups and target areas, the efficiency of PARI products ultimately improves patient outcomes.

Tel: +44 (0)1932 341 122

Email: infouk@pari.eu

Website: www.parimedical.co.uk

PENTAX Lifecare

Stand number 36

PENTAX Lifecare invites you to visit stand 36 at the BTS Winter Meeting.

PENTAX, an established leader in the endoscopy field, continues to gain outstanding reviews from clinicians on its leading edge, highly sophisticated, flexible endoscopic products.

The PENTAX package brings together all essential elements required to make its offering the best in the market. Leading medical institutes affirm PENTAX because it provides superior imaging, and many clinicians prefer PENTAX because Hi Line is the most technologically advanced video endoscopy system available.

PENTAX's excellent customer service facilitates an effortless working relationship with all its customers who state PENTAX provides the best and most effective support and service.

Tel: +44 (0)1753 792 733

Email: lifecare.sales@pentax.co.uk

Website: www.pentax.co.uk

Pfizer

Stand number 20

Pfizer, the world's leading biopharmaceutical company, applies science and global resources to improve health and well-being at every stage of life.

Our commitment to vaccines has a long heritage and spans well into the future. It stretches across a broad range of diseases and populations, including infants, children and adults. Our innovative conjugate vaccines include Prevenar 13®[▼], against pneumococcal disease and Meningitec®, against meningitis C.

We are a reliable and trusted flu vaccine supplier to the NHS with a track record of partnering healthcare professionals to help deliver successful vaccination programmes in the UK.

Tel: +44 (0)1304 616 161

Website: www.pfizer Vaccines.co.uk

PHA UK

Stand number C62

The PHA UK is the only charity in the UK especially for people affected by pulmonary hypertension (PH). It was formed in 2000 and now has over 2500 members. We provide information, support and advice to people with PH, their families and friends, and healthcare professionals working in PH. Our main objectives are to:

- Raise awareness amongst the general public and healthcare professionals
- Provide healthcare professionals further knowledge and education on pulmonary hypertension
- Campaign on issues relevant to people with PH

Tel: +44 (0)1709 761 450

Email: office@phassociation.uk.com

Website: www.phassociation.uk.com

Pharmaxis

Stand number 38

"Focused innovation in respiratory medicine"

Pharmaxis is a specialist pharmaceutical company committed to the research, development and

EXHIBITORS' INFORMATION

commercialisation of human therapeutic products that address chronic respiratory and autoimmune diseases. Our R&D activity has resulted in the successful development of mannitol as a diagnostic test for bronchial hyper-responsiveness. An osmotic agent is also currently being researched as a therapeutic mucoactive agent for potential indications including cystic fibrosis and bronchiectasis.

Website: www.pharmaxis.com.au

Philips Respironics **Stand number 15**

Philips Respironics, a global leader in the sleep and respiratory markets, is passionate about improving the quality of people's lives with solutions that are designed around the needs of our customers and their patients. For Philips Respironics, innovation is driven by gaining insight into the needs of the people who use our products in the areas of sleep management, oxygen therapy, non-invasive ventilation and respiratory drug delivery. This tradition of innovation combined with our ability to anticipate market needs has made Philips Respironics a name acknowledged worldwide as a pace-setter in the markets we serve.

Tel: +44 (0)800 1300 840 or +44 (0)7740 565 379

Email: sarah.booker@philips.com

Website: www.philips.com/respironics

The Primary Ciliary Dyskinesia Family Support Group

Stand number C56

The Primary Ciliary Dyskinesia (PCD) Family Support Group is a registered charity who:

- Provide support to patients and their carers who have, or are suspected of having, PCD
- Bring PCD to the attention of medics who may come across PCD and continue to provide an up to date information service for them and the general public
- To promote research to aid diagnosis and treatment of patients with PCD
- Support the NHS and other bodies to ensure patients have access to diagnostic services and on-going care
- Fundraise to support the above activities

Tel: +44 (0)300 111 0122

Email: chair@pcdsupport.org.uk

Website: www.pcdsupport.org.uk

ResMed UK **Stand number 19**

ResMed are a global leader in the development, manufacture and marketing of innovative medical products for the treatment and management of respiratory disorders and sleep disordered breathing. We are dedicated to delivering the optimum care and promoting best practice in diagnostics and for patients requiring CPAP, invasive or non-invasive ventilation in both the home and hospital settings.

ResMed invite you to come and explore the Stellar and VPAP ST bi-level ventilators, Pixi paediatric and FX range of adult masks and award winning S9 sleep devices.

Tel: +44 (0)1235 862 997

Email: reception@resmed.co.uk

Website: www.resmed.co.uk

Respiratory Education UK **Stand number C50**

At Respiratory Education UK our fundamental goal is to support patients and practitioners through the challenges now faced within the NHS.

This is achieved through a number of key objectives including the design and delivery of practical and academic programmes and study events; influencing respiratory practice via active research and promoting best practice through a number of respiratory related projects.

As a result, we have a wide portfolio of programmes and courses available which continue to adapt and grow, providing 'Steps to Success' for practitioners within respiratory practice.

Recognising that patients are very much at the centre of health care, REUK are currently developing a series of programmes and services which seek to assist individuals with long term conditions to be more aware, involved and engaged in their health and wellbeing. As a result, new provision focusing upon 'Positive Patients' are in development to complement our existing programme.

Tel: +44 (0)151 529 2598

Email: info@respiratoryeduc.com

Website: www.respiratoryeduc.com

Rocket Medical

Stand number 45

Rocket Medical are a UK medical manufacturing and design company with over 40 years' experience supplying to the NHS. Being a UK company Rocket Medical develop products to meet UK guidelines. Our Seldinger insertion packs are a case in point, supplied with an echogenic needle, drapes and gown and Safe Guard dilators that prevent over insertion as well as the all-important catheter allowing you to insert a chest drain whilst being able to meet the BTS guidelines with minimal effort.

This year for the Seldinger insertion packs we are launching our new fixation device that can be used with or without a suture.

The Rocket Indwelling Pleural catheter for recurrent malignant pleural effusions will be available for examination on the stand and while you are with us we can explain to you how the drainage bottles are available on prescription.

Alongside these are the many other products Rocket Medical has developed and manufactured thanks to the feedback and support of the many BTS members. So come and say hello.

Tel: +44 (0)191 419 4488

Website: www.rocketmedical.com

Royal College of Physicians Improving Lung Cancer Outcomes Project

Stand number C61

The Improving Lung Cancer Outcomes Project (ILCOP) is a two year long national initiative aimed at reducing the variation in outcomes across 30 lung cancer

EXHIBITORS' INFORMATION

services in England. ILCOP aims to support teams to deliver improvements in care outcomes and patient experience through a series of interventions that include multidisciplinary service reviews and input by a quality improvement facilitator.

ILCOP is funded by The Health Foundation and it is delivered by a team hosted by the Royal College of Physicians. Other national stakeholders involved in the project are NHS Improvement, the NHS Information Centre for Health and Social Care, Macmillan, the National Forum for Lung Cancer Nurses and The Royal Castle Lung Cancer Foundation.

For further information on the project and its methodology for multidisciplinary service review, contact Senai Jimenez (Project Manager):

Tel: +44 (0)20 3075 1501

Email: senai.jimenez@rcplondon.ac.uk

Website: www.rcplondon.ac.uk/resources/improving-lung-cancer-outcomes-project-ilcop

Royal College of Physicians National Review of Asthma Deaths **Stand number C61**

A National Review of Asthma Deaths (NRAD), run by a consortium of asthma professional and patient bodies, led by the Royal College of Physicians, will look into the circumstances surrounding deaths from asthma.

The NRAD has been commissioned and funded by the Healthcare Quality Improvement Partnership (HQIP).

For a 12 month period from the 1 February 2012, every death from asthma in the UK will be reviewed systematically and will be subject to an in-depth multidisciplinary confidential enquiry. We are expecting the NRAD to build on previous confidential enquiries into asthma deaths in regions of the UK and to provide a more robust body of evidence on which to build our understanding of how life-threatening situations arise and how they can be avoided in future.

For further information on the project and how you can get involved as a panel assessor please see our website or contact Rosie Houston (Programme Manager):

Email: nrad@rcplondon.ac.uk

Tel: +44 (0)20 3075 1500

Website: www.rcplondon.ac.uk/nrad

The Severe Asthma National Network

Stand number C59

The Severe Asthma National Network (SANN), founded in 2007, aims to drive forward the delivery and quality of care of children, young people and adults who have difficult to treat asthma. SANN facilitates education and training and is working in partnership with Asthma UK to put difficult to treat asthma on the map. SANN is affiliated to the British Thoracic Society and welcomes membership from adult and children's respiratory nurses and professionals allied to medicine who are dedicated to raising standards of care across primary and secondary care.

Tel: +44 (0)121 333 8014

Email: susan.frost@bch.nhs.uk

TB Alert

Stand number C63

TB Alert – the UK's national tuberculosis charity.

For over ten years TB Alert has been the only TB-specific charity working to address tuberculosis both in the UK and overseas. We work in both these arenas not only because they are inter-related, with global travel and migration patterns affecting TB rates in the UK, but also because there is much to be learned from one context that can be applied to the other.

Our Vision is the control and ultimate eradication of TB. Our Mission is to increase access to effective treatment for all.

Tel: +44 (0)1273 234 029

Email: info@tbalert.org

Websites: www.tbalert.org
www.thetruthabouttb.org